



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2525385 A1 2004/11/25

(21) **2 525 385**

(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2004/05/12	(51) Cl.Int./Int.Cl. <i>C07H 21/04</i> (2006.01), <i>C12N 15/74</i> (2006.01), <i>C12N 15/00</i> (2006.01), <i>C12N 5/00</i> (2006.01), <i>C07K 17/00</i> (2006.01), <i>A61K 48/00</i> (2006.01)
(87) Date publication PCT/PCT Publication Date: 2004/11/25	(71) Demandeur/Applicant: THE CHILDREN'S HOSPITAL OF PHILADELPHIA, US
(85) Entrée phase nationale/National Entry: 2005/11/09	(72) Inventeurs/Inventors: ARGON, YAIR, US; GIDALEVITZ, TAL, US; BISWAS, CHHANDA, US; SIMEN, BIRGITTE BINDERUP, US; WANDERLING, SHERRY, US; OSTROVSKY, OLGA, US
(86) N° demande PCT/PCT Application No.: US 2004/015120	(74) Agent: BERESKIN & PARR
(87) N° publication PCT/PCT Publication No.: 2004/101766	
(30) Priorités/Priorities: 2003/05/12 (60/469,723) US; 2003/06/12 (60/478,149) US; 2003/06/12 (60/477,990) US; 2004/04/28 (60/566,363) US; 2004/04/28 (60/566,362) US	

(54) Titre : COMPOSITIONS A BASE DE GRP94 ET PROCEDES D'UTILISATION ASSOCIES

(54) Title: GRP94-BASED COMPOSITIONS AND METHODS OF USE THEREOF

(57) **Abrégé/Abstract:**

Mini chaperones and methods of use thereof for the treatment of cancer and other disorders are provided. Also provided are tools to facilitate screening therapeutic agents which have selective binding affinity for GRP94.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 November 2004 (25.11.2004)

PCT

(10) International Publication Number
WO 2004/101766 A3

(51) International Patent Classification⁷: **C07H 21/04**,
C07K 17/00, C12N 5/00, 15/00, 15/74, A61K 48/00

(74) Agents: **RIGAUT, Kathleen, D.** et al.; Dann, Dorfman,
Herrell and Skillman, Suite 2400, 1601 Market Street,
Philadelphia, PA 19103-2307 (US).

(21) International Application Number:

PCT/US2004/015120

(22) International Filing Date: 12 May 2004 (12.05.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/469,723	12 May 2003 (12.05.2003)	US
60/477,990	12 June 2003 (12.06.2003)	US
60/478,149	12 June 2003 (12.06.2003)	US
60/566,362	28 April 2004 (28.04.2004)	US
60/566,363	28 April 2004 (28.04.2004)	US

(71) Applicant (for all designated States except US): **THE CHILDREN'S HOSPITAL OF PHILADELPHIA** [US/US]; 34th and Civic Center Boulevard, Philadelphia, PA 19104-4318 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ARGON, Yair** [US/US]; 1231 Wyngate Road, Wynnwood, PA 19096 (US). **GIDALEVITZ, Tali** [IL/US]; 1211 Michigan Avenue, Apt. 3, Evanston, IL 60202 (US). **BISWAS, Chhanda** [IN/US]; 250 East Wynnwood Road, Apt. G-16, Wynnwood, PA 19096 (US). **SIMEN, Birgitte, Binderup** [DK/US]; 816 Indian Hill Road, Orange, CT 06477 (US). **WANDERLING, Sherry** [US/US]; 141 Raymond Avenue, Brookfield, IL 60513 (US). **OSTROVSKY, Olga** [IL/US]; 4211 Pine Street, Philadelphia, PA 19104 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

24 March 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GRP94-BASED COMPOSITIONS AND METHODS OF USE THEREOF

(57) Abstract: Mini chaperones and methods of use thereof for the treatment of cancer and other disorders are provided. Also provided are tools to facilitate screening therapeutic agents which have selective binding affinity for GRP94.



WO 2004/101766 A3

GRP94-BASED COMPOSITIONS AND METHODS OF USE THEREOF

5

10

The present invention claims priority to the following US Provisional Applications, 60/469,723 filed May 12, 2003, 60/477,990 and 60/478,1489 each filed June 6, 2003 and 60/566,362 and 60/566,363 each filed April 28, 2004. The disclosure of each of the foregoing provisional applications is incorporate by reference herein.

Pursuant to 35 U.S.C. §202(c), it is acknowledged that the U.S. Government has certain rights in the invention described herein, which was made in part with funds from the National Institutes of Health, Grant Numbers: CA-74182, and NIH/NIAID RO1 AI30178.

FIELD OF THE INVENTION

This invention relates to the fields of immunomodulation, cancer treatment and embryogenesis. More specifically, the invention provides GRP94 based compositions and methods of use thereof for beneficially and therapeutically impacting these processes.

BACKGROUND OF THE INVENTION

Several publications and patent documents are cited throughout the specification in order to describe the state of the art to which this invention pertains. Each of these citations is incorporated herein by reference as though set forth in full.

Glucose Regulated Protein 94 (GRP94) resides in the endoplasmic reticulum and is a molecular chaperone or stress protein which is a member of the heat shock protein (HSP) 90 family. The family includes the htpG gene in bacteria, HSP82 in yeast, HSP90 α and β in higher eukaryotes and the TRAP1

protein in mitochondria (Buchner, J. 1999. Hsp90 & Co. - a holding for folding. *Trends Biochem Sci* 24:136). HSP 90 proteins are ligand regulated and participate in the conformational maturation of protein substrates involved in diverse cellular activities ranging from cell signaling to bacterial recognition and immunomodulation. Extensive work in cell culture models show that GRP94 expression is regulated by reduced levels of glucose (Lee, A.S., et al., *Transcriptional Regulation of Two Genes Specifically Induced by Glucose Starvation in a Hamster Mutant Fibroblast Cell Line*. J. Biol. Chem., 1983. **258**: p. 597-603), perturbations of cellular calcium level (Drummond, I.A., et al., *Depletion of intracellular calcium stores by calcium ionophore A23187 induces the genes for glucose-regulated proteins in hamster fibroblasts*. J. Biol. Chem., 1987. **262**(26): p. 12801-5; Little, E. and A.S. Lee, *Generation of a mammalian cell line deficient in glucose-regulated protein stress induction through targeted ribozyme driven by a stress-inducible promoter*. J. Biol. Chem., 1995. **270**(16): p. 9526-34) or the redox potential (Kim, Y.K., K.S. Kim, and A.S. Lee, *Regulation of the glucose-regulated protein genes by b-mercaptoethanol requires de novo protein synthesis and correlates with inhibition of protein glycosylation*. J. Cell. Physiol., 1987. **133**(3): p. 553-559), inhibition of glycosylation, or activation of the unfolded protein response (Gass, J.N., N.M. Gifford, and J.W. Brewer, *Activation of an unfolded protein response during differentiation of antibody-secreting B cells*. J Biol Chem, 2002. **277**(50): p. 49047-54).

Given all the factors that regulate its expression, it is intriguing that GRP94 is absent from the yeast genome, even though yeast cells respond to these stress situations much like mammalian cells. GRP94 is essentially a protein of multi-cellular organisms, but is clearly not necessary for global protein folding in the ER, nor for the secretory process *per se*. Therefore, the question arises as to whether and for what processes GRP94 is essential.

Tumors generally contain mutated proteins that often are associated with the transformation process itself. The same mutated proteins also make the tumors biochemically distinct. Accordingly such proteins should be recognized as foreign and elicit vigorous immune response by the T cell arm of the immune system (Velders, M.P., H. Schreiber, and W.M. Kast, *Active immunization against cancer cells: impediments and advances*. Semin Oncol, 1998. 25:69).

Yet, despite the natural capabilities of T cells to kill tumor cells, in practice the immune responses to cancer, while detectable, are weak. This is due to the evolution of multiple mechanisms within tumor cells to evade the immune reconnaissance system altogether, or to decrease the “fire power” of T cells.

5 Srivastava et al., showed that GRP94 within tumors binds peptides (See Tamura, Y., et al., *Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations*. Science, 1997. 278:117-120), is released from dying cells (See Basu, S., et al., *Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and*
10 *activate the NF-kappa B pathway*. Int Immunol, 2000. 12:1539-1546) and then is taken up by macrophages and/or dendritic cells (See Binder, R.J., D.K. Han, and P.K. Srivastava, *CD91: a receptor for heat shock protein gp96*. Nat Immunol, 2000. 1:151-155; Berwin, B., J. P. Hart, S. Rice, C. Gass, S. V. Pizzo, S. R. Post, and C. V. Nicchitta. 2003. *Scavenger receptor-A mediates gp96/GRP94 and*
15 *calreticulin internalization by antigen-presenting cells*. **Embo J 22:6127**), where the peptide dissociates from GRP94 and is transferred onto class I histocompatibility proteins as described by Tamura, Y., et al. (Figure 1). Because peptides displayed by class I molecules stimulate primarily CD8⁺ T cells, this so-called “peptide re-presentation” pathway leads to enhanced killer cell activity
20 against the tumors, shown to be increased 10-100 fold by this pathway, in cultured cells by the inventor’s laboratory and in mouse models by Srivastava’s laboratory (See Suto, R. and P.K. Srivastava, *A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides*. Science, 1995. 269:1585-1588 and Blachere, N.E., et al., *Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and*
25 *tumor immunity*. J. Exp. Med., 1997. 186:1315-1322). GRP94 elicits antigen-presenting cell (APC) activation and directs peptides into the cross- presentation pathways of APC through interactions with Toll-like (APC activation) and endocytic (cross-presentation) receptors of APC (Vabulas, R. M., S. Braedel, N.
30 Hilf, H. Singh-Jasuja, S. Herter, P. Ahmad-Nejad, C. J. Kirschning, C. Da Costa, H. G. Rammensee, H. Wagner, and H. Schild. 2002. *The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway*. **J Biol Chem 277:20847**).

5 Based on the foregoing, it is clear that a need exists for further elucidation of the role played by GRP94 and fragments thereof in modulating the immune process. Such information will provide novel GRP94 based therapeutics for the treatment of cancer, viral infections and other metabolic disorders.

10

15

20

25

30

invention and at least one virus specific peptide comprising an antigen specific for said virus and administering an effective amount of said complex to a patient in need thereof, such that a virus specific cytotoxic T cell (CTL) response is mounted which causes a reduction in said viral load thereby treating said
5 infection.

Also encompassed by the present invention is a transgenic mouse embryo harboring a homozygous null mutation in its endogenous GRP94 gene wherein the mutation has been introduced into said mouse via homologous recombination in embryonic stem cells, and further wherein said mouse does not express a
10 functional mouse GRP94 protein.

GRP94 deficient cell lines derived from the transgenic mouse embryo described above is also disclosed. Such cell lines can include without limitation embryonic stem cell line, stem lines which have been induced to undergo cellular differentiation. Cell types obtainable using the GRP94 deficient cell lines of the
15 invention include, for example, neurons, adipocytes, hepatocytes and lymphocytes.

Methods for screening for therapeutic agents which selectively affect GRP94 activity using the GRP94 deficient cell lines of the invention are also within the scope of the invention. One such method entails administering a test
20 compound to the GRP94 deficient cells and cells derived from wild type mouse embryos and assessing said GRP94-deficient and wild type cells for an alteration in a GRP94-related physiological process, thereby identifying agents which selectively modulate GRP94 activity.

Finally, the invention also discloses a nucleic acid encoding an HSP90
25 mini chaperone comprising amino acids 1-210 of human HSP90, wherein at least one amino acid residue selected from the group consisting of Thr90, Ile81, Pro82 has been altered to another amino acid. Methods for stimulating an immune response to tumor or viral antigens using the HSP90 mini chaperone are also provided.

30

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. A minimal portion of GRP94 is sufficient for peptide binding. Fig 1A. Schematic of recombinant proteins used. N1-355, the protein used in [15], contains the first 355 amino acids of GRP94, starting from the DDEVN-terminus of the mature protein. N34-355 is a version expressed in bacteria, where the first 33 amino acids of mature GRP94 are deleted. Hatched box, the N-terminal domain, containing the nucleotide/geldanamycin/radicicol binding site. Dark grey box, an acidic domain needed for at least one of the activities residing in the N-terminal domain. Light grey box, His6 tag. In N34-355 the tag is followed by a factor Xa cleavage site. N1-355 terminates with a KDEL ER retrieval signal, which is absent in N34-355. The single thrombin cleavage site after Arg222 is marked, as is the region containing the 9G10 monoclonal anti-GRP94 epitope (*). **Fig 1B.** Peptide binding ability of N1-355 and N34-355. The two versions of recombinant chaperone were tested, at the doses indicated, for binding of the 8-mer peptide VSV8 in the 96-well plate assay (see Experimental Procedures). Filled triangles, N1-355; filled squares, N34-355; empty symbols show inhibition of peptide binding by radicicol. **Fig 1C.** Thrombin digestion of N1-355 - iodinated peptide complex. C.B., Coomassie blue stained gel after partial proteolysis with thrombin, showing the cleavage of the recombinant protein into two fragments. ¹²⁵I, autoradiography of the same gel, showing that the iodinated peptide co-migrates with the larger thrombin fragment. α-His, western blot for the N-terminal His tag identifying the 22.4 kDa band as the N-terminal fragment. 9G10, western blot for the epitope residing in the acidic domain identifying the 14.6 kDa band as the C-terminal fragment. The larger band at the top of the gels is undigested material.

Figure 2. Molecular docking model. The relevant sequence of murine GRP94 (from amino acid 46 to 269) was threaded through the solved structure of the N-terminal domain of yeast HSP90 (PDB file 1YER; [20]), using the BioSym software, and energy minimized. The structure of the peptide VSV8 was taken from the solved structure of the complex of VSV8 and MHC class I Kb [9]. VSV8 was then docked onto the modeled GRP94 structure using the program PatchDock (Schneidman-Duhovny, D., Y. Inbar, V. Polak, M. Shatsky, I.

Halperin, H. Benyamini, A. Barzilai, O. Dror, N. Haspel, R. Nussinov, and H. J. Wolfson. 2003. Taking geometry to its edge: fast unbound rigid (and hinge-bent) docking. *Proteins* 52:107), assuming that it would bind to GRP94 in the same conformation as to MHC class I. The highest ranking docking solutions are

5 shown. They are divided between two possible sites, shown in green in panel A and B, respectively. **Fig. 2A.** Three peptide docking solutions partially overlap with the radicicol/geldanamycin binding site. Left panel, side view from the C-terminal end along the axis of the β sheet. Right panel, bottom view. White oval, outline of the radicicol-binding site. **Fig. 2B.** Four docking solutions map over

10 part of the β sheet. Left panel, view along the axis of the β sheet, same as in A. Right panel, top view. The sole cysteine and three histidines are shown in ball-and-stick representation, in yellow and light blue, respectively. Red arrow, Cys117; red arrowhead, His125; A-H, strands of the β sheet.

15 **Figure 3. The radicicol-refractive mutant N34-355 D128N,G132A still binds peptide.** **Fig. 3A.** D128N, G132A mutant of N34-355 (RadR) is refractive to radicicol treatment N34-355 (WT) and RadR proteins were incubated for 15 min with either DMSO or radicicol and resolved on a blue native gel. Radicicol-bound WT protein migrates through the gel more rapidly, due to a conformational

20 change in the protein [15]. The ability of the RadR protein to bind radicicol is dramatically reduced. Black arrow, unmodified protein; white arrow, radicicol bound protein. **Fig. 3B.** Peptide binding by RadR mutant is not affected by radicicol and is similar at saturation to that of WT protein. Binding of N34-355 and RadR proteins to VSV8 peptide was measured by the plate assay (see

25 Experimental Procedures). Black bars, binding in the absence of inhibitor; grey bars, binding in the presence of radicicol. Data are averages of triplicate samples. **Fig. 3C.** Dose binding of N34-355 and RadR proteins. Binding to VSV8 peptide was measured in a plate assay. Circles, WT protein; squares, RadR mutant. Data are averages of triplicate samples.

30

Figure 4. The predicted peptide binding site is in proximity to a deep hydrophobic pocket and to the inhibitor-binding site. **Fig. 4A.** Multiple sequence alignment of parts of the N-terminal domains of GRP94 and HSP90.

Black lines above the sequence, strands G and F (see panel B), containing Cys117 and His125, respectively. Red lines below the sequence, inhibitor-binding pocket constituents [17, 20] within the partial sequence. Green line, 35 amino acids in HSP90 whose position is different between the geldanamycin-bound and free conformations. These are HSP90 residues 100-134 (numbers in parentheses), corresponding to residues 135-174 in GRP94. Yellow highlight, position 125; grey highlights, Asp128 and Gly132, residues mutated in the RadR mutant; green highlights, Ile115, Leu124 and Val126, residues contributing to the hydrophobic pocket. Other residues from the hydrophobic pocket are Leu80, Ile84, Leu240, Ile243, Val247, Ile254, Ile258, Pro259 and Val260. Amino acids are colored blue for E or D, red for K, R or H, purple for N or Q, green for F or Y, brown for C, black for A, G, P, S, T, and yellow for I, L, M, V, **Fig. 4B**. Model of the hydrophobic pocket. A spacefill model showing the protein in the same view as in Fig.2B, left panel. Peptides are shown in light green. Dark green residues, I, L and V; blue, F; purple, T; brown, P; yellow, C; light blue, H. Red arrow, Cys117, red arrowhead, His125. Red dashed line, approximate location of the residues shown to crosslink to bis-ANS [22].

Figure 5. Peptide binding affects the environment of the hydrophobic pocket containing Cys117. Fig. 5A. Peptide A binding affects the emission of N1-355-bound ANS. N1-355 was first reacted with ANS (N1-355-ANS) and then bound to saturating amount of peptide A (N1-355-ANS+peptA). Emission maximum of N1-355 -ANS is 478nm, indicating a highly hydrophobic environment. Addition of peptide A partially quenches the fluorescence of N1-355-ANS, but not that of free ANS. N1-355 itself does not fluoresce in the wavelength range shown. **Fig. 5B.** Acrylodan binds covalently to the Cys within the predicted hydrophobic pocket. N1-355 and N34-355 were reacted with acrylodan overnight at 40°C. A sample with identical amount of acrylodan without protein served as a control. Half of each sample was then supplemented with guanidine chloride to a final concentration of 6M and another with equivalent volume of buffer. The emission maximum of N1-355-bound acrylodan under nondenaturing conditions was around 473nm, indicating highly hydrophobic environment. In 6M guanidine chloride, the emission maxima were

around 522nm for both N1-355-bound and free acrylodan, while the fluorescence intensity of the protein-bound acrylodan was significantly higher than that of the free dye, indicating covalent linkage. **Fig. 5C.** Acrylodan conjugated N1-355 binds peptide to the same extent as unconjugated N1-355. Free or acrylodan-conjugated protein (3.6 μ M) was reacted with 800 mM ^{125} I-VSV8 under saturating conditions and unbound peptide was removed using a spin column [15]. Free ^{125} I-VSV8 was used to control for the efficiency of removal of the unbound peptide. N1-355 and N1-355-acr, free and acrylodan-conjugated protein respectively; N1-355+VSV8* and N1-355-acr+VSV8*, same proteins bound to ^{125} I-VSV8; VSV8*, free ^{125} I-VSV8 peptide. **Fig. 5D.** Fluorescence of acrylodan covalently bound to N1-355 is affected by the addition of peptide. Fluorescence emission scans of acrylodan-conjugated N1-355 in the presence of either VSV8 (800 mM final concentration) or equivalent volume of buffer were taken at excitation wavelength 390 nm. VSV8 alone had no fluorescence in the measured wavelength range.

Figure 6. Peptide binding requires His residues. **Fig. 6A.** Peptide binding is pH dependent. Binding of N1-355 to the peptide VSV8 was assessed at various pH values using the solution binding assay described in [15]. At pH 7.2, either Hepes or Pipes were used with equal results, and the average set to 100%. Hepes was used at pH 8.2, and Pipes was used at pH 6.2, with the average binding values normalized to that obtained at the standard pH of 7.2. **Fig. 6B.** Peptide binding is sensitive to imidazole. Binding of N34-355 to peptide A was measured using the 96-well plate assay (Experimental Procedures). Imidazole was added to the indicated final concentrations and the binding at each concentration normalized to that without imidazole. Peptide binding in the presence of radicicol is shown as a measure of the nonspecific binding. Triangles, binding in the absence of the inhibitor; squares, binding in the presence of radicicol. **Fig. 6C.** Binding activity is abolished by DEPC modification. The His6 tag of recombinant N355 was cleaved with factor Xa according to the manufacturer's instructions (Novagen) and the protein re-purified over a Ni-NTA column. The protein was treated with DEPC, as described herein, to modify histidines selectively. A portion of the modified protein was treated with 0.4M

hydroxylamine (HA), to reverse the DEPC effect. Modification with ethanol was used as a solvent control. Radicicol treatment was used to measure specific peptide binding. The untreated and modified proteins were allowed to bind to peptide A-coated plates (0.7 μ g protein per well) and binding was quantified by indirect reaction with 9G10 Mab (Affinity Bioreagents) followed by HRP-goat anti-rat (Jackson Labs). Triplicate data points are from a representative experiment. DEPC decreased binding to the background level while HA completely reversed the DEPC effect. Removal of the His6 tag had no effect on either efficiency or specificity of binding. R, radicicol; Et, ethanol; DEP, treatment with DEPC; HA, treatment with DEPC followed by hydroxylamine.

Figure 7. Site-Directed mutagenesis demonstrates the importance of histidine 125 for peptide binding. Fig. 7A. Alteration of His125 affects N34-355 binding to peptide A. Wild type N34-355, H125Y or H125D proteins were purified by metal chelate chromatography and their ability to bind peptide was tested in the plate assay (see Methods). Inhibition by radicicol (300 μ M) served as a specificity control (Rad). The binding was measured at two protein input levels (0.7 or 2 μ g) based on the level of saturation binding for the WT protein. The data shown are averages and standard error of triplicate points in two experiments. Black bars, 0.7 μ g protein; grey bars, 2 μ g protein. **Fig. 7B.** Fractional occupancy curves of wild type and H125Y. The amounts of peptide-bound protein, calculated as a fraction of the saturation binding level for each protein, is shown as a function of the input of protein. Filled squares, values from three independent dose-binding experiments for the wild type protein. Empty squares, values from three independent experiments for H125Y. **Fig. 7C.** The H125D mutant shows the expected structural change upon radicicol binding. H125D and H125Y were compared to WT protein using blue native gel electrophoresis. Each protein (10 μ g) was treated with either 300 μ M radicicol or with DMSO and then loaded on each of two adjacent gel lanes. After electrophoresis, the gel was stained with Coomassie blue. Wild type and H125D proteins migrated predominantly as monomers and the characteristic radicicol-induced mobility shift was observed for both. Although H125Y protein also migrated as a monomer, it was present in two different conformations.

Approximately half of H125Y showed increased mobility even in the absence of radicicol, while the other half showed both expected mobility and radicicol-induced conformational change. Black arrow, unbound protein; white arrow, radicicol-bound protein.

5

Figure 8. Targeted disruption of the mouse GRP94 gene. Schematic of the murine gene and the targeting vector. The 18 exons of the GRP94 gene (black boxes) and the introns (thin lines, lengths determined by exon primer PCR and/or sequencing analysis) are drawn to scale, with a gap between exons 11 and 18. The targeting vector contains 1.2 kb 5' homology generated by PCR amplification and 8.0 kb 3' homology in an EcoRV fragment. The *neo* resistance cassette interrupts the coding region at the end of exon 3, 61 amino acids into the mature protein. Its transcriptional orientation is opposite that of the GRP94 gene, as marked by the arrow. The 5' homology region is flanked by *tk*, the herpes virus thymidine kinase gene used for negative selection. **Fig. 8B.** Correct targeting in two mice was determined by Southern blotting with probe A located 5' of the insertion (see arrow in panel A), after digestion with HindIII (H) or EcoRI (R).

Figure 9. *Grp94*^{-/-} embryos fail to gastrulate. Figs. 9A-H. Histological and immuno-staining analysis of WT (left panels) and mutant (right panels) embryos. E5.5 embryos (A-D) and E6.5 embryos (E-H) were fixed, sectioned and stained, as described in Materials and Methods, with either hematoxylin and eosin (H&E, A-B, E-F) or Mab 9G10 (α GRP94, C-D, G-H). VE, visceral endoderm; EPC, ectoplacental cone. * in panels E-F mark the developing pro-amniotic cavity. **Figs. 9I-L.** Histological analysis of E7.5 embryos, showing the lack of mesoderm formation and lack of cavitation in mutant embryos (J) compared to WT embryos (I). PA Cav, pro-amniotic cavity; EC Cav, exocoelomic cavity; PE, parietal endoderm. The double arrow in panel I and the arrow in panel K mark the junction between the embryonic and extra-embryonic regions. K, higher magnification image of WT endoderm, showing the cuboidal architecture of cells on the extra-embryonic side of the junction and the squamous morphology of the endoderm cells on the embryonic side of the

junction. L, a similar view of a mutant embryo, where the VE cells on both sides of the junction are cuboidal. Note also the lack of any evidence for pro-amniotic cavity. The PE cells do not look different in the mutant and WT embryos.

5 **Figure 10. Expression of GRP94 in pre-gastrulation embryos.**

Immunohistochemistry of E5.5 (A) and E6.5 (B) WT embryos with the anti-GRP94 monoclonal antibody 9G10. The sections shown are representative of multiple samples and were stained as described in Materials and Methods.

Arrowhead point to clusters of visceral endoderm cells that display high protein
10 expression. Bars, 50 μ m in (A) and 100 μ m in (B).

Figure 11. *grp94* $-/-$ embryos do not develop a primitive streak.

Analysis of developmental markers in *grp94* mutant embryos by whole mount *in situ* hybridization. In all pairs, the WT embryo is on the left, while the mutant
15 embryo is on the right. All embryos are E7.5 except where noted. The figures shown are representative mutant and WT embryos from 2-7 litters for each marker. **Fig. 11A.** *Oct4* is normally expressed throughout the epiblast at E6.5 and later localized to the primitive streak (ps) at E7.5 in WT embryos. Mutants show sustained overall epiblast (e) expression. **Fig. 11B.** *Otx2* expression at E7.5 is
20 localized to the anterior region of normal embryos, but is expressed in the entire epiblast of the mutant. **Fig. 11C.** *Brachyury* is expressed in the primitive streak at E7.5 in normal embryos, but is not detectable in E7.5 mutant embryos. **Fig. 11D.** *Eomes* is expressed in the extra-embryonic ectoderm (ee) and developing primitive streak at E6.5 and is later localized to the primitive streak at E7.5 in
25 WT embryos. Mutant embryos at E7.5 resemble WT embryos at E6.5. **Fig. 11E.** *Bmp4* expression in E6.5. *Bmp4* is expressed normally in the proximal extra-embryonic ectoderm of both normal and mutant embryos (arrows). **Fig. 11F.** *Bmp4* expression is also detected at E7.5 in the extra-embryonic mesoderm lining the exocoelomic cavity (ec) of WT embryos. Mutant embryos express *Bmp4* only
30 in the proximal extra-embryonic ectoderm, as shown by arrows. **Fig. 11G.** *Lim1* is expressed in the AVE and mesodermal wings of WT E7.5 embryos, but in mutants, mesoderm expression is absent.

Figure 12. Analysis of transcription of mesodermal markers. Fig. 12A. cDNA was prepared from whole E7.5 embryos carefully dissected away from maternal tissue. One wild type (WT) and two *grp94*^{-/-} embryos (KO1 and KO2) are shown. The amount of input cDNA was normalized using HPRT primers in the linear range of the PCR reaction (lanes 1-6). Lane 1-3, 7-9: 0.25, 0.125, 0.063 μ l WT cDNA, respectively. Lanes 4-5, 10-11: 1.5 μ l *grp94*^{-/-} cDNA from two separate ^{-/-} embryos. Fig. 12B. The same cDNAs as in A were used to estimate the expression of *brachyury*, the canonical early mesoderm marker. Adjusting for the differences of input cDNA, the signal from KO1 is approximately 4 times more intense than the signal from KO2, but 2 orders of magnitude weaker than that from WT cDNA. The experiment shown is one out of four. Fig. 12C. RT-PCR quantitation of Eomes expression. cDNA input was normalized using amplification of β -tubulin. Two WT and two mutant (KO) embryos are shown, out of 5 each. Fig. 12D. RT-PCR analysis of VE marker expression. cDNAs from 3 WT and 3 KO embryos were compared, normalized as per β -tubulin expression. TTR, transthyretin; TFN, transferrin; AFP, α fetoprotein; ApoA1, apolipoprotein A1; ApoE, apolipoprotein E; RBP, retinol binding protein.

Figure 13. Heterozygous mice are normal. Fig. 13A. *grp94*^{+/-} mice have a 50% reduction in GRP94 protein. Liver homogenates were prepared from heterozygous and WT mice and equal amounts of total protein were loaded in dilution series from left to right (100, 50, 25 μ g) and analyzed by immunoblotting with anti-GRP94 (9G10) (top panel) or with anti- β tubulin (bottom panel). The three GRP94 bands are the full-length protein and two smaller degradation products that are commonly seen in liver extracts. The blot shown is representative of four repetitions. Essentially the same result was also obtained by analysis of spleen lysates. Fig. 13B. Expression of surface markers on splenocytes. Spleen cells from heterozygous (HET) or WT mice were cultured, treated with 50 μ g/ml LPS to initiate proliferation of B cells and differentiation to Ig secreting cells. Three days later stained with either anti-CD3 antibodies to mark T cells (light gray) or with anti-IgM antibodies to mark B cells (dark grey).

Black traces, unstained cells. Fig. 13C. Induction of Ig secretion in splenocytes. Spleen cells from heterozygous or WT mice where treated with 50 µg/ml LPS as above, and three days later the levels of Ig in the medium were determined by ELISA with either anti-µ or anti-κ antibodies. The ratio of Ig in the medium
 5 before and after LPS treatment was calculated for each spleen culture and is plotted as the magnitude of the induction.

Figure 14. Growth and stress responses of *grp94* ^{-/-} cells.

Wild type and mutant ES cell clones were established from E3.5 blastocysts and
 10 adapted to growth without feeders. Cells were either grown in high glucose medium (4.5 g/L)(Fig. 14A), or adapted to growth in low (0.1 g/L) glucose medium (Fig. 14B) and then their growth rates measured over one week (n=3). Fig. 14C, sensitivity of mutant cells to serum deprivation. Serum was withdrawn at time 0 and the live, attached cell counted at the indicated times (n=4). All the
 15 detached cells were trypan blue positive and failed to grow when re-plated in complete medium. Blue squares, WT cells of clone 42.1. Red circles, mutant cells of clone 14.1. Fig. 14D. Differential sensitivity to Thapsigargin (Tg). WT and mutant ES cells were treated with 300 nM Thapsigargin (+), or mock treated (-), and their viability assessed after 6 hrs, a time where toxicity to WT cells was
 20 still marginal. Figs. 14E-F. WT and mutant ES cells were grown for the indicated times in the presence of absence of 1 mM EGTA and their viability was assessed.

Figure 15. A graph showing that GRP94-deficient cells are sensitive to serum withdrawal.

25

Figure 16. A micrograph and binding assay showing that The N-terminal domain of GRP94 is taken up by dendritic cells.

**Figure 17. A series of micrographs showing that GRP94 knockout
 30 (KO) cells can differentiate into cell types from all three germ layers.**

Figure 18. A series of micrographs and blot showing that GRP94 deficient cells do not differentiate into muscle.

Figure 19. A series of micrographs showing that knockout (KO) embryos arrest around E6.5.

5 **Figure 20 shows the Srivastava model for presentation of peptides to T cells.** A fraction of GRP94 derived from dying tumor cells 10 is loaded with tumor-specific peptide. It binds to CD91 on the plasma membrane of certain dendritic cells and macrophages (APC) and is consequently internalized by receptor-mediated endocytosis. In the endosomal compartment, the peptide is
10 dissociated from GRP94, is extruded to the cytosol of the APC and then is transported via the endoplasmic reticulum peptide transporter (TAP) into the ER lumen, where it is loaded onto newly-synthesized class I molecules 20 and 22. The loaded class I then traffics to the plasma membrane, where it displays the tumor-derived peptide for recognition by T cells. Some peptides may be trimmed
15 by the proteasome 30 after their release from GRP94 and before their loading onto class I molecules.

Figure 21 shows a peptide binding assay. Multi-well plates (96) were coated with the indicated peptides and then incubated with His6 tagged N355,
20 comprising of amino acids 34-355 of GRP94, in the absence or presence of the inhibitor radicicol. Each reaction contained 0.7 μ mole chaperone. VSV8 and PepA are known GRP94 binder peptides, whereas NYL is a non-binder. Lysate, amount of total protein in a bacterial lysate, each containing 0.7 μ mole chaperone, accounting for only partial inhibition of binding. Binding of
25 chaperone to the peptide-coated plates was detected by HRP-conjugated anti-His antibody.

Figures 22A and 22B show the protein and nucleic acid sequences for full length GRP94 . Fig. 22A. GRP94 protein sequence (SEQ ID NO: 2). Fig.
30 **22B. GRP94 nucleic acid (SEQ ID NO: 1).**

DETAILED DESCRIPTION OF THE INVENTION

Since the stress protein GRP94 can augment presentation of peptides to T cells, it is important to define how it, as well as all other HSP90 family members, binds peptides. Having previously shown that the N-terminal half of GRP94 can
5 account for the peptide binding activity of the full-length protein, we now locate this binding site by testing predictions of a molecular docking model. The best predicted site was on the opposite face of the β sheet from the pan-HSP90 radicicol-binding pocket, in close proximity to a deep hydrophobic pocket. The peptide and radicicol binding sites are distinct, as shown by the ability of a
10 radicicol-refractive mutant to bind peptide. When the fluorophore acrylodan is attached to Cys117 within the hydrophobic pocket, its fluorescence is reduced upon peptide binding, consistent with proximity of the two ligands. Substitution of His125, which contacts the bound peptide, compromises peptide binding activity. We conclude that peptide binds to the concave face of the β sheet of the
15 N terminal domain, where binding is regulated during the action cycle of the chaperone. In connection with these studies we have also designed truncated GRP94 polypeptides which retain certain functions of GRP94. Such peptides are useful in screening methods to identify agonists and antagonists of GRP94 mediated biological functions.

20 GP94 is expressed ubiquitously, but has few known client proteins, none of them involved in important developmental checkpoints. Targeted disruption of the murine GRP94 gene shows that it has an essential function in embryonic development. *Grp94* $-/-$ embryos die *in utero* on day 7 of gestation, at the egg cylinder stage of development. They fail to develop mesoderm, a primitive
25 streak, and the proamniotic cavity, the main differentiation events that normally occur at that stage and do not express key genes involved in mesoderm induction. The developmental defect is not due to dilution of maternal GRP94 and seems to reflect the activities of the chaperone. *Grp94* $-/-$ cells divide at similar pace to their wild type counterparts. Furthermore, despite the known transcriptional
30 regulation of GPR94 by low glucose tension, mutant ES cells proliferated like wild type cells in low glucose medium. On the other hand, mutant cells were much more sensitive to serum deprivation as well as to perturbation of calcium homeostasis. These data suggest that the requirements for GRP94 are very

selective. We hypothesize that some secreted or cell-surface proteins, critical for mesoderm induction, depend on GRP94 for their proper expression, and that in the absence of this chaperone they fail to be efficiently presented when cell-cell interactions specify the proper fates of embryonic cells.

5 GRP 94 plays a role in tumor rejection. Enhancing this activity should prove useful for the treatment of malignancy. Accordingly, the GRP94 based compositions of the invention can be used in the creation of tumor vaccines.

The following definitions are provided to facilitate an understanding of the present invention.

10 Following long-standing patent law convention, the terms "a" and "an" mean "one or more" when used in this application, including the claims.

As used herein the term "GRP94 protein" is meant to refer to a molecular chaperone which resides in the endoplasmic reticulum and is also known in the art as gp96, ERp99, and endoplasmin. GRP94 is found only in higher plants and
15 metazoans (Nicchitta (1998) Curr Opin Immunol 10:103-109). Stress proteins such as GRP94 are involved in directing the proper folding and trafficking of newly synthesized proteins and in conferring protection to the cell during conditions of heat shock, oxidative stress, hypoxic/anoxic conditions, nutrient deprivation, other physiological stresses, and disorders or traumas that promote
20 such stress conditions such as, for example, stroke and myocardial infarction.

As used herein, the term "ligand binding domain (LBD) of GRP94" refers to the region of GRP94 where the nucleotides ADP, ATP or NECA, or the fungal metabolites geldanamycin, 17AAG or radicicol bind. Even more preferably, our work shows that GRP94 fragments comprising amino acids 34-355 (SEQ ID NO:
25 4, encoded by SEQ ID NO: 3), preferably residues 34-221 (SEQ ID NO: 6, encoded by SEQ ID NO: 5, preferably residues 70-221 (SEQ ID NO: 8, encoded by SEQ ID NO: 7) of mammalian (human, canine) GRP94. These are sufficient for the binding activities of the entire, full-length protein.

As used herein, the terms "binding pocket of the GRP94 ligand binding
30 domain", "GRP94 ligand binding pocket" and "GRP94 binding pocket" are used interchangeably, and refer to the large cavity within the GRP94 ligand binding domain (LBD) where a ligand can bind. This cavity can be empty, or can contain water molecules or other molecules from the solvent, or can contain ligand

atoms. The binding pocket also includes regions of space near the "main" binding pocket not occupied by atoms of GRP94 but that are near the "main" binding pocket, and that are contiguous with the "main" binding pocket.

"Antigenic molecule" as used herein refers to the peptides with which GRP94 endogenously associates in vivo (e.g., in infected cells or precancerous or cancerous tissue) as well as exogenous antigens/immunogens (i.e., not complexed with GRP94 in vivo) or antigenic/immunogenic fragments and derivatives thereof.

The phrase "shared tumor antigens" refers to those tumor specific antigens that are commonly found in patients having similar tumor types. Representative shared tumor antigens are provided in Table 3.

The term "biological activity" is meant to refer to a molecule having a biological or physiological effect in a subject. Adjuvant activity is an example of a biological activity. Activating or inducing production of other biological molecules having adjuvant activity is also a contemplated biological activity.

The term "adjuvant activity" is meant to refer to a molecule having the ability to enhance or otherwise modulate the response of a vertebrate subject's immune system to an antigen.

The term "immune system" includes all the cells, tissues, systems, structures and processes, including non-specific and specific categories, that provide a defense against antigenic molecules, including potential pathogens, in a vertebrate subject. As is well known in the art, the non-specific immune system includes phagocytic cells such as neutrophils, monocytes, tissue macrophages, Kupffer cells, alveolar macrophages, dendritic cells and microglia. The specific immune system refers to the cells and other structures that impart specific immunity within a host. Included among these cells are the lymphocytes, particularly the B cell lymphocytes and the T cell lymphocytes. These cells also include natural killer (NK) cells. Additionally, antibody-producing cells, like B lymphocytes, and the antibodies produced by the antibody-producing cells are also included within the term "immune system".

The term "immune response" is meant to refer to any response to an antigen or antigenic determinant by the immune system of a vertebrate subject. Exemplary immune responses include humoral immune responses (e.g.

production of antigen-specific antibodies) and cell-mediated immune responses (e.g. lymphocyte proliferation), as defined herein below.

5 The term "systemic immune response" is meant to refer to an immune response in the lymph node-, spleen-, or gut-associated lymphoid tissues wherein cells, such as B lymphocytes, of the immune system are developed. For example, a systemic immune response can comprise the production of serum IgG's. Further, systemic immune response refers to antigen-specific antibodies circulating in the blood stream and antigen-specific cells in lymphoid tissue in systemic compartments such as the spleen and lymph nodes.

10 The terms "humoral immunity" or "humoral immune response" are meant to refer to the form of acquired immunity in which antibody molecules are secreted in response to antigenic stimulation.

The terms "cell-mediated immunity" and "cell-mediated immune response" are meant to refer to the immunological defense provided by lymphocytes, such as that defense provided by T cell lymphocytes when they come into close proximity to their victim cells. A cell-mediated immune response also comprises lymphocyte proliferation. When "lymphocyte proliferation" is measured, the ability of lymphocytes to divide in response to specific antigen is measured. Lymphocyte proliferation is meant to refer to B cell, T-helper cell or CTL cell proliferation.

20 The term "CTL response" is meant to refer to the ability of an antigen-specific cell to lyse and kill a cell expressing the specific antigen. As described herein below, standard, art-recognized CTL assays are performed to measure CTL activity. In such assays, the cell which is being killed is referred to as the "target cell".

"Adoptive immunotherapy" as used herein refers to a therapeutic approach with particular applicability to cancer whereby immune cells with an antitumor reactivity are administered to a tumor-bearing host, with the aim that the cells mediate either directly or indirectly, the regression of an established tumor.

30 An "immunogenic composition" is meant to refer to a composition that can elicit an immune response. A vaccine is contemplated to fall within the

meaning of the term "immunogenic composition", in accordance with the present invention.

The term "a biological response modifier" is meant to refer to a molecule having the ability to enhance or otherwise modulate a subject's response to a particular stimulus, such as presentation of an antigen.

As used herein, the terms "candidate substance" and "candidate compound" are used interchangeably and refer to a substance that is believed to interact with another moiety as a biological response modifier. For example, a representative candidate compound is believed to interact with a complete GRP94 protein, or fragment thereof, and which can be subsequently evaluated for such an interaction. Exemplary candidate compounds that can be investigated using the methods of the present invention include, but are not restricted to, agonists and antagonists of a GRP 94 protein, viral epitopes, peptides, enzymes, enzyme substrates, co-factors, lectins, sugars, oligonucleotides or nucleic acids, oligosaccharides, proteins, chemical compounds small molecules, and monoclonal antibodies.

As used herein, the term "modulate" means an increase, decrease, or other alteration of any or all chemical and biological activities or properties of a wild-type or mutant GRP94 polypeptide. The term "modulation" as used herein refers to both upregulation (i.e., activation or stimulation) and downregulation (i.e. inhibition or suppression) of a response.

As used herein, the term "agonist" means an agent that supplements or potentiates the biological activity of a functional GRP94 protein.

As used herein, the term "antagonist" means an agent that decreases or inhibits the biological activity of a functional GRP94 protein, or that supplements or potentiates the biological activity of a naturally occurring or engineered non-functional GRP94 protein.

As used herein, the term "alpha helix" refers to the conformation of a polypeptide chain wherein the polypeptide backbone is wound around the long axis of the molecule in a left-handed or right-handed direction, and the R groups of the amino acids protrude outward from the helical backbone, wherein the repeating unit of the structure is a single turn of the helix, which extends about 0.56 nm along the long axis.

As used herein, the term "β strand" refers to the conformation of a polypeptide chain stretched into an extended zig-zig conformation. β strands of polypeptide chains aligned side-by-side form "β sheets". Strands that run "parallel" all run in the same direction. Strands of polypeptide chains that are
5 "antiparallel" run in the opposite direction to each other.

As used herein, the terms "cells," "host cells" or "recombinant host cells" are used interchangeably and mean not only to the particular subject cell, but also to the progeny or potential progeny of such a cell. Because certain modifications can occur in succeeding generations due to either mutation or environmental
10 influences, such progeny might not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

The terms "chimeric protein" or "fusion protein" are used interchangeably herein and mean a fusion of a first amino acid sequence encoding a GRP94 polypeptide with a second amino acid sequence defining a polypeptide domain
15 foreign to, and not homologous with, any domain of GRP94. For example, a chimeric protein can include a foreign domain that is found in an organism that also expresses the first protein, or it can be an "interspecies" or "intergenic" fusion of protein structures expressed by different kinds of organisms. In general, a fusion protein can be represented by the general formula X-GRP94-Y, wherein
20 GRP94 represents a portion of the protein which is derived from a GRP94 polypeptide, and X and Y are independently absent or represent amino acid sequences which are not related to a GRP94 sequence in an organism, which includes naturally occurring mutants.

As used herein, the term "detecting" means confirming the presence of a
25 target entity by observing the occurrence of a detectable signal, such as a radiologic, spectroscopic or another signal that will appear exclusively in the presence of the target entity.

As used herein, the term "interact" means detectable interactions between molecules, such as can be detected using, for example, a yeast two-hybrid assay.
30 The term "interact" is also meant to include "binding" interactions between molecules. Interactions can, for example, be protein-protein or protein-nucleic acid in nature.

As used herein, the term "modified" means an alteration from an entity's normally occurring state. An entity can be modified by removing discrete chemical units or by adding discrete chemical units. The term "modified" encompasses detectable labels as well as those entities added as aids in
5 purification.

As used herein, the term "mutation" carries its traditional connotation and means a change, inherited, naturally occurring or introduced, in a nucleic acid or polypeptide sequence, and is used in its sense as generally known to those of skill in the art.

10 As used herein, the term "partial agonist" means an entity that can bind to a target and induce only part of the changes in the target that are induced by agonists. The differences can be qualitative or quantitative. Thus, a partial agonist can induce some of the conformation changes induced by agonists, but not others, or it can only induce certain changes to a limited extent.

15 As used herein, the term "partial antagonist" means an entity that can bind to a target and inhibit only part of the changes in the target that are induced by antagonists. The differences can be qualitative or quantitative. Thus, a partial antagonist can inhibit some of the conformation changes induced by an antagonist, but not others, or it can inhibit certain changes to a limited extent.

20 "Nucleic acid" or a "nucleic acid molecule" as used herein refers to any DNA or RNA molecule, either single or double stranded and, if single stranded, the molecule of its complementary sequence in either linear or circular form. In discussing nucleic acid molecules, a sequence or structure of a particular nucleic acid molecule may be described herein according to the normal convention of
25 providing the sequence in the 5' to 3' direction. With reference to nucleic acids of the invention, the term "isolated nucleic acid" is sometimes used. This term, when applied to DNA, refers to a DNA molecule that is separated from sequences with which it is immediately contiguous in the naturally occurring genome of the organism in which it originated. For example, an "isolated nucleic
30 acid" may comprise a DNA molecule inserted into a vector, such as a plasmid or virus vector, or integrated into the genomic DNA of a prokaryotic or eukaryotic cell or host organism.

When applied to RNA, the term "isolated nucleic acid" refers primarily to an RNA molecule encoded by an isolated DNA molecule as defined above.

Alternatively, the term may refer to an RNA molecule that has been sufficiently separated from other nucleic acids with which it would be associated in its natural state (i.e., in cells or tissues). An "isolated nucleic acid" (either DNA or RNA) may further represent a molecule produced directly by biological or synthetic means and separated from other components present during its production.

The terms "percent similarity", "percent identity" and "percent homology" when referring to a particular sequence are used as set forth in the University of Wisconsin GCG software program.

The term "substantially pure" refers to a preparation comprising at least 50 60% by weight of a given material (e.g., nucleic acid, oligonucleotide, protein, etc.). More preferably, the preparation comprises at least 75% by weight, and most preferably 90-95% by weight of the given compound. Purity is measured by methods appropriate for the given compound (e.g. chromatographic methods, agarose or polyacrylamide gel electrophoresis, HPLC analysis, and the like).

A "replicon" is any genetic element, for example, a plasmid, cosmid, bacmid, plastid, phage or virus, that is capable of replication largely under its own control. A replicon may be either RNA or DNA and may be single or double stranded.

A "vector" is a replicon, such as a plasmid, cosmid, bacmid, phage or virus, to which another genetic sequence or element (either DNA or RNA) may be attached so as to bring about the replication of the attached sequence or element.

An "expression operon" refers to a nucleic acid segment that may possess transcriptional and translational control sequences, such as promoters, enhancers, translational start signals (e.g., ATG or AUG codons), polyadenylation signals, terminators, and the like, and which facilitate the expression of a polypeptide coding sequence in a host cell or organism.

The term "oligonucleotide" as used herein refers to sequences, primers and probes of the present invention, and is defined as a nucleic acid molecule comprised of two or more ribo or deoxyribonucleotides, preferably more than

three. The exact size of the oligonucleotide will depend on various factors and on the particular application and use of the oligonucleotide.

The phrase "specifically hybridize" refers to the association between two single stranded nucleic acid molecules of sufficiently complementary sequence to permit such hybridization under pre determined conditions generally used in the art (sometimes termed "substantially complementary"). In particular, the term refers to hybridization of an oligonucleotide with a substantially complementary sequence contained within a single stranded DNA or RNA molecule of the invention, to the substantial exclusion of hybridization of the oligonucleotide with single stranded nucleic acids of non complementary sequence.

The term "probe" as used herein refers to an oligonucleotide, polynucleotide or nucleic acid, either RNA or DNA, whether occurring naturally as in a purified restriction enzyme digest or produced synthetically, which is capable of annealing with or specifically hybridizing to a nucleic acid with sequences complementary to the probe. A probe may be either single stranded or double stranded. The exact length of the probe will depend upon many factors, including temperature, source of probe and method of use. For example, for diagnostic applications, depending on the complexity of the target sequence, the oligonucleotide probe typically contains 15 25 or more nucleotides, although it may contain fewer nucleotides. The probes herein are selected to be "substantially" complementary to different strands of a particular target nucleic acid sequence. This means that the probes must be sufficiently complementary so as to be able to "specifically hybridize" or anneal with their respective target strands under a set of pre-determined conditions. Therefore, the probe sequence need not reflect the exact complementary sequence of the target. For example, a non complementary nucleotide fragment may be attached to the 5' or 3' end of the probe, with the remainder of the probe sequence being complementary to the target strand. Alternatively, non complementary bases or longer sequences can be interspersed into the probe, provided that the probe sequence has sufficient complementarity with the sequence of the target nucleic acid to anneal therewith specifically.

The term "primer" as used herein refers to an oligonucleotide, either RNA or DNA, either single stranded or double stranded, either derived from a

biological system, generated by restriction enzyme digestion, or produced synthetically which, when placed in the proper environment, is able to functionally act as an initiator of template-dependent nucleic acid synthesis. When presented with an appropriate nucleic acid template, suitable nucleoside triphosphate precursors of nucleic acids, a polymerase enzyme, suitable cofactors and conditions such as appropriate temperature and pH, the primer may be extended at its 3' terminus by the addition of nucleotides by the action of a polymerase or similar activity to yield a primer extension product. The primer may vary in length depending on the particular conditions and requirement of the application. For example, in diagnostic applications, the oligonucleotide primer is typically 15-25 or more nucleotides in length. The primer must be of sufficient complementarity to the desired template to prime the synthesis of the desired extension product, that is, to be able to anneal with the desired template strand in a manner sufficient to provide the 3' hydroxyl moiety of the primer in appropriate juxtaposition for use in the initiation of synthesis by a polymerase or similar enzyme. It is not required that the primer sequence represent an exact complement of the desired template. For example, a non complementary nucleotide sequence may be attached to the 5' end of an otherwise complementary primer. Alternatively, non complementary bases may be interspersed within the oligonucleotide primer sequence, provided that the primer sequence has sufficient complementarity with the sequence of the desired template strand to functionally provide a template primer complex for the synthesis of the extension product.

Polymerase chain reaction (PCR) has been described in U.S. Patents Nos. 4,683,195, 4,800,195, and 4,965,188, the entire disclosures of which are incorporated by reference herein.

As used herein, the terms "reporter," "reporter system", "reporter gene," or "reporter gene product" shall mean an operative genetic system in which a nucleic acid comprises a gene that encodes a product that when expressed produces a reporter signal that is a readily measurable, e.g., by biological assay, immunoassay, radio immunoassay, or by colorimetric, fluorogenic, chemiluminescent or other methods. The nucleic acid may be either RNA or DNA, linear or circular, single or double stranded, antisense or sense polarity,

and is operatively linked to the necessary control elements for the expression of the reporter gene product. The required control elements will vary according to the nature of the reporter system and whether the reporter gene is in the form of DNA or RNA, but may include, but not be limited to, such elements as

5 promoters, enhancers, translational control sequences, poly A addition signals, transcriptional termination signals and the like.

The terms "transform", "transfect", "transduce", shall refer to any method or means by which a nucleic acid is introduced into a cell or host organism and may be used interchangeably to convey the same meaning. Such methods

10 include, but are not limited to, transfection, electroporation, microinjection, PEG-fusion and the like.

The introduced nucleic acid may or may not be integrated (covalently linked) into nucleic acid of the recipient cell or organism. In bacterial, yeast, plant and mammalian cells, for example, the introduced nucleic acid may be

15 maintained as an episomal element or independent replicon such as a plasmid. Alternatively, the introduced nucleic acid may become integrated into the nucleic acid of the recipient cell or organism and be stably maintained in that cell or organism and further passed on or inherited to progeny cells or organisms of the recipient cell or organism. Finally, the introduced nucleic acid may exist in the

20 recipient cell or host organism only transiently.

The term "selectable marker gene" refers to a gene that when expressed confers a selectable phenotype, such as antibiotic resistance, on a transformed cell or plant.

The term "operably linked" means that the regulatory sequences necessary

25 for expression of the coding sequence are placed in the DNA molecule in the appropriate positions relative to the coding sequence so as to effect expression of the coding sequence. This same definition is sometimes applied to the arrangement of transcription units and other transcription control elements (e.g. enhancers) in an expression vector.

30 Amino acid residues are identified in the present application according to conventional three letter or one letter abbreviations.

Amino acid residues described herein are preferred to be in the "L" isomeric form. However, residues in the "D" isomeric form may be substituted

for any L amino acid residue, provided the desired properties of the polypeptide are retained. All amino acid residue sequences represented herein conform to the conventional left-to-right amino terminus to carboxy terminus orientation.

5 The term "isolated protein" or "isolated and purified protein" is sometimes used herein. This term refers primarily to a protein produced by expression of an isolated nucleic acid molecule of the invention. Alternatively, this term may refer to a protein that has been sufficiently separated from other proteins with which it would naturally be associated, so as to exist in "substantially pure" form. "Isolated" is not meant to exclude artificial or synthetic mixtures with other
10 compounds or materials, or the presence of impurities that do not interfere with the fundamental activity, and that may be present, for example, due to incomplete purification, or the addition of stabilizers.

"Mature protein" or "mature polypeptide" shall mean a polypeptide possessing the sequence of the polypeptide after any processing events that
15 normally occur to the polypeptide during the course of its genesis, such as proteolytic processing from a polyprotein precursor. In designating the sequence or boundaries of a mature protein, the first amino acid of the mature protein sequence is designated as amino acid residue 1. As used herein, any amino acid residues associated with a mature protein not naturally found associated with that
20 protein that precedes amino acid 1 are designated amino acid -1, 2, 3 and so on. For recombinant expression systems, a methionine initiator codon is often utilized for purposes of efficient translation. This methionine residue in the resulting polypeptide, as used herein, would be positioned at -1 relative to the mature GRP94 protein sequence.

25 A low molecular weight "peptide analog" shall mean a natural or mutant (mutated) analog of a GRP94 protein, comprising a linear or discontinuous series of fragments of that protein and which may have one or more amino acids replaced with other amino acids and which has altered, enhanced or diminished biological activity when compared with the parent or non-mutated protein.

30 The present invention also includes active portions, fragments, derivatives and functional or non functional mimetics of GRP94 polypeptides, or proteins of the invention. An "active portion" of such a polypeptide means a peptide that is

less than the full length polypeptide, but which retains measurable biological activity.

A "fragment" or "portion" of a GRP94 polypeptide means a stretch of amino acid residues of at least about five to seven contiguous amino acids, often
5 at least about seven to nine contiguous amino acids, typically at least about nine to thirteen contiguous amino acids and, most preferably, at least about twenty to thirty or more contiguous amino acids. Fragments of the GRP94 polypeptide sequence, antigenic determinants, or epitopes are useful for eliciting immune responses to a portion of the GRP94 protein amino acid sequence for the effective
10 production of immunospecific anti-GRP94 antibodies.

Different "variants" of the GRP94 polypeptides exist in nature. These variants may be alleles characterized by differences in the nucleotide sequences of the gene coding for the protein, or may involve different RNA processing or post translational modifications. The skilled person can produce variants having
15 single or multiple amino acid substitutions, deletions, additions or replacements. These variants may include but are not limited to: (a) variants in which one or more amino acids residues are substituted with conservative or non conservative amino acids, (b) variants in which one or more amino acids are added to the polypeptide, (c) variants in which one or more amino acids include a substituent
20 group, and (d) variants in which the polypeptide is fused with another peptide or polypeptide such as a fusion partner, a protein tag or other chemical moiety, that may confer useful properties to the GRP94-related polypeptide, such as, for example, an epitope for an antibody, a polyhistidine sequence, a membrane fusion sequence, a cytoplasmic targeting sequence, a nuclear targeting sequence,
25 a biotin moiety and the like. Other GRP94 polypeptides of the invention include variants in which amino acid residues from one species are substituted for the corresponding residue in another species, either at the conserved or non conserved positions. In another embodiment, amino acid residues at non conserved positions are substituted with conservative or non conservative
30 residues. The techniques for obtaining these variants, including genetic (suppressions, deletions, mutations, etc.), chemical, and enzymatic techniques are known to the person having ordinary skill in the art. To the extent such allelic variations, analogues, fragments, derivatives, mutants, and modifications,

including alternative nucleic acid processing forms and alternative post translational modification forms, result in derivatives of the apoptosis modulator polypeptides that retain any of the biological properties of the GRP94s, they are included within the scope of this invention.

5 The term "functional" as used herein implies that the nucleic or amino acid sequence is functional for the recited assay or purpose.

 The phrase "consisting essentially of" when referring to a particular nucleotide or amino acid means a sequence having the properties of a given SEQ ID NO. For example, when used in reference to an amino acid sequence, the
10 phrase includes the sequence per se and molecular modifications that would not affect the basic and novel characteristics of the sequence.

 The term "tag," "tag sequence" or "protein tag" refers to a chemical moiety, either a nucleotide, oligonucleotide, polynucleotide or an amino acid, peptide or protein or other chemical, that when added to another sequence,
15 provides additional utility or confers useful properties, particularly in the detection or isolation, of that sequence. Thus, for example, a homopolymer nucleic acid sequence or a nucleic acid sequence complementary to a capture oligonucleotide may be added to a primer or probe sequence to facilitate the subsequent isolation of an extension product or hybridized product. In the case
20 of protein tags, histidine residues (e.g., 4 to 8 consecutive histidine residues) may be added to either the amino or carboxy terminus of a protein to facilitate protein isolation by chelating metal chromatography. Alternatively, amino acid sequences, peptides, proteins or fusion partners representing epitopes or binding determinants reactive with specific antibody molecules or other molecules (e.g.,
25 flag epitope, c myc epitope, transmembrane epitope of the influenza A virus hemagglutinin protein, protein A, cellulose binding domain, calmodulin binding protein, maltose binding protein, chitin binding domain, glutathione S transferase, and the like) may be added to proteins to facilitate protein isolation by procedures such as affinity or immunoaffinity chromatography. Chemical tag moieties
30 include such molecules as biotin, which may be added to either nucleic acids or proteins and facilitates isolation or detection by interaction with avidin reagents, and the like. Numerous other tag moieties are known to, and can be envisioned

by the trained artisan, and are contemplated to be within the scope of this definition.

A "clone" or "clonal cell population" is a population of cells derived from a single cell or common ancestor by mitosis.

5 A "cell line" is a clone of a primary cell or cell population that is capable of stable growth in vitro for many generations.

An "antibody" or "antibody molecule" is any immunoglobulin, including antibodies and fragments thereof, that binds to a specific antigen, such as epitopes of an GRP94 protein. The term includes polyclonal, monoclonal,
10 chimeric, and bispecific antibodies. As used herein, antibody or antibody molecule contemplates both an intact immunoglobulin molecule and an immunologically active portion of an immunoglobulin molecule such as those portions known in the art as Fab, Fab', F(ab')₂ and F(v).

15 I. Preparation of GRP94-Encoding Nucleic Acid Molecules, GRP94 Polypeptides, and Fragments Thereof

A. Nucleic Acid Molecules

Nucleic acid molecules encoding the GRP94-related sequences of the invention may be prepared by two general methods: (1) Synthesis from
20 appropriate nucleotide triphosphates, or (2) Isolation from biological sources. Both methods utilize protocols well known in the art.

The availability of nucleotide sequence information, such as the full length cDNA having Sequence I.D. No. 1, enables preparation of an isolated nucleic acid molecule of the invention by oligonucleotide synthesis. Synthetic
25 oligonucleotides may be prepared by the phosphoramidite method employed in the Applied Biosystems 38A DNA Synthesizer or similar devices. The resultant construct may be purified according to methods known in the art, such as high performance liquid chromatography (HPLC). Long, double-stranded polynucleotides, such as a DNA molecule of the present invention, must be
30 synthesized in stages, due to the size limitations inherent in current oligonucleotide synthetic methods. Thus, for example, a 2.4 kb double-stranded molecule may be synthesized as several smaller segments of appropriate complementarity. Complementary segments thus produced may be annealed

such that each segment possesses appropriate cohesive termini for attachment of an adjacent segment. Adjacent segments may be ligated by annealing cohesive termini in the presence of DNA ligase to construct an entire 2.4 kb double-stranded molecule. A synthetic DNA molecule so constructed may then be
 5 cloned and amplified in an appropriate vector.

Nucleic acid sequences encoding GRP94 or homologs thereof may be isolated from appropriate biological sources using methods known in the art. In a preferred embodiment, a cDNA clone is isolated from a cDNA expression library of human origin. In an alternative embodiment, utilizing the sequence
 10 information provided by the cDNA sequence, genomic clones encoding GRP94 may be isolated. Alternatively, cDNA or genomic clones having homology with GRP94 may be isolated from other species, such as mouse, using oligonucleotide probes corresponding to predetermined sequences within the GRP94 gene.

In accordance with the present invention, nucleic acids having the
 15 appropriate level of sequence homology with the protein coding region of Sequence I.D. No. 1 may be identified by using hybridization and washing conditions of appropriate stringency. For example, hybridizations may be performed, according to the method of Sambrook et al., (supra) using a hybridization solution comprising: 5X SSC, 5X Denhardt's reagent, 0.5-1.0%
 20 SDS, 100 µg/ml denatured, fragmented salmon sperm DNA, 0.05% sodium pyrophosphate and up to 50% formamide. Hybridization is carried out at 37-42°C for at least six hours. Following hybridization, filters are washed as follows: (1) 5 minutes at room temperature in 2X SSC and 0.5-1% SDS; (2) 15 minutes at room temperature in 2X SSC and 0.1% SDS; (3) 30 minutes-1 hour at
 25 37°C in 1X SSC and 1% SDS; (4) 2 hours at 42-65°C in 1X SSC and 1% SDS, changing the solution every 30 minutes.

One common formula for calculating the stringency conditions required to achieve hybridization between nucleic acid molecules of a specified sequence homology is (Sambrook et al., 1989):

$$30 \quad T_m = 81.5^{\circ}\text{C} + 16.6\text{Log} [\text{Na}^+] + 0.41(\% \text{ G+C}) - 0.63 (\% \text{ formamide}) - 600/\text{\#bp in duplex}$$

As an illustration of the above formula, using $[\text{Na}^+] = [0.368]$ and 50% formamide, with GC content of 42% and an average probe size of 200 bases, the T_m is 57°C. The T_m of a DNA duplex decreases by 1 - 1.5°C with every 1%

decrease in homology. Thus, targets with greater than about 75% sequence identity would be observed using a hybridization temperature of 42°C. Such a sequence would be considered substantially homologous to the nucleic acid sequence of the present invention.

5 The stringency of the hybridization and wash depend primarily on the salt concentration and temperature of the solutions. In general, to maximize the rate of annealing of the probe with its target, the hybridization is usually carried out at salt and temperature conditions that are 20-25°C below the calculated T_m of the hybrid. Wash conditions should be as stringent as possible for the degree of
10 identity of the probe for the target. In general, wash conditions are selected to be approximately 12-20°C below the T_m of the hybrid. In regards to the nucleic acids of the current invention, a moderate stringency hybridization is defined as hybridization in 6X SSC, 5X Denhardt's solution, 0.5% SDS and 100 µg/ml denatured salmon sperm DNA at 42°C, and washed in 2X SSC and 0.5% SDS at
15 55°C for 15 minutes. A high stringency hybridization is defined as hybridization in 6X SSC, 5X Denhardt's solution, 0.5% SDS and 100 µg/ml denatured salmon sperm DNA at 42°C, and washed in 1X SSC and 0.5% SDS at 65°C for 15 minutes. A very high stringency hybridization is defined as hybridization in 6X SSC, 5X Denhardt's solution, 0.5% SDS and 100 µg/ml denatured salmon sperm
20 DNA at 42°C, and washed in 0.1X SSC and 0.5% SDS at 65°C for 15 minutes.

Nucleic acids for use in the present invention may be maintained as DNA in any convenient cloning vector. In a preferred embodiment, clones are maintained in a plasmid cloning/expression vector, such as pBluescript (Stratagene, La Jolla, CA), which is propagated in a suitable *E. coli* host cell.
25 Genomic clones of the invention encoding the human or mouse GRP94 gene may be maintained in lambda phage FIX II (Stratagene).

GRP94-encoding nucleic acid molecules of the invention include cDNA, genomic DNA, RNA, and fragments thereof which may be single- or double-stranded. Thus, this invention provides oligonucleotides (sense or antisense
30 strands of DNA or RNA) having sequences capable of hybridizing with at least one sequence of a nucleic acid molecule of the present invention, such as selected segments of the cDNA having SEQ ID NO: 1.

It will be appreciated by persons skilled in the art that variants (e.g., allelic variants) of these sequences exist in the human population, and must be taken into account when designing and/or utilizing oligos of the invention. Accordingly, it is within the scope of the present invention to encompass such
5 variants, with respect to the GRP94 sequences disclosed herein or the oligos targeted to specific locations on the respective genes or RNA transcripts. With respect to the inclusion of such variants, the term "natural allelic variants" is used herein to refer to various specific nucleotide sequences and variants thereof that would occur in a human population. Genetic polymorphisms giving rise to
10 conservative or neutral amino acid substitutions in the encoded protein are examples of such variants. Additionally, the term "substantially complementary" refers to oligo sequences that may not be perfectly matched to a target sequence, but the mismatches do not materially affect the ability of the oligo to hybridize with its target sequence under the conditions described.

15 Thus, the coding sequence may be that shown in SEQ ID NO: 1, or it may be a mutant, variant, derivative or allele of this sequence. The sequence may differ from that shown by a change which is one or more of addition, insertion, deletion and substitution of one or more nucleotides of the sequence shown. Changes to a nucleotide sequence may result in an amino acid change at the
20 protein level, or not, as determined by the genetic code.

Thus, nucleic acid according to the present invention may include a sequence different from the sequence shown in SEQ ID NO: 1 yet encode a polypeptide with the same amino acid sequence.

On the other hand, the encoded polypeptide may comprise an amino acid
25 sequence which differs by one or more amino acid residues from the amino acid sequence shown in SEQ ID NO: 2. Nucleic acid encoding a polypeptide which is an amino acid sequence mutant, variant, derivative or allele of the sequence shown in SEQ ID NO:2 is further provided by the present invention. Nucleic acid encoding such a polypeptide may show greater than 60% homology with the
30 coding sequence shown in Sequence I.D. No. 1, greater than about 70% homology, greater than about 80% homology, greater than about 90% homology or greater than about 95% homology.

The present invention provides a method of obtaining nucleic acid of interest, the method including hybridization of a probe having part or all of the sequence shown in SEQ ID NO: 1 or a complementary sequence, to target nucleic acid. Hybridization is generally followed by identification of successful
5 hybridization and isolation of nucleic acid which has hybridized to the probe, which may involve one or more steps of PCR.

Such oligonucleotide probes or primers, as well as the full-length sequence (and mutants, alleles, variants, and derivatives) are useful in screening a test sample containing nucleic acid for the presence of alleles, mutants or
10 variants, especially those that have enhanced tumor antigen binding activity, the probes hybridizing with a target sequence from a sample obtained from the individual being tested. The conditions of the hybridization can be controlled to minimize non-specific binding, and preferably stringent to moderately stringent hybridization conditions are used. The skilled person is readily able to design
15 such probes, label them and devise suitable conditions for hybridization reactions, assisted by textbooks such as Sambrook et al (1989) and Ausubel et al (1992).

In some preferred embodiments, oligonucleotides according to the present invention that are fragments of the sequences shown in SEQ ID NO: 1, or any
20 allele associated with peptide binding activity, are at least about 10 nucleotides in length, more preferably at least 15 nucleotides in length, more preferably at least about 20 nucleotides in length. Such fragments themselves individually represent aspects of the present invention. Fragments and other oligonucleotides may be used as primers or probes as discussed but may also be generated (e.g. by PCR)
25 in methods concerned with determining the presence in a test sample of a sequence encoding a GRP94 polypeptide.

B. Proteins

GRP94 protein is a molecular chaperone which resides in the
30 endoplasmic reticulum and functions to help other secreted proteins or membrane receptors that form in the endoplasmic reticulum to attain their three-dimensional shapes. A full-length GRP94 protein of the present invention may be prepared in a variety of ways, according to known methods. The protein may be purified

from appropriate sources, e.g., transformed bacterial or animal cultured cells or tissues, by immunoaffinity purification. However, this is not a preferred method due to the low amount of protein likely to be present in a given cell type at any time. The availability of nucleic acid molecules encoding GRP94 enables
5 production of the protein using *in vitro* expression methods known in the art. For example, a cDNA or gene may be cloned into an appropriate *in vitro* transcription vector, such as pSP64 or pSP65 for *in vitro* transcription, followed by cell-free translation in a suitable cell-free translation system, such as wheat germ or rabbit reticulocyte lysates. *In vitro* transcription and translation systems are
10 commercially available, e.g., from Promega Biotech, Madison, Wisconsin or BRL, Rockville, Maryland.

Alternatively, according to a preferred embodiment, larger quantities of GRP94 may be produced by expression in a suitable prokaryotic or eukaryotic system. For example, part or all of a DNA molecule, such as the cDNA having
15 Sequence I.D. No. 1 or desired fragments thereof, may be inserted into a plasmid vector adapted for expression in a bacterial cell, such as *E. coli*. Such vectors comprise the regulatory elements necessary for expression of the DNA in the host cell (e.g. *E. coli*) positioned in such a manner as to permit expression of the DNA in the host cell. Such regulatory elements required for expression include
20 promoter sequences, transcription initiation sequences and, optionally, enhancer sequences.

GRP94 produced by gene expression in a recombinant prokaryotic or eukaryotic system may be purified according to methods known in the art. In a preferred embodiment, a commercially available expression/secretion system can
25 be used, whereby the recombinant protein is expressed and thereafter secreted from the host cell, to be easily purified from the surrounding medium. If expression/secretion vectors are not used, an alternative approach involves purifying the recombinant protein by affinity separation, such as by immunological interaction with antibodies that bind specifically to the
30 recombinant protein or nickel columns for isolation of recombinant proteins tagged with 6-8 histidine residues at their N-terminus or C-terminus. Alternative tags may comprise the FLAG epitope or the hemagglutinin epitope. Such methods are commonly used by skilled practitioners.

The GRP94 proteins or peptide fragments of the invention, prepared by the aforementioned methods, may be analyzed according to standard procedures. For example, such proteins may be subjected to amino acid sequence analysis, according to known methods.

5 As discussed above, a convenient way of producing a polypeptide according to the present invention is to express nucleic acid encoding it, by use of the nucleic acid in an expression system. The use of expression systems has reached an advanced degree of sophistication today.

Accordingly, the present invention also encompasses a method of making
10 a polypeptide (as disclosed), the method including expression from nucleic acid encoding the polypeptide (generally nucleic acid according to the invention). This may conveniently be achieved by growing a host cell in culture, containing such a vector, under appropriate conditions which cause or allow production of the polypeptide. Polypeptides may also be produced in in vitro systems, such as in a
15 reticulocyte lysate.

Polypeptides which are amino acid sequence variants, alleles, derivatives or mutants are also provided by the present invention. A polypeptide which is a variant, allele, derivative, or mutant may have an amino acid sequence that differs from that given in SEQ ID NO: 2 by one or more of addition, substitution,
20 deletion and insertion of one or more amino acids. Preferred such polypeptides have GRP94 function, that is to say have one or more of the following properties: peptide binding activity; binding activity towards ADP, ATP, or NECA; binding activity towards geldanamycin, or radicicol, or their synthetic variants, immunological cross-reactivity with an antibody reactive with the polypeptide for
25 which the sequence is given in SEQ ID NO: 2. A polypeptide which is an amino acid sequence variant, allele, derivative or mutant of the amino acid sequence shown in SEQ ID NO: 2 may comprise an amino acid sequence which shares greater than about 35% sequence identity with the sequence shown, greater than about 40%, greater than about 50%, greater than about 60%, greater than about
30 70%, greater than about 80%, greater than about 90% or greater than about 95%. Particular amino acid sequence variants may differ from that shown in SEQ ID NO: 2 by insertion, addition, substitution or deletion of 1 amino acid, 2, 3, 4, 5-10, 10-20, 20-30, 30-40, 40-50, 50-100, 100-150, or more than 150 amino acids.

A polypeptide according to the present invention may be used in screening for molecules which affect or modulate its activity or function. Such molecules may be useful in a therapeutic (possibly including prophylactic) context.

5

II. Uses of GRP94-Encoding Nucleic Acids,

GRP94 Proteins and GRP94 peptide fragments

GRP94 appears to be an important immunomodulatory protein which plays a role in antigen presentation and tumor rejection. The GRP94 molecules
10 of the invention may be used to advantage in methods to augment the immune response particularly for the treatment of cancer.

Additionally, GRP94 nucleic acids, proteins and antibodies thereto, according to this invention, may be used as a research tool to identify other proteins that are intimately involved in antigen repair, protein folding and tumor
15 rejection reactions. Biochemical elucidation of these pathways will facilitate the development of novel reagents for the treatment of cancer and other immune function disorders.

A. GRP94-Encoding Nucleic Acids

GRP94-encoding nucleic acids may be used for a variety of purposes in accordance with the present invention. GRP94-encoding DNA, RNA, or fragments thereof may be used as probes to detect the presence of and/or expression of genes encoding GRP94 proteins. Methods in which GRP94-encoding nucleic acids may be utilized as probes for such assays include, but are
20 not limited to: (1) *in situ* hybridization; (2) Southern hybridization (3) northern hybridization; and (4) assorted amplification reactions such as polymerase chain reactions (PCR).
25

The GRP94-encoding nucleic acids of the invention may also be utilized as probes to identify related genes from other animal species. As is well known in the art, hybridization stringencies may be adjusted to allow hybridization of nucleic acid probes with complementary sequences of varying degrees of homology.

5 Thus, GRP94-encoding nucleic acids may be used to advantage to identify and characterize other genes of varying degrees of relation to GRP94, thereby enabling further characterization of the molecular chaperone system. Additionally, they may be used to identify genes encoding proteins that interact with GRP94 (e.g., by the "interaction trap" technique), which should further accelerate identification of
10 the components involved in antigen presentation and tumor rejection.

Nucleic acid molecules, or fragments thereof, encoding GRP94 may also be utilized to control the production of GRP94, thereby regulating the amount of protein available to participate in immunomodulation reactions. Alterations in the physiological amount of GRP94 protein may dramatically affect the activity of
15 other protein factors involved in antigen presentation, for example.

The availability of GRP94 encoding nucleic acids enables the production of strains of laboratory mice carrying part or all of the GRP94 gene or mutated sequences thereof. Such mice may provide an in vivo model for immunomodulation and tumor rejection. Alternatively, the GRP94 sequence
20 information provided herein enables the production of knockout mice in which the endogenous gene encoding GRP94 has been specifically inactivated. See Example 2. Methods of introducing transgenes in laboratory mice are known to those of skill in the art. Three common methods include: 1. integration of retroviral vectors encoding the foreign gene of interest into an early embryo; 2. injection of
25 DNA into the pronucleus of a newly fertilized egg; and 3. the incorporation of genetically manipulated embryonic stem cells into an early embryo. Production of the transgenic mice described above will facilitate the molecular elucidation of the role GRP94 plays in embryonic development and immune regulation.

A transgenic mouse carrying the human GRP94 gene is generated by direct
30 replacement of the mouse GRP94 gene with the human gene. These transgenic animals are useful for drug screening studies as animal models for human diseases and for eventual treatment of disorders or diseases associated with biological activities modulated by GRP94. A transgenic animal carrying a "knock out" of GRP94 is useful for assessing the role of GRP94 plays in embryonic development.

As a means to define the role that GRP94 plays in mammalian systems, mice may be generated that cannot make GRP94 protein because of a targeted mutational disruption of the GRP94 gene.

5 The term "animal" as used in this section includes all vertebrate animals, except humans. It also includes an individual animal in all stages of development, including embryonic and fetal stages. A "transgenic animal" is any animal containing one or more cells bearing genetic information altered or received, directly or indirectly, by deliberate genetic manipulation at the subcellular level, such as by targeted recombination or microinjection or infection with recombinant
10 virus. The term "transgenic animal" is not meant to encompass classical cross-breeding or in vitro fertilization, but rather is meant to encompass animals in which one or more cells are altered by or receive a recombinant DNA molecule. This molecule may be specifically targeted to a defined genetic locus, be randomly integrated within a chromosome, or it may be extrachromosomally replicating
15 DNA. The term "germ cell line transgenic animal" refers to a transgenic animal in which the genetic alteration or genetic information was introduced into a germ line cell, thereby conferring the ability to transfer the genetic information to offspring. If such offspring, in fact, possess some or all of that alteration or genetic information, then they, too, are transgenic animals.

20 The alteration or genetic information may be foreign to the species of animal to which the recipient belongs, or foreign only to the particular individual recipient, or may be genetic information already possessed by the recipient. In the last case, the altered or introduced gene may be expressed differently than the native gene.

25 The altered GRP94 gene generally should not fully encode the same GRP94 protein native to the host animal and its expression product should be altered to a minor or great degree, or absent altogether. However, it is conceivable that a more modestly modified GRP94 gene will fall within the compass of the present invention if it is a specific alteration.

30 The DNA used for altering a target gene may be obtained by a wide variety of techniques that include, but are not limited to, isolation from genomic sources, preparation of cDNAs from isolated mRNA templates, direct synthesis, or a combination thereof.

A type of target cell for transgene introduction is the embryonal stem cell (ES). ES cells may be obtained from pre-implantation embryos cultured in vitro (Evans et al., (1981) Nature 292:154-156; Bradley et al., (1984) Nature 309:255-258; Gossler et al., (1986) Proc. Natl. Acad. Sci. 83:9065-9069). Transgenes can
5 be efficiently introduced into the ES cells by standard techniques such as DNA transfection or by retrovirus-mediated transduction. The resultant transformed ES cells can thereafter be combined with blastocysts from a non-human animal. The introduced ES cells thereafter colonize the embryo and contribute to the germ line of the resulting chimeric animal.

10 One approach to the problem of determining the contributions of individual genes and their expression products is to use isolated GRP94 genes to selectively inactivate the wild-type gene in totipotent ES cells (such as those described above) and then generate transgenic mice. The use of gene-targeted ES cells in the generation of gene-targeted transgenic mice was described, and is reviewed
15 elsewhere (Frohman et al., (1989) Cell 56:145-147; Bradley et al., (1992) Bio/Technology 10:534-539).

Techniques are available to inactivate or alter any genetic region to a mutation desired by using targeted homologous recombination to insert specific changes into chromosomal alleles. However, in comparison with homologous
20 extrachromosomal recombination, which occurs at a frequency approaching 100%, homologous plasmid-chromosome recombination was originally reported to only be detected at frequencies between 10^{-6} and 10^{-3} . Non-homologous plasmid-chromosome interactions are more frequent occurring at levels 10^5 -fold to 10^2 -fold greater than comparable homologous insertion.

25 To overcome this low proportion of targeted recombination in murine ES cells, various strategies have been developed to detect or select rare homologous recombinants. One approach for detecting homologous alteration events uses the polymerase chain reaction (PCR) to screen pools of transformant cells for homologous insertion, followed by screening of individual clones. Alternatively, a
30 positive genetic selection approach has been developed in which a marker gene is constructed which will only be active if homologous insertion occurs, allowing these recombinants to be selected directly. One of the most powerful approaches developed for selecting homologous recombinants is the positive-negative selection (PNS) method developed for genes for which no direct selection of the

alteration exists. The PNS method is more efficient for targeting genes which are not expressed at high levels because the marker gene has its own promoter. Non-homologous recombinants are selected against by using the Herpes Simplex virus thymidine kinase (HSV-TK) gene and selecting against its nonhomologous
5 insertion with effective herpes drugs such as gancyclovir (GANC) or (1-(2-deoxy-2-fluoro-B-D arabinofluranosyl)-5-iodouracil, (FIAU). By this counter selection, the number of homologous recombinants in the surviving transformants can be increased.

As used herein, a "targeted gene" or "knock-out" is a DNA sequence
10 introduced into the germline or a non-human animal by way of human intervention, including but not limited to, the methods described herein. The targeted genes of the invention include DNA sequences which are designed to specifically alter cognate endogenous alleles.

Methods of use for the transgenic mice of the invention are also provided
15 herein. Therapeutic agents for the treatment or prevention of cancer may be screened in studies using GRP94 transgenic mice.

In another embodiment of the invention, GRP94 knockout mice may be used to produce an array of monoclonal antibodies specific for GRP94 protein.

In yet another embodiment of the invention, the GRP94 gene has been
20 replaced with a GRP94 gene that is flanked by short sequences that can be deleted (i.e.- cut out of) from the genome. Methods employing two different bacteriophage recombinases for the excision and integration of foreign DNA into the genome have been described. Several prokaryotic and lower eukaryotic site-specific recombination systems have been shown to operate successfully in higher
25 eukaryotes. In yeast, plant and animal cells functional site-specific recombination systems have been described from bacteriophages P1 (CRE-*loxP*)(see below) and Mu (Gin-*gix*), and from the inversion plasmids of *Saccharomyces cerevisiae* (FLP-*frt*)(Morris et al. 1991; Lyznik et al. 1996) and *Zygosaccharomyces rouxii* (R-*RS*)(Onouchi et al. 1991; Onouchi et al. 1995). This approach can be employed in
30 tissue-specific manner or in developmentally-specific manner, by methods known in the art. Such mice, in which GRP94 is inactivated in selected cells and not in others, are termed "conditional knockout mice" and serve as animal models for disease. For example, the finding that GRP94 is essential for muscle development,

provides an important animal model for genetic deficiencies of muscle tissues and muscle degeneration diseases.

The availability of GRP94 deficient mice and GRP94 deficient ES cells enables the production of cell lines that can be used for developing therapeutics.

- 5 First, the GRP94 deficient cell lines can be used to develop assays that distinguish the functions of GRP94 from the functions of the other three members of the mammalian HSP90family. The stress responses that rely predominantly on GRP94 should be affected in these cells and therefore discernible (as has already been shown in the data herein). Second, the GRP94 deficient cell lines can be used
10 to develop drugs that are specific for either HSP90 or for GRP94, thus allowing creation of better anti-tumor drugs than those which target all members of the family, with fewer unwanted side effects. Third, the GRP94 deficient ES cell lines can be used to create differentiated cell lines in culture, for tissue-specific or cell type-specific applications. For example, the liver cells (hepatocytes) or fat cells
15 (adipocytes) that have already been generated from such cells and can be used to determine the role of GRP94 in normal and/or pathological liver functions and/or in adipose tissue biology, using whole-genome and whole-proteome techniques such as DNA arrays and protein arrays. GRP94 is a known sensor for glucose metabolism, so cell types of interest will also include pancreatic cells and muscle
20 cells, where the absence of GRP94 will enable the investigation and generation of drugs that either rely on GRP94's sensor functions or on its absence to affect the physiology of these tissues.

- In the context of cancer therapy, the availability of GRP94 deficient mice and ES cells enables genetic testing of the model promoted by Srivastava et al. for
25 tumor immunotherapy. Tumors can be generated that lack GRP94 and they can be injected into mice to determine the in vivo role of GRP94 in stimulating the immune system. The utility of such lab tests will be the discovery of other proteins, either stress proteins or others, that also have immuno-modulating activities, and whose action has so far been masked by the presence of GRP94.

30

B. GRP94 Protein and Fragments Thereof

Purified GRP94, or fragments thereof, may be used to produce polyclonal or monoclonal antibodies which also may serve as sensitive detection reagents for the presence and accumulation of GRP94 (or complexes containing GRP94) in

mammalian cells. Recombinant techniques enable expression of fusion proteins containing part or all of the GRP94 protein. The full length protein or fragments of the protein may be used to advantage to generate an array of monoclonal antibodies specific for various epitopes of the protein, thereby providing even
5 greater sensitivity for detection of the protein in cells.

Polyclonal or monoclonal antibodies immunologically specific for GRP94 may be used in a variety of assays designed to detect and quantitate the protein. Such assays include, but are not limited to: (1) flow cytometric analysis; (2) immunochemical localization of GRP94 in tumor cells; and (3) immunoblot
10 analysis (e.g., dot blot, Western blot) of extracts from various cells. Additionally, as described above, anti-GRP94 can be used for purification of GRP94 (e.g., affinity column purification, immunoprecipitation).

From the foregoing discussion, it can be seen that GRP94-encoding nucleic acids, GRP94 expressing vectors, GRP94 proteins and anti-GRP94 antibodies of
15 the invention can be used to detect GRP94 gene expression and alter GRP94 protein accumulation for purposes of assessing the genetic and protein interactions involved in protein folding, antigen presentation and tumor rejection. According to another aspect of the invention, methods of screening drugs for cancer therapy to identify suitable drugs for restoring or augmenting GRP94 product functions are
20 provided. The GRP94 deficient cell lines described above provide superior screening tools for this purpose.

The GRP94 polypeptide or fragment employed in drug screening assays may either be free in solution, affixed to a solid support or within a cell. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are
25 stably transformed with recombinant polynucleotides expressing the polypeptide or fragment, preferably in competitive binding assays. Such cells, either in viable or fixed form, can be used for standard binding assays. One may determine, for example, formation of complexes between a GRP94 polypeptide or fragment and the agent being tested, or examine the degree to which the formation of a complex
30 between a GRP94 polypeptide or fragment and a known ligand is interfered with by the agent being tested. Such assays, using the cell lines of the invention, facilitate the identification of agents which demonstrate differential binding between HSP90 and GRP94.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the GRP94 polypeptides and is described in detail in Geysen, PCT published application WO 84/03564, published on Sep. 13, 1984. Briefly stated, large numbers of different, small peptide test
5 compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with GRP94 polypeptide and washed. Bound GRP94 polypeptide is then detected by methods well known in the art.

Purified GRP94 can be coated directly onto plates for use in the
10 aforementioned drug screening techniques. However, non-neutralizing antibodies to the polypeptide can be used to capture antibodies to immobilize the GRP94 polypeptide on the solid phase. A preferred method of attaching GRP94 to plates or other solid matrices is the use of modified GRP94 that has a C-terminal tag which directs site-specific biotin addition. Specifically, the authors showed that a
15 biotinylation site can be created at the C-terminus of N1-355, N34-355 and N34-222.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of specifically binding the GRP94 polypeptide compete with a test compound for binding to the GRP94 polypeptide
20 or fragments thereof. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants of the GRP94 polypeptide.

A further technique for drug screening involves the use of host eukaryotic cell lines or cells (such as described above) which have a nonfunctional GRP94
25 gene. These host cell lines or cells are defective at the GRP94 polypeptide level. The host cell lines or cells are grown in the presence of drug compound. The rate of growth of the host cells is measured to determine if the compound is capable of regulating the growth of GRP94 defective cells.

For example, tumor cells are distinguished from normal cells by their
30 uncontrolled proliferation. Many cancer treatment regimes are therefore designed to selectively inhibit rapidly dividing cells. The growth regulation of cells depends on many receptor proteins in the external cells membrane and on enzymes termed "kinases" enclosed within the cell membrane and whose function is to phosphorylate (add phosphate moieties) other growth-regulatory proteins. Many

of the receptors and the kinases involved in cell growth regulation interact with heat shock protein 90 (HSP90), and depend on this interaction for their proper function and accurate deposition within the cell. Notably, HSP90 has been sought as a possible anti-tumor drug target. However, HSP90 is very homologous to
5 GRP94, shares structural elements with GRP94 and binds most of the same ligands that bind to GRP94. To date, all inhibitors that are designed to interfere with HSP90 activity also bind to and inhibit GRP94. This leads to unwanted side effects as a consequence of using anti-HSP90 drugs. Accordingly, use of the GRP94 deficient cell lines will enable identification of agents which demonstrate
10 selective binding of either GRP94 or HSP90.

A second strategy against cancer is aimed not at the growth differences between cancerous and normal cells, but at the chemical differences between them. Due to the exquisite ability of T lymphocytes to detect differences in protein fragments that are hallmarks of tumor cells, it should be possible to enlist the T cell
15 arm of the immune system to act and kill such cells. GRP94 has been shown, initially by Srivastava et al, and later by others, to stimulate the recognition of tumor cells by such T lymphocytes.

A variation on this technique is the growth of cells with defective GRP94 under various stress conditions of interest, determining the ability of the cells to
20 cope with the stress and measuring the ability of drugs to modulate the cellular stress response. An important extension of this technique to whole animals is the measurements of stress responses in mice in which the GRP94 gene had been inactivated in specific tissues and/or cell types.

The goal of rational drug design is to produce structural analogs of
25 biologically active polypeptides of interest or of small molecules with which they interact (e.g., agonists, antagonists, inhibitors) in order to fashion drugs which are, for example, more active or stable forms of the polypeptide, or which, e.g., enhance or interfere with the function of a polypeptide *in vivo*. See, e.g., Hodgson, (1991) Bio/Technology 9:19-21. In one approach, one first determines the three-
30 dimensional structure of a protein of interest (e.g., GRP94 polypeptide) or, for example, of the GRP94-peptide complex, by x-ray crystallography, by nuclear magnetic resonance, by computer modeling or most typically, by a combination of approaches. Less often, useful information regarding the structure of a polypeptide may be gained by modeling based on the structure of homologous proteins. An

example of rational drug design is the development of HIV protease inhibitors (Erickson et al., (1990) Science 249:527-533). In addition, peptides (e.g., GRP94 polypeptide) may be analyzed by an alanine scan (Wells, 1991, Meth. Enzym. 202:390-411). In this technique, an amino acid residue is replaced by Ala, and its
5 effect on the peptides activity is determined. Each of the amino acid residues of the peptide is analyzed in this manner to determine the important regions of the peptide.

The discovery of the peptide binding site of GRP94, and the high degree of homology of sequence and/or structure with other members of the HSP90 family
10 of proteins, presents another aspect of the invention relating to peptides and similar ligands that bind to the homologous sites in the other members of the family. Targeting htpG, for example, in bacteria, may lead to novel antibiotics. Targeting the HSP90 peptide binding site, as another example, may lead to modulation of its activity. Third, the knowledge of one peptide binding site will lead to rational,
15 structure-based genetic engineering of the binding sites of all other members of the HSP90 family of stress proteins.

It is also possible to isolate a target-specific antibody, selected by a functional assay, and then to solve its crystal structure. In principle, this approach yields a pharmacore upon which subsequent drug design can be based. It is
20 possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the anti-ids would be expected to be an analog of the original molecule. The anti-id could then be used to identify and isolate peptides from banks of chemically or biologically produced banks of
25 peptides. Selected peptides would then act as the pharmacore.

Thus, one may design drugs which have, e.g., improved GRP94 polypeptide activity or stability or which act as inhibitors, agonists, antagonists, etc. of GRP94 polypeptide activity. By virtue of the availability of cloned GRP94 sequences, sufficient amounts of the GRP94 polypeptide may be made available to
30 perform such analytical studies as x-ray crystallography. In addition, the knowledge of the GRP94 protein sequence provided herein will guide those employing computer modeling techniques in place of, or in addition to x-ray crystallography.

III Therapeutics

A. Pharmaceuticals and Peptide Therapies

The GRP94 polypeptides/proteins, antibodies, peptides and nucleic acids of the invention can be formulated in pharmaceutical compositions. These
5 compositions may comprise, in addition to one of the above substances, a pharmaceutically acceptable excipient, carrier, buffer, stabilizer or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material may depend on the route of administration, e.g. oral,
10 intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes.

Whether it is a polypeptide, antibody, peptide, nucleic acid molecule, small molecule or other pharmaceutically useful compound according to the present invention that is to be given to an individual, administration is preferably in a
15 "prophylactically effective amount" or a "therapeutically effective amount" (as the case may be, although prophylaxis may be considered therapy), this being sufficient to show benefit to the individual.

B. Methods of Gene Therapy

20 As a further alternative, the nucleic acid encoding the authentic biologically active GRP94 polypeptide could be used in a method of gene therapy, to treat a patient whose immune system requires modulation, or who is suffering from cancer, etc. In one approach, a modified version of GRP94 can be administered that is not susceptible to pan-HSP90 drugs, in this manner increasing the
25 specificity of anti-HSP90 drugs and preventing the unwanted side effects due to simultaneous targeting of GRP94. In another approach, GRP94 may be used in gene therapy of diseases involving proteins that are not secreted efficiently and require GRP94 for efficient secretion, such as immunoglobulins, Toll-like receptors (Randow, F., and B. Seed. 2001. Endoplasmic reticulum chaperone gp96
30 is required for innate immunity but not cell viability. Nat Cell Biol 3:891), etc.

A major advantage of using a minimal and sufficient version of the GRP94 gene for gene therapy (and of a mini-protein for protein-based therapy) is that unwanted effects and activities of the administered gene/protein are minimized. GRP94, like all other HSP90s, has modular structure. It consists of distinct

domains with unique activities. For example, at least 3 proteins are known to bind to the C-terminal domain of HSP90, and at least one binds to the middle domain (Young, J. C., I. Moarefi, and F. U. Hartl. 2001. *Hsp90: a specialized but essential protein-folding tool*. J Cell Biol 154:267; Buchner, J. 1999. *Hsp90 & Co. - a holding for folding*. Trends Biochem Sci 24:136). By limiting the therapy to a construct that consists of only the ligand binding domain and the charged domain of GRP94, there is no possibility for the other interactions to take place, making the introduced gene/protein a more specific therapy.

A second advantage of using a minimal-chaperone module is that a small protein is easier to produce in recombinant form. A small 355 amino acid protein is obtained in higher yields and in better activity (presumably due to higher percentage of protein molecules that fold correctly) than the full length GRP94, in either bacterial, insect cell or mammalian cell expression systems.

Vectors such as viral vectors have been used in the prior art to introduce genes into a wide variety of different target cells. Typically the vectors are exposed to the target cells so that transformation can take place in a sufficient proportion of the cells to provide a useful therapeutic or prophylactic effect from the expression of the desired polypeptide. The transfected nucleic acid may be permanently incorporated into the genome of each of the targeted tumor cells, providing long lasting effect, or alternatively the treatment may have to be repeated periodically.

A variety of vectors, both viral vectors and plasmid vectors are known in the art, see US Patent No. 5,252,479 and WO 93/07282. In particular, a number of viruses have been used as gene transfer vectors, including papovaviruses, such as SV40, vaccinia virus, herpes viruses including HSV and EBV, and retroviruses. Many gene therapy protocols in the prior art have employed disabled murine retroviruses.

Gene transfer techniques which selectively target the GRP94 nucleic acid to tumor tissues are preferred. Examples of this include receptor-mediated gene transfer, in which the nucleic acid is linked to a protein ligand via polylysine, with the ligand being specific for a receptor present on the surface of the target cells.

The following examples are provided to illustrate certain embodiments of the invention. They are not intended to limit the invention in any way.

EXAMPLE 1**Identification of the N-terminal peptide binding site of GRP94**

Glucose Regulated Protein 94 (GRP94), also known as gp96, is a member
5 of the HSP90 family of molecular chaperones and can dramatically stimulate T
cell responses by two mechanisms: enhancement of peptide presentation to the
adaptive arm of the immune system [1] and stimulation of innate immunity [2].
Because of these activities, tumor-derived GRP94 can be used to elicit immune
response against the tumor and is potentially a powerful immunotherapeutic tool
10 [3]. The antigen-presentation activity was shown not to be due to any mutation in
GRP94 that would enhance its immunogenicity, but rather due to its ability to bind
peptides [1, 4]. The GRP94-peptide complexes are known to be taken up by a
subset of antigen presenting cells via receptor mediated endocytosis [5] and the
chaperoned peptides are then represented on endogenous antigen presenting cells
15 to MHC class I molecules on the cell surface. While peptide binding is a general
activity of many molecular chaperones, it has been argued that GRP94 is among
the most effective of such chaperones in enhancing antigen presentation. Despite
its importance, the GRP94-peptide interaction and the identity of the peptide-
binding site have not been characterized in detail. They are crucial issues towards
20 understanding the immuno-stimulatory action of GRP94. The mode of peptide
binding by GRP94 may also inform about its activity as a chaperone of selected
membrane-bound and secreted proteins [6], though the connection between the two
activities has yet to be elucidated. The same questions are also unanswered for all
other HSP90 chaperones, despite the central role of these cytosolic chaperones in
25 organizing signaling complexes and regulating transcription factors [7]. Several
peptides derived from vesicular stomatitis virus (VSV) have been shown to bind
GRP94. VSV8 is an octamer (RGYVYQGL) from the N protein of VSV and is the
dominant T cell epitope of the virus, presented via MHC class I Kb to specific T
cells [8]. The structure of a complex of this peptide with MHC class I has been
30 solved [9]. VSV8 has been eluted from GRP94 purified from a VSV N protein-
transfected cell line [10] and the peptide has been shown to bind directly to
purified GRP94 *in vitro* [1]. Peptide A is a 15-mer KRQIYTDLEMNRLGK) from
the glycoprotein of the virus and is not known to be immunogenic [1,11,12].
However, this peptide binds GRP94, as do other peptides, including

LSSLFRPKRRPIYKS from VSV G protein [1]. No common sequence motif is obvious from comparing these peptides. Spee and Neefjes used radioactive peptides with photo-reactive side chains to explore the peptide preferences of GRP94 [13]. No obvious size preference was found, and even 40mers could bind
5 the chaperone. The only sequence specificity found was that 9mers with basic or acidic amino acids in positions 2 and 9 bind relatively weakly to GRP94. Thus, either sequences or the structural features that are compatible with binding to GRP94 are still not known.

The limited amount of information about GRP94's peptide binding activity
10 is due in part to the low stoichiometry of binding (only about 1% of the protein had been shown to bind peptides [14]) and slow binding kinetics [15]. These technical obstacles also hindered the identification of structural determinants of the peptide binding site and its regulation. We showed that the N-terminal third of GRP94 constituted a peptide-binding entity and demonstrated that peptide binding to this
15 fragment is specific, is inhibited by the pan-HSP90 inhibitors radicicol and geldanamycin, and has a binding stoichiometry close to 1 mole peptide per mole of GRP94 [15]. In addition, our data indicated that the peptide specificity of this site is different from that of another ER-resident stress protein, BiP [15]. In the present example we use molecular modeling, biochemical characterization and site-
20 directed mutagenesis to identify a peptide binding site located within the N-terminal domain, on the face opposite the radicicol binding site, and show that His125 is located in the binding site and is directly involved in the binding activity.

The following materials and methods are provided to facilitate the practice
25 of Example 1.

Recombinant Proteins

N1-355: The construct for expression of N1-355 in insect cells and the purification procedure are described in [15]. Recombinant N1-355 contained an N-
30 terminal His6 tag, followed by the first 355 amino acids of a mature sequence of GRP94 and a C-terminal ER1 targeting signal KDEL.

N34-355: The sequence coding for the first 33 amino acids of N1-355 was deleted by PCR cloning. The resultant PCR product was inserted into the pQEXa vector (Qiagen) using BamH1 and XmaI so as to add a His6 tag followed by a
35 factor Xa recognition sequence at amino terminus. The plasmid was transformed

into M15 *E. coli*, which were allowed to grow to midlog phase and then incubated with 1mM IPTG for 4 hrs at 27°C to induce protein expression. Bacteria were harvested and lysed in 1% NP40 (Sigma Chemicals) in 20 mM phosphate buffer pH 7.2, containing 500 mM NaCl and 20 mM imidazole. N34-355 was purified
5 from the detergent lysates by affinity chromatography on Ni-NTA columns (Qiagen), according to the manufacturer's instructions. Bound proteins were eluted with 500 mM imidazole, dialysed and concentrated. The protein was stored in 25 mM HEPES (pH 7.2), 110 mM KOAc, 20 mM NaCl, 1 mM Mg(OAc)₂, 0.1 mM CaCl₂ (buffer A) containing 10-20% sucrose at -80°C. When needed, the amino
10 terminal extension containing the His6 tag was removed by digestion with factor Xa (Novagen) according to the manufacturer instructions. The reaction mixture was re-purified over a small Ni-NTA column and the flow through containing only the cleaved N34-355 was used. The cleaved protein appeared 2-3 kDa smaller on SDS-PAGE compared to the parent protein, consistent with the removal of 17
15 amino acids (not shown). After digestion, the heptamer PYNGTGS precedes Ala34 or the mature N34-355 sequence.

Constructs for mini-GRP94 (e.g., amino acids 34-355, 70-221) and/or for mini-HSP90 recombinant proteins were created by PCR amplification of the desired sequences and cloning into the multiple cloning site of the expression
20 vector pQE30 (Qiagen Corp.), by standard procedures. A hexa-histidine site is provided by this vector at the N-terminus of the expressed protein, to enable affinity purification.

The HSP90 fragment consisting of amino acids 1-210 will be used, expressed as described for GRP94. In preference to using the normal
25 HSP90 sequence, we will mutate the region between amino acids 100-134 (see Figure 4 of example 1). Site directed mutagenesis will be guided by the amino acids in GRP94 that contact the bound peptides, and will include, but will not be limited to, Thr90, Ile81, Pro82 and insertion of residues before amino acid 130, to match the GRP94
30 sequence.

Mutant proteins: Amino acids substitutions were introduced into the vector encoding N34-355 with the QuikChange kit (Stratagene). Mutations were verified by sequencing and, when appropriate by restriction enzyme analyses. The proteins were expressed in bacteria and purified as described above.

Peptides

Peptides were synthesized at the University of Chicago facility and verified by mass spectroscopy. The sequences of the two binder peptides are: VSV8,
5 RGYVYQGL, from the VSVN protein; Pep A, KRQIYTDLEMNRLGK, from the VSV G protein. Stock solutions were prepared in water and stored at -80°C. Peptide concentrations were determined by a BCA assay (Pierce). Where indicated, peptides were iodinated by the IodoBead method (Pierce) and unincorporated iodine was removed by passage over a short Dowex AG1X8
10 column. The specific radioactivity of the peptides was routinely 2×10^{14} - 1×10^{15} cpm/mole.

Peptide binding assays

Two types of binding assays were used. The solution binding assay was
15 performed as described in [15]. Briefly, recombinant proteins were incubated with iodinated peptide under saturating conditions and radioactivity associated with protein-peptide complexes was measured after separation of free peptide over spin columns containing 0.8 μ l of packed P-30 beads (Bio Rad) in buffer A. Iodinated peptide without protein was used as background control for spin column
20 separation.

A solid phase binding assay (referred to as plate assay in the text) is described and validated elsewhere (Biswas et al., manuscript in preparation). Briefly, 96-well plates (Costar 3590 High Binding, Corning, NY) were coated with peptides prior to assay and the recombinant proteins in 100 μ l of buffer A were
25 allowed to bind for 90 min. Binding was quantified by HRP-rabbit anti-His₆ (Amersham) and color development was monitored at 415 nm with a BioTek plate reader. Since both N1-355 and N34-355 normally reached saturation at the input level of 0.7 or 1 μ g, the OD415 value at this level was defined as 1 and all data points were normalized to it. Inhibition by 300 μ M radicicol (Sigma; stock solution
30 in DMSO) was used as a specificity control.

Since peptide binding to GRP94 is saturable and specific, yet the off rate is exceedingly slow [15], K_a values were estimated graphically from the fractional occupancy curves (OD415 value at a given protein input relative to OD415 value at saturation as a function of protein input). When the binding reaction is not in

equilibrium, these values are valid as comparative parameters among the various mutants.

Gel Electrophoresis

5 Analysis of protein conformation by blue native gel electrophoresis was accomplished by using 5-15% gradient acrylamide gels in the Laemli gel system without SDS [40], with Coomassie brilliant blue G 250 (Sigma Chemicals) included in the cathode buffer. Thyroglobulin, ferritin and BSA were used as molecular weight standards.

10

Protein modifications

 Binding of the fluorescent dye 8-ANS (Molecular Probes, Eugene, OR) to proteins was performed by incubating 5 μ M ANS with 0.5 μ M of the appropriate N355 construct in 500 μ l of buffer A.

15

 For acrylodan (6-acryloyl-2-dimethylaminonaphthalene) modification, recombinant protein (10 μ M) was incubated at 40°C overnight in the presence of 100 μ M acrylodan (Molecular Probes) in 50 mM ammonium acetate buffer, pH 6.9, and free acrylodan was removed using a spin column. For the experiments measuring the effect of peptide on N355-acrylodan, peptide was added to the final concentration of 100 μ M; equivalent volume of buffer was added to control samples. The mixtures were heat-shocked at 50°C for 10 min, diluted to 500 μ l and fluorescence measurements were performed on PTI fluorimeter. Samples were excited at 350nm for ANS and 390 nm for acrylodan and the emission spectra collected between 400 and 600 nm. The slit widths were set at 2 nm for excitation and 2-6 nm for emission.

25

 Before modification of histidines with DEPC, wild type or H125D N34-355 (800 μ g each) were treated with 24 units Factor Xa (Novagen) in buffer A overnight at 25°C, and then repurified using Xarex Agarose (Novagen) to remove factor Xa and Ni-NTA Agarose to remove the His6 containing peptide. The His-cleaved proteins were reacted with peptide A (or solvent alone) at 12 μ M protein and 2.8mM peptide in buffer A overnight at 25°C. Free peptide was removed and the buffer exchanged to 50 mM ammonium acetate, pH 6.8, using P10 spin columns. Both free N34-355 and the protein-peptide complexes were reacted with 1 mM DEPC (Sigma Chemicals) at 25°C or with EtOH as a solvent control.

30

Incubation for 15-20 min gave complete His modification, as determined by monitoring the reaction at 240 nm [25]. Where indicated, the carboxyhistidine was reverted back to histidine by treatment with 400 mM hydroxylamine for 15 min at 25°C [26].

5

Mass spectrometry

Samples were diluted to 20 µM final concentration in sinapinic acid saturated with acetonitrile and 1% TFA. 1-2 µl of each sample was adsorbed onto a CIPHERgen gold chip and allowed to air dry. Masses were measured by the SELDI-TOF ProteinChip Reader (Ciphergen).

10

RESULTS

15 GRP94-bound peptide is contained within a 188-residue fragment

Previously we demonstrated that a truncated version of GRP94, containing amino acids 1-355 is sufficient to account for the ability of the full-length protein to bind immunologically relevant peptides, such as the VSV major T cell antigen, VSV8. We also showed that this activity was subject to regulation by the pan-HSP90 inhibitors radicicol and geldanamycin [15]. To further locate this peptide-binding site, a shorter version of recombinant GRP94 that lacked the first 33 amino acids of the mature protein (N34-355; Fig. 1A) was cloned and over expressed in *E. coli*. This recombinant protein bound VSV8 with a binding curve very similar to that of N1-355 (Fig. 1B), showing that the first 33 amino acids are not essential for the peptide binding activity. To define an even smaller fragment containing the peptide-binding site, we took advantage of the single thrombin site in N34-355, C-terminal to Arg222, and asked whether a complex of N34-355 and peptide remains intact after cleavage with thrombin. Following the digestion, two bands were detectable by Coomassie blue staining corresponding to the predicted N-terminal 22.4 kDa and C-terminal 14.6 kDa fragments (Fig. 1C). The assignment of the fragments was confirmed by antibodies specific to either the N-terminus of N34-355 (anti-His₆) or to residues 261-276 near the C-terminus (9G10 [16]). Because the GRP94-peptide complex is resistant to SDS [1], peptide-bound protein fragments can be detected after SDS-PAGE by the radioactivity of the bound iodinated peptide. In the absence of thrombin, a radioactive band corresponding to the uncleaved complex was detectable. After partial thrombin digestion, an

20

25

30

35

additional radiolabeled band of apparent molecular weight of 22.4 kDa is detected after SDS-PAGE separation, whilst the other 14.6 kDa fragment is not labeled (Fig.1C). These data suggest, therefore, that amino acids 34-222 of GRP94 are sufficient to retain the bound peptide.

5

Molecular modeling of the GRP94-peptide complex

We next took advantage of previously published data [17] [18] to create a computer model of potential peptide-binding sites. First, we used the crystal structure of the N-terminal domain of HSP90 (PDB files 1YER and 1A4H) to
10 generate an energy minimized, predicted structure of the highly homologous segment of GRP94 (51% identity between yeast HSP82 and mouse GRP94). Second, we used the known structure of the antigenic peptide VSV8, which was determined in association with MHC class I (2MHC; [9]). Third, making the simplifying assumption that the conformation of VSV8, when bound to GRP94, is
15 essentially similar to its conformation when bound to MHC class I, we used the docking algorithm PatchDock [19] to predict potential binding sites. The algorithm searches the protein surface for locations with highest geometric shape complementarity to the ligand molecule and docks the ligand into these locations. Such docking solutions usually produce clusters in different protein cavities, since
20 binding in cavities enables greater shape complementarity. In addition, statistical data about atomic contacts of VSV8 with MHC class I was collected and used to score the docking solutions. The highest scoring solutions in terms of shape complementarity and statistical score were selected.

25 The peptide-binding site is distinct from the Radicicol-binding pocket

The seven best solutions mapped to two potential docking sites. One site overlaps with the radicicol-binding pocket (Fig 2A), the largest cavity in the protein. This site was considered unlikely, because previous data showed that radicicol and peptide can bind simultaneously [15]. We therefore asked whether
30 mutants that did not bind radicicol could still bind peptides. Relying on the solved structure of the complex between yeast HSP90 N-terminal domain and radicicol [18] and on the similarity between HSP90 and GRP94 [19], we mutated residues Asp128 and Gly132 simultaneously, to Asn and Ala, respectively. Asp93 in HSP90 (corresponding to Asp128 in GRP94) makes a crucial hydrogen bond with

radicicol, and Gly97 packs tightly against the inhibitor and also serves to position helix 4, an important portion of the binding pocket [17, 18, 20]. The D93N mutant of HSP90 does not bind ATP [21], so the double mutant of GRP94 was expected to be unable to bind radicicol. Recombinant N34-355 D128N,G132A mutant (RadR) was soluble, mostly monomeric and expressed the conformational-sensitive epitope for the antibody 9G10, like the wild type protein. To test whether the RadR mutant binds radicicol, we used two functional tests (see [15] for details): loss of the 9G10 epitope and acquisition of a compact conformation with increased mobility in native blue gels. Both changes have been shown to reflect the conformational change in the protein upon radicicol binding [15]. The resultant mutant was refractive to treatment with radicicol, as judged by the continued exposure of the 9G10 epitope (data not shown) and lack of acquisition of a compact conformation (Fig. 3A). Despite lack of radicicol binding, the RadR protein bound peptide effectively (Fig. 3C), with only a small reduction in the apparent association constant compared to the WT protein. Consistent with lack of radicicol binding, the peptide binding activity of RadR mutant was not inhibited by pre-treatment with radicicol, whereas the activity of wild type N34-355 was inhibited significantly (Fig. 3B). We conclude that not only is the peptide-binding site within N34-355 distinct from the radicicol-binding site [15], but abolition of inhibitor binding does not affect the ability to bind peptides.

Peptide binding affects the environment of the binding site for two hydrophobic probes.

The other potential peptide docking site is on the opposite side of the β sheet, where there is a large saddle-like surface made of 8 β strands. Side barriers to this saddle are provided by two loops - Asp170-Arg222 and Lys119-Asn122, plus part of a strand H (Val260-Ser263) that is the end of the modeled sequence (Fig. 2B). Four of the highest scoring solutions predicted that VSV8 could fit well within this saddle (Fig. 2B). The peptides would fit at an angle of approximately 70 degrees relative to the long axis of the β sheet across strands E-H, and most of the surface contact would be with the β sheet.

This putative peptide-binding site is in close proximity to a deep hydrophobic pocket (Fig. 4). Hydrophobic residues from strands E, F, G and H, as well as from the helix and loop leading to the strand H and the long helix are

predicted to form this pocket. The edge strand (H) of the β sheet and preceding loop, which form a part of an entrance to this pocket (Fig.4B), have been shown to contribute to the binding site of the hydrophobic dye bis-ANS [22]. We therefore speculated that this pocket can accommodate various hydrophobic probes, such as

5 bis-ANS, ANS, acrylodan and Nile Red, which have been reported to bind to GRP94 [12,22]. The emission spectrum of ANS-labeled N1-355 had a maximum around 474nm (Fig. 5A), as expected if ANS was indeed bound in a hydrophobic environment [23]. When ANS-labeled N1-355 was incubated with peptide A, the intensity of ANS fluorescence decreased and its emission maximum was blue

10 shifted slightly (Fig. 5A). Such decreased ANS fluorescence is consistent with peptide A binding affecting, either directly, or via conformational changes, the environment of the fluorophore. Alternatively, if ANS and peptide compete for the same binding site, it may be due to the release of ANS. The latter explanation can be ruled out due to blue shift of ANS emission, so we favor the notion that peptide

15 binds in proximity to the hydrophobic pocket.

If peptide in fact binds as predicted, it should also affect the environment of other hydrophobic probes. Strand G has the sole cysteine residue (Cys117) in N1-355, whose sidechain points into the hydrophobic pocket (Fig. 4), so we modified the protein with the Cys-specific naphthalene derivative acrylodan [12]. While

20 acrylodan has a very low quantum yield in aqueous solutions, its fluorescence is markedly increased upon reaction with thiols [24], and then the fluorescence is highly sensitive to the hydrophobicity of its environment. As shown in Fig. 5B, when excited at 390 nm, acrylodan-modified N1-355 had emission maximum around 474 nm, as expected if the fluorophore was in a highly hydrophobic

25 environment. Free acrylodan had a maximum at about 520 nm. Denaturation of the N1-355-acrylodan conjugate with 6M guanidine hydrochloride abolished the fluorescence at 474 nm and gave rise to the same emission maximum as free acrylodan in 6M guanidine, indicating that the observed fluorescence is dependent on the tertiary structure of the protein. As expected for the covalent modification,

30 the fluorescence intensity of the denatured N1-355-acrylodan conjugate was significantly higher than that of free acrylodan (Fig. 5B). These spectral properties fulfill the expectation that acrylodan is located in a hydrophobic pocket when bound covalently to Cys117. Therefore, acrylodan modification of N1-355 provides a defined fluorescence probe for detection of molecular changes.

To test whether modification with acrylodan affects peptide binding by N1-355, we incubated acrylodan-modified and unmodified proteins with saturating amount of iodinated VSV8 and measured peptide binding to each. Acrylodan-conjugated protein was capable of binding peptide essentially like the unmodified protein (Fig. 5C), showing that acrylodan does not interfere with the binding activity. Importantly, the fluorescence of acrylodan was partly quenched in the presence of peptide (Fig. 5D). These data are in good agreement with the model in Fig. 2B, which predicts that the peptide-binding site is distinct from but in close proximity to the hydrophobic pocket. These data cannot, however, distinguish quenching due to peptide binding in close proximity to the acrylodan from that due to conformational changes as a result of peptide binding to a more distant site. However, we have shown previously [15] that peptide binding does not induce the same conformational change as inhibitor binding, nor does it alter protease sensitivity of N355 (data not shown), arguing against global conformational changes. This, together with the data presented below (Table 1), argue in favor of peptide binding in proximity to Cys117.

Peptide binding is sensitive to modification of Histidine residues

The third approach to defining the peptide-binding site derived from the observation that peptide binding was pH sensitive (Fig. 6A and ref. [1]). Binding was inhibited above pH 7.2 and was stimulated at pH near 6.0. In addition, binding was sensitive to imidazole; the presence of 6 mM imidazole reduced peptide binding by half (Fig. 6B). Both observations suggested that histidine residues might be involved in peptide binding by GRP94. Diethyl pyrocarbonate (DEPC) N-carbethoxylates the imidazole ring of histidine in a highly specific manner under certain conditions [25, 26] and is therefore useful in defining the role of histidines. DEPC treatment of N34-355 (after cleavage of the His6 tag) abolished the peptide-binding activity of the protein as effectively as the inhibitor radicicol, while the ethanol solvent alone had no inhibitory effect (Fig. 6C). Hydroxylamine (HA) treatment restored the activity of the DEPC modified protein (Fig. 6C), confirming that only modified His residues and not other amino acids [26] were important for the change in activity.

His125 is important for peptide binding

The N34-355 protein has 4 His residues, at positions 125, 194, 200 and 353. Based on the model (Fig. 2B), His125 was deemed to be the histidine residue most likely to be involved in peptide binding site. We therefore mutated His125 to either Asp, altering the charge, or to Tyr, replacing the imidazole ring with a phenol ring. The mutated H125D protein had almost no peptide binding activity, and the H125Y protein - only partial activity (Fig. 7A). Because the binding reaction has an unusually slow off rate [15] and therefore is not in equilibrium, Hill plots cannot be used to calculate the affinity, but the fractional occupancy plot can be used to estimate the association constants. The fractional occupancies calculated for the wild type and H125Y proteins are super-imposable (Fig. 7B), showing no significant difference between the association constants of the wild type and H125Y proteins. Because the saturation level of H125Y is approximately 0.6 of that of wild type, this analysis suggests that the H125Y mutation affects the active fraction of the protein, rather than binding by the active fraction. The loss of binding activity is not due to global misfolding of the mutant proteins. First, both were purified as soluble proteins and displayed chromatographic properties akin to the wild type protein. Second, both H125D and H125Y expressed the monoclonal 9G10 epitope (data not shown). Third, H125D retained its ability to bind the inhibitor radicicol and respond to it by altering its conformation, as shown by the native gel mobility test in Fig. 7C. The same test shows that approximately half of the H125Y mutant is found in the fast migrating conformation even in the absence of radicicol, supporting the conclusion that the H125Y mutation decreases the fraction of active protein. However, the population of this protein that shows correct mobility (approximately 50%) does appear to be capable of radicicol binding induced conformational change (Fig. 7C). The relative abundance of this population is in agreement with the peptide saturation level of H125Y (approximately 0.6 of that of wild type, Fig. 7A). Therefore, tyrosine at position 125 of N34-355, while decreasing the proportion of active protein, does not preclude peptide binding *per se*. Since, in contrast to histidine and tyrosine, aspartic acid at position 125 abolishes peptide binding, we propose that the nature of residue 125 is critical for peptide binding, confirming a strong prediction of the structural model.

His125 is in physical proximity to the bound peptide

Although the data above show that the environment of Cys117 changes upon peptide binding and that His125 modification either by DEPC or by a charge-altering mutation abolishes peptide binding, they can be explained in terms of transmission of conformational changes and thus do not formally show physical association. Therefore, we used the DEPC modification procedure in a peptide-protection experiment. The extent of DEPC modification was compared between a peptide-bound and peptide-free N34-355 (from which the His6 tag was removed), reasoning that if peptide is bound as modeled, it should protect His125 from modification. The proteins were analyzed by SELDI-TOF mass spectrometry (Table 1). Each Ncarbetoxylation adds 72 Da per His residue modified. The mass of N34-355 modified with DEPC increased by 289 Da compared to the unmodified protein, as expected from modification of all four His residues. That only His were modified was shown by the reversibility of the mass increase upon subsequent treatment with hydroxylamine [26]. When N34-355 was saturated with peptide A prior to the modification with DEPC, the mass gain was 73 Da less than in the absence of peptide (Table 1), as expected if one residue was protected from DEPC modification. Mass spectrometry of proteolytic fragments of DEPC-modified proteins confirms that the protected residue is His125 (data not shown). When the H125D mutant was used in the same manner, its mass increased by only 211-215 Da after modification with DEPC, whether peptide was present or not, as expected from a protein with only 3 His and unable to bind peptide (Table 1). These modification experiments argue that of the four histidines, only His125 is involved in peptide binding, and it is physically associated with the peptide.

Table 1. Protection of His125 from modification by peptide binding

Protein and treatment	Observed MW	Observed Difference ^a	Expected Difference ^b
Wild type	37742	--	--
Wild type + DEPC	38031	+289	+288 (4)
Wild type + DEPC + HA	37758	+16	0
Wild type + peptid A + DEPC	37955	+213	+216 (3)
H125D	37767	--	--
H125F + DEPC	37978	+211	+216 (3)
H125D + DEPC + HA	37737	-30	0
H125D + peptide A + DEPC	37982	+215	+216 (3)

Wild type N34-355 or the H125D mutant proteins were incubated with saturating concentration of peptide A (or buffer alone) and the complexes purified by spin column gelfiltration. Proteins or protein-peptide complexes were then modified with DEPC (or the ethanol solvent alone) and adsorbed onto gold CIPHERGEN Protein chips. Masses of the treated proteins were determined by SELDI-TOF on a CIPHERGEN mass spectrometer calibrated with a standard set of proteins and peptides. The values given are for the single ionized peaks in each sample. They are from one experiment. **a**, the observed differences were calculated with respect to the unmodified protein (either wild type or H125D). The calculated molecular weight of wild type N34-355 is 37781 daltons and that of the H125D mutant is 22 daltons smaller. The differences obtained in two additional experiments were essentially identical. **b**, the expected differences were calculated based on modification of 3 or 4 His residues (indicated in parenthesis) and the addition of 72 daltons to the mass of the protein by N-carboxy-modification of each His.

DISCUSSION

Central to understanding the chaperone activity of GRP94, or its ability to stimulate peptide-specific T cell responses, is deciphering how it binds peptides. The work presented here provides an important part of the answer by locating the peptide-binding site. Together with our previous data [15], we show that the peptide-binding site of the chaperone GRP94 is located in a large groove in the N-terminal domain, opposite the nucleotide/geldanamycin/radicicol binding site. This peptide binding site was predicted by a computer docking algorithm and the following experimental observations are consistent with the prediction. **a**) Residues 1-33 and 223-355 are dispensable for retention of bound peptide, if not for binding; **b**) peptide binding is not hydrophobic in nature, consistent with the rather hydrophilic nature of the site; **c**) Cys117, located in a hydrophobic pocket, is affected by peptide binding, but can be modified covalently without inhibiting peptide binding; **d**) alteration of the binding site for the inhibitor radicicol does not prevent peptide binding; **e**) the nature of residue 125 is critical for peptide binding and His-125 is protected from modification with DEPC when peptide is bound; **f**) none of the other 3 histidines in N1-355 seems to be involved.

Substitution of Asp for His125 is sufficient to abolish the peptide binding activity of the protein. While mutations that reduce or abolish peptide binding can lie outside the binding pocket and act by affecting protein conformation, we show physical association between His125 and peptide, because of the protection from modification by the small molecule DEPC when peptide is bound. Therefore, we

propose that the curved β sheet in the N-terminal domain is a peptide-binding site of this chaperone, at least *in vitro*, and is not merely a regulatory site. A more extensive survey of amino acids by mutagenesis and other biochemical methods to map the extent of the binding site is in progress.

5 If the computer-generated model is correct also in predicting the mode of peptide association, then binding is along the axis of the groove with contacts along the entire length of the peptide, reminiscent of the interactions of peptides with the groove of MHC class I proteins. The saddle-like geometry of the proposed binding site would allow GRP94-binding peptides to 'slide' along the axis of the
10 groove, accounting for the observation that VSV8 binds with similar kinetics to VSV19, a peptide whose middle 8 amino acids are the VSV8 sequence. This aspect of the binding site would also explain the ability of GRP94 to bind peptides of different lengths, from 8-mers to 40-mers, with similar affinity [1, 13, 15].

 While chaperones are generally thought to recognize hydrophobic peptides,
15 as is true for HSP70s [27, 28], the features of peptides recognized by GRP94 seem different. The GRP94 groove identified here is lined with basic side chains (lysines and a histidine) and hydroxylic side chains (e.g. threonines), with only few hydrophobic side chains. The two binder peptides used in the present invention are also quite hydrophilic, their binding is sensitive to pH and is dissociated with high
20 salt [15]. Thus, binding of at least these peptides seems to be driven by polar and electrostatic interactions, not hydrophobic. This observation is also consistent with the nature of the His125 mutations that affect binding: replacing the imidazole ring with a Tyr side chain still allowed partial binding, and substituting with Asp completely inhibited binding.

25 The β strands that form the floor for the peptide-binding site separate it from the radicicol-binding pocket. The β sheet in the center of the domain appears to play a role in both activities of the N-terminal domain. This is clearly demonstrated here for strand F of this β sheet (Fig. 4A). It contains at least one residue, Asp128, whose side chain is directed toward, and is important for binding
30 to radicicol, as predicted from the homology with HSP90 [18] and shown directly in this work. The same strand F also houses His125, whose central role in peptide binding is demonstrated here. Yet, despite their proximity, substitution of residues on the side of the strand that contacts the inhibitor does not significantly affect the contacts on the other side of the strand with bound peptide, and *vice versa*. We

show that a radicicol-refractive mutant is able to bind peptide, and that a mutant in peptide binding still responds normally to radicicol. Peptide binding can be inhibited by binding of radicicol, but the inhibitor has to occupy its binding site first [15]. This suggests that binding of radicicol transmits a unidirectional change, either across the β sheet or more indirectly, so as to alter the peptidebinding groove.

The crystal structure of HSP90 has been solved both in the presence and absence of geldanamycin/radicicol/ATP and the differences in structure help define the conformational change induced by occupation of the nucleotide site [17, 18, 20, 29]. The two forms differ in three helices and a loop, about 35 residues altogether, which mostly either enable or constrain the entrance to the nucleotide binding pocket. The corresponding region in GRP94 is amino acids 135-174 (Fig. 4A). There is no obvious difference in the β sheet that would explain the inhibition of peptide binding by geldanamycin or radicicol. The observed inhibition, therefore, could be due to subtle changes or to more indirect transmission of conformational change from the 135-174 region to the opposite side of the molecule.

The identification of the peptide-binding site of GRP94 has direct relevance to all HSP90 proteins, since they have been reported to bind peptides, but none of their binding sites has yet been mapped. Scheibel *et al.* showed that the N-terminal 210 amino acids of yeast HSP90 form a monomeric domain sufficient to bind peptides, in geldanamycin- and ATP-sensitive manner [30], much like the minimal GRP94 construct described here. Addition of the negatively charged domain to the N-terminal domain increases peptide-binding affinity without affecting specificity [31]. Another similarity between yeast HSP90 and murine GRP94 is the apparent non-equilibrium nature of peptide binding ([15, 31] and this invention). Comparison of residues contributing to the saddle-like binding site shows that His125 is absent from all HSP90s, replaced by Thr in most HSP90 sequences. Because the HSP90 1-210 domain binds VSV8 less tightly than longer peptides [31], it is possible that the HSP90 N-terminal site is not as efficient in peptide binding as that of GRP94, or that its peptide specificity is different.

It is instructive to compare peptide binding by GRP94 with other peptide-binding sites. In HSP70 proteins, peptides also bind on top of a β sheet delineated by loops from the β sandwich domain [32, 33]. The peptide makes contacts with three β strands, is perpendicular to them and the binding groove has both

hydrophobic and polar amino acids, but no charged residues [32, 33]. In comparison, the GRP94 peptide groove is wider, is made up of mostly polar residues and the peptide makes contacts more or less along the axis of three strands (strands G, F, and H). The interaction of GRP94 with peptide has several features
5 in common with MHC proteins. In both MHC class I and class II the association constants are low and the off rates very slow. GRP94-peptide complexes are very stable, resistant even to SDS, like many MHC-peptide complexes [34]. When complexed with the Kb class I protein, the same VSV8 peptide used in the current work lies at approximately a 450 across a three-strand β sheet, constrained between
10 two α helices [9], a topology that is similar to the one we suggest for the GRP94 binding groove. Interestingly, just like strand F, which provides important contact residues also on the other face of the β sheet with the inhibitors geldanamycin or radicicol, the same three β strands in MHC class I that interact with peptide also provide important contacts on the other face of the sheet with the β_2m subunit of
15 the protein [35]. Depending on the MHC allele [36], mutations in β_2m can alter such contacts and affect peptide loading on the other face of the β sheet [37].

MHC-peptide complexes are designed to leave one face of the bound peptide solvent accessible, available for subsequent contacts with a T cell receptor. In HSP70 proteins, on the other hand, the bound peptide is buried, locked in place
20 by an α helical domain acting as a reversible latch, whose motion is controlled by a nucleotide-induced conformational change [33]. Our present data are not sufficient to decide whether GRP94-peptide complexes resemble one or the other models. It is possible that the second, acidic domain of GRP94 provides a locking mechanism for peptide, because it is needed for at least one activity of the N-terminal domain
25 [19] and because it is involved a conformational change induced by binding of inhibitor to the N-terminal domain [15]. The recently published structure of the N-terminal residues 48-316 of GRP94 [38] (residues 69-337 in the nomenclature used in that paper) shows no obvious part acting to constrain the bound peptide from above. On the other hand, the acidic domain is unordered in the crystal structure
30 and therefore can potentially regulate access to the peptide binding pocket, in analogy to the long helix in HSP70 proteins [33].

The peptide-binding site identified in this work plays a key role in the T cell stimulatory activity of GRP94. Together with the data showing that the N-terminal GRP94 fragment can bind to antigen presenting cells and activate T cells

[39], our data indicate that immunologically relevant peptides bind at this site and that the N34-355 fragment of GRP94 appears to account for peptide-specific activation of T cells. Because this site can be regulated by ligands that bind to the nucleotide site and to the hydrophobic pocket, binding of peptide to this site can be regulated by intracellular co-factors that are yet to be discovered.

REFERENCES FOR EXAMPLE 1

1. Blachere, N. E., Li, Z., Chandawarkar, R. Y., Suto, R., Jaikaria, N. S., Basu, S., Udono, H., and Srivastava, P. K. (1997) *J. Exp. Med.* **186**, 1315-1322.
- 10 2. Singh-Jasuja, H., Scherer, H. U., Hilf, N., Arnold-Schild, D., Rammensee, H. G., Toes, R. E., and Schild, H. (2000) *Eur J Immunol* **30**, 2211-2215.
3. Tamura, Y., Peng, P., Liu, K., Daou, M., and Srivastava, P. K. (1997) *Science* **278**, 117-120.
4. Suto, R., and Srivastava, P. K. (1995) *Science* **269**, 1585-1588.
- 15 5. Binder, R. J., Han, D. K., and Srivastava, P. K. (2000) *Nat Immunol* **1**, 151-155.
6. Argon, Y., and Simen, B. B. (1999) *Semin Cell Dev Biol* **10**, 495-505.
7. Young, J. C., Moarefi, I., and Hartl, F. U. (2001) *J Cell Biol* **154**, 267-273.
8. Imarai, M., Goyarts, E. C., van Bleek, G. M., and Nathenson, S. G. (1995) *Cell Immunol* **160**, 33-42.
- 20 9. Zhang, W., Young, A. C., Imarai, M., Nathenson, S. G., and Sacchettini, J. C. (1992) *Proc Natl Acad Sci U S A* **89**, 8403-8407.
10. Nieland, T. J., Tan, M. C., Monne-van Muijen, M., Koning, F., Kruisbeek, A. M., and vanBleek, G. M. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 6135-6139.
11. Wearsch, P. A., and Nicchitta, C. V. (1997) *J. Biol. Chem.* **272**, 5152-5156.
- 25 12. Wearsch, P. A., Voglino, L., and Nicchitta, C. V. (1998) *Biochemistry* **37**, 5709-5719.
13. Spee, P., and Neefjes, J. (1997) *Eur. J. Immunol.* **27**, 2441-2449.
14. Baker-LePain, J. C., Reed, R. C., and Nicchitta, C. V. (2003) *Curr Opin Immunol* **15**, 89-94.
- 30 15. Vogen, S. M., Gidalevitz, T., Biswas, C., Simen, B. S., Stein, E., Gulmen, F., and Argon, Y. (2002) *J. Biol. Chem.* **277**, 40742-40750.
16. Robert, J., Menoret, A., Basu, S., Cohen, N., and Srivastava, P. R. (2001) *Eur J Immunol* **31**, 186-195.
17. Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., and Pearl, L. H. (1997) *Cell* **90**, 65-75.
- 35 18. Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., and Pearl, L. H. (1999) *J. Med. Chem.* **42**, 260-266.
19. Schulte, T. W., Akinaga, S., Murakata, T., Agatsuma, T., Sugimoto, S., Nakano, H., Lee, Y. S., Simen, B. B., Argon, Y., Felts, S., Toft, D. O., Neckers, L. M., and Sharma, S. V. (1999) *Mol. Endocrinol.* **13**, 1435-1448.
- 40 20. Stebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., and Pavletich, N. P. (1997) *Cell* **89**, 239-250.
21. Prodromou, C., Siligardi, G., O'Brien, R., Woolfson, D. N., Regan, L., Panaretou, B., Ladbury, J. E., Piper, P. W., and Pearl, L. H. (1999) *EMBO J.* **18**, 754-762.
- 45 22. Wassenberg, J. J., Reed, R. C., and Nicchitta, C. V. (2000) *J. Biol. Chem.* **275**, 22806-22814.

23. Slavik, J. (1982) *Biochim Biophys Acta* **694**, 1-25.
24. Prendergast, F. G., Meyer, M., Carlson, G. L., Iida, S., and Potter, J. D. (1983) *J Biol Chem* **258**, 7541-7544.
25. Kalkum, M., Przybylski, M., and Glocker, M. O. (1998) *Bioconjug Chem.* **9**,
5 226-235.
26. Rai, S. S., and Wolff, J. (1998) *J Biol Chem* **273**, 31131-31137.
27. Blond-Elguindi, S., Cwirla, S. E., Dower, W. J., Lipshutz, R. J., Sprang, S. R.,
Sambrook, J.F., and Gething, M. J. (1993) *Cell* **75**, 717-728.
28. Gragerov, A., and Gottesman, M. E. (1994) *J. Mol. Biol.* **241**, 133-135.
- 10 29. Prodromou, C., Roe, S. M., Piper, P. W., and Pearl, L. H. (1997) *Nat. Struct. Biol.* **4**, 477-482.
30. Scheibel, T., Weikl, T., and Buchner, J. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 1495-1499.
31. Scheibel, T., Siegmund, H. I., Jaenicke, R., Ganz, P., Lilie, H., and Buchner, J.
15 (1999) *Proc Natl Acad Sci U S A* **96**, 1297-1302.
32. Burkholder, W. F., Zhao, X., Zhu, X., Hendrickson, W. A., Gragerov, A., and
Gottesman, M. E. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 10632-10637.
33. Zhu, X., Zhao, X., Burkholder, W. F., Gragerov, A., Ogata, C. M., Gottesman,
M. E., and Hendrickson, W. A. (1996) *Science* **272**, 1606-1614.
- 20 34. Collins, E. J., and Frelinger, J. A. (1998) *Immunol Rev* **163**, 151-160.
35. Shields, M. J., Assefi, N., Hodgson, W., Kim, E. J., and Ribaldo, R. K. (1998)
J Immunol **160**, 2297-2307.
36. Smith, R. A., Myers, N. B., Robinson, M., Hansen, T. H., and Lee, D. R.
(2002) *J Immunol* **169**, 3105-3111.
- 25 37. Shields, M. J., Kubota, R., Hodgson, W., Jacobson, S., Biddison, W. E., and
Ribaldo, R. K. (1998) *J Biol Chem* **273**, 28010-28018.
38. Soldano, K. L., Jivan, A., Nicchitta, C. V., and Gewirth, D. T. (2003) *J Biol Chem.*
39. Baker-LePain, J. C., Sarzotti, M., Fields, T. A., Li, C. Y., and Nicchitta, C. V.
30 (2002) *J Exp Med* **196**, 1447-1459 .
40. Schagger, H., Cramer, W. A., and von Jagow, G. (1994) *Analytical Biochemistry* **217**, 220-230.

35 Example 2

THE ENDOPLASMIC RETICULUM CHAPERONE GRP94 IS ESSENTIAL FOR MOUSE GASTRULATION AND MESODERM INDUCTION

The endoplasmic reticulum chaperone GRP94 is expressed ubiquitously, but has few known client proteins, none of them involved in important developmental checkpoints.

40 Targeted disruption of the murine GRP94 gene shows that it has an essential function in embryonic development. *Grp94* ^{-/-} embryos die *in utero* on day 7 of gestation, at the egg cylinder stage of development. They fail to develop mesoderm, a primitive streak, and the proamniotic cavity, the main differentiation events that normally occur at that stage and do not express key genes involved in mesoderm induction. The developmental defect is not due

45 to dilution of maternal GRP94 and seems to reflect the activities of the chaperone. *Grp94* ^{-/-}

cells divide at similar pace to their wild type counterparts. Furthermore, despite the known transcriptional regulation of GPR94 by low glucose tension, mutant ES cells proliferated like wild type cells in low glucose medium. On the other hand, mutant cells were much more sensitive to serum deprivation as well as to perturbation of calcium homeostasis. These data suggest that the requirements for GRP94 are very selective. We hypothesize that some secreted or cell-surface proteins, critical for mesoderm induction, depend on GRP94 for their proper expression, and that in the absence of this chaperone they fail to be efficiently presented when cell-cell interactions specify the proper fates of embryonic cells.

There is little known about GRP94 expression during mammalian development, although much of differentiation and organogenesis can be considered as involving natural metabolic stress responses. GRP94 transcripts are found ubiquitously, including in oocytes and 2-cell stage embryos [6]. At the protein level, it was not detected in undifferentiated F9 cells, whereas GRP78/BiP, another major ER stress protein, was found to be constitutively expressed. However, upon stress induced by a Ca^{++} ionophore, both GRP94 and GRP78 protein expression was induced, just as in adult differentiated cells [6]. A 100 kDa protein, which is likely to be GRP94, but was not rigorously identified, was shown to be expressed on cells of the developing mouse embryo as early as the 4-cell stage [7]. At the egg cylinder stage and in 7- to 8.5-day embryos, expression was highest in the embryonic and extra-embryonic ectoderm and much lower in the visceral endoderm [8]. Additionally, mesoderm cells emerging from the primitive streak were positive [7]. At later stages (E9.5-13.5), during organogenesis, GRP94 was found to be constitutively expressed and localized most obviously within the developing heart, neuroepithelium, and surface ectoderm tissues [9]. These patterns of expression are often considered with respect to energy metabolism in the developing embryo: GRP94 expression is highest when and where there is most demand for its function as a stress protein.

The important functions of GRP94 have been investigated by several genetic methods. Antisense [10] or ribozyme-mediated depletion of GRP94 levels [8] affect both GRP94 and GRP78/BiP proteins and has shown that while their induction by stress conditions can be inhibited, their basal expression remains and is sufficient to support cell growth and proliferation. GRP94 shares many of its transcriptional regulatory elements with GRP78/BiP [11]. A GRP94-deficient murine pre-B lymphocyte line, 70Z/3, was isolated by Randow and Seed [12] based on sensitivity to lipopolysaccharide (LPS) stimulation, and shown to be capable of growth in culture. In *Arabidopsis*, a null *grp94* mutation shows the protein to be important for plant development [13]. Both the Shepherd mutation and the

70Z/3 cell line show genetically that loss of GRP94 is not cell-lethal, but rather affects selected processes. These studies and the absence of GRP94 from yeast, are consistent with the correlation between GRP94 expression and multi-cellularity.

The above conclusion is probably related to another unusual feature of GRP94, which distinguishes it from most other chaperones: its small number of client proteins. In the GRP94-deficient cell line, only the surface expression of some, but not all integrins and Toll-like receptors was shown to be affected [12]. Similarly, we have shown that immunoglobulin biosynthesis is sensitive to pharmacological inhibition of GRP94, while the biosynthesis of MHC class I is not. Among the secreted and membrane proteins that are known to associate with GRP94 during their folding, there is no identifiable common structural element. It is therefore not presently possible to predict GRP94 substrates based on protein structure. Because of the apparent selectivity of GRP94 it was of interest to determine the effects of ablating GRP94 expression in the mouse.

Here we report that despite its ubiquitous expression in mouse tissues, targeting the murine gene for GRP94 gives rise to an embryonic lethal phenotype with a specific defect in a critical developmental checkpoint – the induction of mesoderm.

The following materials and methods are provided to facilitate the practice of Example 2.

20 Cloning and mapping of *grp94*

Srivastava *et al.* [41] have shown that there is one mouse GRP94-encoding gene, located on chromosome 10, but only a partial genomic sequence is available. We used the porcine *grp94* gene [42] as a guide to map the exon/intron organization of murine *grp94*. Nine phages encoding overlapping portions of murine GRP94 were isolated from a Sv129 genomic λ phage library (Stratagene), and their *grp94* gene content mapped by exon PCR analysis. Phages containing approximately 23 kb genomic DNA each (data not shown) were used to construct the targeting vector.

The targeting construct was assembled in the vector pPNT1 [43]. An 8 kb EcoRV fragment extending from the intron between exons 3 and 4 to exon 8 was used as the right arm. The left arm was PCR-amplified and fully sequenced. It contains 1.5 kb of the *grp94* starting in the 5'UTR and ending inside exon 3. The two arms are separated by a neomycin resistance cassette inserted in the opposite transcriptional direction. This created a stop codon, predicting a protein product that contains only 61 of the 781 amino acids of the mature GRP94 protein (plus 3 additional amino acids derived from the vector). Upstream of

the *grp94* sequence the targeting construct contained a thymidine kinase (*tk*) gene for negative selection.

Generation of *grp94* gene targeted mice

5 The targeting construct was electroporated into C1 ES cells (a kind gift from Dr. B. Hendrikson, the University of Chicago) and clones resistant to both ganciclovir and G418 were isolated and expanded. Twelve correctly targeted clones were identified, corresponding to a ratio of approximately 1 in 4 targeted to non-targeted ES clones. Six of these clones were expanded further and injected into blastocysts from pseudopregnant C57Bl/6 WT
10 female mice. The blastocysts were implanted and the females allowed to progress to term and produce chimeric animals. Seven male chimeric offspring with a brown coat color percentage of more than 75% were then bred to WT C57Bl/6 females and the resulting offspring genotyped. Heterozygotes were inter-crossed to yield the F1 generation. Two independent mouse lines with germline transmission of the disrupted gene were derived. The
15 phenotype of both lines was indistinguishable, so the data reported here were derived from line 18. The data are from mice backcrossed to the C57Bl/6 background for at least 6 generations.

Generation of ES cell lines from targeted mice

20 ES cells from *grp94* +/- intercrosses were isolated by flushing the uterine ducts of E3.5 pregnant females with M2 medium (Sigma) using a 30-1/2" gauge needle. Blastocysts were seeded in gelatinized tissue culture dishes in complete ES medium (DMEM, 20% FCS, Pen-Strep Glutamine, β -mercaptoethanol, non-essential amino acids, Hepes, 1000 u/ml ESGRO). The inner cell mass was isolated after 4 days and
25 expanded on irradiated murine embryonic fibroblasts. Colonies with ES cell morphology were genotyped and expanded.

Cell proliferation and survival assays

 Proliferation assays were performed using the CellTiter 96 AQueous Non-Radioactive Proliferation assay kit (Promega). Cells were grown for 2 weeks in medium
30 containing different levels of glucose before proliferation assays were performed. Glucose-free medium and high glucose medium (4.5 g/L) were purchased from Invitrogen. In some experiments, cells were grown in the presence of 1 mM EGTA and their proliferation was quantified over a number of cell divisions. Serum deprivation experiments were set up by

plating a known number of cells at 60% confluency or higher, and replacing the growth medium with serum-free medium when the cells were properly attached to the gelatin-coated plates. At the indicated time points, the plates were washed and the remaining attached cells were assayed for trypan blue (Fisher) exclusion. The detached cells were mostly trypan blue
5 positive and were not able to attach upon replating. For the thapsigargin sensitivity assays, cell cultures were treated with drug concentrations of 0.25-3 μ M between 3 and 24 hrs.

Immunohistochemistry and whole mount *in situ* hybridization

Decidual swellings were isolated from uterine muscular tissue and fixed over night in
10 4% paraformaldehyde at 4°C. The tissue was embedded in paraffin, sectioned at 5-7 μ m and mounted on Superfrost slides (Fisher). For immunohistochemistry, the slides were dewaxed, blocked with H₂O₂ and treated with boiling 10mM Citrate pH 6.0 for 10 minutes and then cooled to room temperature before antibody detection with 9G10 (Neomarkers). For H&E staining, slides were dewaxed and rehydrated, then stained for 4 minutes in Harris'
15 hematoxylin (Sigma), rinsed until clear with tap water, dipped in 1% acid alcohol (1% HCl in 70% ethanol) to decolorize, rinsed in running tap water, and dipped in 100% ethanol. Slides were then dipped 3-4 times in eosin-phloxine (Fisher), dehydrated, cleared with xylene (Fisher) and mounted. FACS analysis of splenocytes was performed with fluorescent anti-IgM and anti-CD3 monoclonal antibodies (Pharmingen), using standard procedures.

20 For whole mount *in situ* hybridization, embryos (E6.5 and E7.5) were dissected from freshly isolated decidua, fixed for 45 minutes in cold 4% paraformaldehyde, and processed as described [44]. Briefly, embryos were re-hydrated, bleached in H₂O₂, permeabilized with proteinase K, and re-fixed. After treatment with sodium borohydride, the embryos were washed and pre-hybridized 1h at 63°C. DIG-labeled probe (2 μ g/ml)(Company for DIG) was
25 added and hybridization proceeded for 20 hours at 63°C. Following washes at increasing stringency, probe binding was detected with Purple AP (Roche). The embryos were photographed through a dissection microscope using T-100 tungsten film (Kodak).

All riboprobes, except *brachyury* (T), were synthesized using T3 RNA polymerase (Promega) from cDNAs cloned into pBluescriptIIKS+ (Stratagene). The *brachyury* template
30 construct, a kind gift from Dr. Hermann, Max-Planck-Institut für Entwicklungsbiologie, Tübingen, Germany, was transcribed with T7 RNA polymerase (Promega).

LPS Assay

B cells from freshly isolated and homogenized mouse spleens were purified with Lympholyte M (Accurate Chemical) according to the manufacturer's instructions. Cells were plated in triplicates in 96 well plates in the absence or presence of 5 µg LPS (*E. coli* serotype 0127:B8, Sigma) per 10⁶ cells in 200 µl medium. The cells were incubated 72 hours at 37°C, 7.5% CO₂ and supernatants analyzed by enzyme-linked immunosorbent assay (ELISA) using alkaline phosphatase-labeled anti-mouse IgG (Southern Biotechnology Associates Clonotyping System) and 1 mg/ml PNPP substrate in substrate buffer (0.24 M MgCl₂·6H₂O, 0.9 M diethanolamine in 500 ml, pH 9.8) for detection.

RNA and cDNA preparation

To prepare total RNA, entire embryos were homogenized by pipetting in 100 µl Trizol (Sigma). 10 µg glycogen was added as carrier, and the RNA was extracted with phenol/chloroform and precipitated with ethanol. RNA from other embryos was prepared using the Qiagen RNeasy Mini kit (Qiagen). Typically, half of each RNA sample was used for cDNA preparation. Random primers (Gibco or Invitrogen) and dNTP mixture were added, incubated for 5 minutes at 65°C and rapidly cooled on ice. After addition of reaction buffer and Placental RNase inhibitor (Roche), was added and the first strand synthesized using either Superscript II enzyme (Invitrogen) at for 50 minutes at 42°C, or Sensiscript reverse transcriptase (Qiagen) for 1 hour at 37°C. RNase H was subsequently used to remove the RNA template and minimize interference with PCR analysis.

Results

Targeting the murine *grp94* gene.

Because GRP94 is found only in multi-cellular organisms, is not necessary for cell growth, and has a limited substrate range, this chaperone is probably not necessary for the folding of most proteins in the secretory pathway. We therefore hypothesized that targeted ablation of mouse *grp94* would yield a defined phenotype rather than a catastrophic growth defect.

The murine *grp94* gene, located on chromosome 10 [14], was targeted in strain 129 C1 ES cells (Fig. 8A) and six correctly targeted clones, resistant to both ganciclovir and G418, were selected and injected into blastocysts from pseudo-pregnant C57Bl/6 wild type (WT) female mice. Seven males exhibiting more than 75% coat color chimerism from two independent lines were then bred to WT C57Bl/6 females and the resulting offspring

genotyped. Heterozygotes were interbred as well as backcrossed to WT C57Bl/6 for 12 generations.

The expected protein product from this targeting construct contains 61 amino acids of the mature GRP94 protein (out of 781), plus three additional amino acids derived from the vector. This fragment is insufficient for either of the known activities of the protein - peptide binding and nucleotide binding [15-17]. A Southern blot analysis on genomic DNA isolated from one WT and two heterozygous F1 mice, using a 3' probe external to the targeting construct, is shown in Fig. 8B. RT-PCR analysis extended this finding by showing the absence of GRP94 transcripts from *-/-* embryos (Fig 4A). Absence of GRP94 protein was verified by immunoblots of embryonic tissues and cells (see below) with the 9G10 monoclonal anti-GRP94, which recognizes an epitope between amino acids 266 and 347 [18].

Homozygous deletion of *grp94* has an embryonic lethal phenotype

As seen in Table 2, viable *grp94*^{-/-} mice were never obtained out of more than 900 progeny of intercrosses between heterozygotes. The fraction of heterozygous live-born mice was 55.4%, instead of the 66.7% expected in the absence of *-/-* mice. Therefore, it appears that in addition to the homozygous mutant lethality, there is skewed inheritance of the knockout allele, a phenotype that is yet to be explored.

To determine the stage of embryonic lethality, we dissected out embryos at different stages of embryogenesis. At E14.5 and E10.5, no *-/-* embryos were found and even at E8.5, only few mutant embryos were identified (Table 2). Between E8.5 and E9.5, resorbing embryos were common. Between E5.5 and E7.5, however, we found a genotype distribution consistent with the expected 1:2:1 Mendelian ratio.

Up to the egg cylinder stage of development, *grp94*^{-/-} embryos were morphologically indistinguishable from *grp94*^{+/+} embryos (Fig. 9A-D). GRP94 protein expression was readily detected throughout the WT embryo (Fig. 9C). A day later, the *grp94*^{-/-} embryos were still almost indistinguishable from WT embryos (Fig. 9E-F). However, by E7.0-7.5, a dramatic difference was observed between *grp94*^{-/-} and *grp94*^{+/+} embryos (Fig. 9I and J). The *grp94*^{-/-} embryos were much smaller than normal embryos and lacked any apparent lateral symmetry. Since they do not elongate properly, there is extra space in the yolk sac around the distal tip. Neither amnion nor chorion was formed and no proamniotic cavity was evident (Fig. 9J). The junction between the epiblast and the extra-embryonic region was less pronounced than in WT embryos, and the endodermal cell layer appeared abnormal (Fig. 9K). In normal embryos at this stage, the extra-embryonic region of

the endoderm was composed of cuboidal/columnar cells with apical vacuoles and microvilli, and the embryonic region of the endodermal layer, beyond the junction, mostly consisted of squamous cells. In contrast, the endoderm of *grp94*^{-/-} embryos appeared to consist of cuboidal cells in both the embryonic and the extra-embryonic regions (Fig. 9L, black arrowheads). The parietal endoderm, attached to Reichert's membrane, seemed normal in the *-/-* embryos (Fig. 9L).

Remarkably, *-/-* embryos only occasionally exhibited ingression of primitive ectodermal cells as they start to form mesoderm, and only two germ layers were evident in these embryos, while normal ones clearly elaborated three germ layers (Fig. 9I-L).

Table 2: Genotype distribution with age

Stage	+/+	+/-	-/-
Newborn	414	515	0
E14.5	8	5	0
E10.5	3	2	0*
E8.5	3	5	1**
E7.5	40	81	43
E6.5	8	12	6

All genotype assignments are based on PCR reactions of genomic DNA isolated from either embryos or mice at the indicated ages.

* two empty sacs were found. ** one empty sac

The defect in *grp94*^{-/-} development occurs at the time of gastrulation

At the time the defect in development becomes evident in the *grp94*^{-/-} embryos, normal embryos initiate gastrulation. During this process, the visceral endoderm cells are replaced and all three germ layers are derived from the epiblast. The visceral endoderm cells contribute only to the yolk sac and part of the extra-embryonic region, but have nevertheless been shown to have a role in the formation of body axes [19, 20]. Immunochemical staining for GRP94 showed it to be expressed in all cells at either E5.5 (Fig. 10A) or E6.5 (Fig. 10B). However, the staining is not uniform and there are clearly clusters of visceral endoderm cells that express more GRP94 than other endoderm or ectoderm cells (Fig. 10). Importantly, the level of expression in the embryo proper and in the extra-embryonic tissue is not significantly different from that in the surrounding maternal tissue.

The progression of gastrulation is commonly monitored by the expression of transcription factors involved in cell fate specification, and therefore we analyzed *grp94*^{-/-} embryos by *in situ* hybridization and semi-quantitative RT-PCR. Oct4, a transcription factor whose expression is detected in normal embryos already at E4.5 [21], is expressed throughout the epiblast at E6.5, and over the next day becomes progressively concentrated in

the primitive streak (Fig. 11A). In E7.5 *-/-* embryos, the distribution of Oct4 transcripts resembles that of E6.5 WT embryos (Fig. 11A). Otx2 is a homeobox transcription factor expressed ubiquitously in the embryonic ectoderm and visceral endoderm before gastrulation and is progressively restricted to the anterior region of the embryo between E6.5 and 7.5, as the primitive streak elongates [45]. In E7.5 *grp94**-/-* embryos, Otx2 expressed in the entire ectoderm of the mutant embryos, similar to its distribution in E6.5 WT embryos. Both of these markers confirm at a molecular level the conclusion that *grp94**-/-* embryos do not progress past the E6.5 stage.

To determine if distinct regions of the embryo were specifically affected, we tested the expression of a number of markers for the anterior visceral endoderm (AVE). The expression of *lim-1*, which at E6.5-7.5 is restricted to the AVE [22], seemed reasonably normal in mutant embryos, though the domain of expression did not extend as proximally as in WT embryos of equivalent age (Fig. 11G). Similarly, a second AVE marker, *Hex* [23], is expressed anteriorly in mutant embryos (data not shown). Because a functional visceral endoderm is crucial for proper gastrulation [24], several other VE markers were tested by RT-PCR. Transcripts for transthyretin, transferrin, α fetoprotein, apolipoprotein A1 and E and retinol binding protein were all expressed equivalently in WT and mutant embryos (Fig. 12D). In conclusion, this marker analysis indicates that at least part of the axial differentiation program, formation of the AVE organizer, is not disrupted by the deficiency in GRP94.

Another region examined was the extra-embryonic ectoderm. Both normal and mutant embryos display expression of the marker *Bmp4* [46] in the extra-embryonic ectoderm at E6.5 (Fig. 11E). At E7.5, *grp94**-/-* embryos express *Bmp4* only in the proximal extra-embryonic ectoderm, while in WT embryos it is expressed in the extra-embryonic mesoderm lining the exocoelomic cavity (Fig. 11F). This is again consistent with arrested differentiation at E6.5 without an obvious effect on the extra-embryonic ectoderm.

In contrast, the expression of *brachyury* (T), an early mesoderm marker [47], was markedly affected. E7.5 *grp94**-/-* embryos were negative by *in situ* hybridization to a T antisense probe, while in the normal littermates *brachyury* was expressed in the primitive streak (Fig. 11C). Absence, or very low expression of *brachyury* was also confirmed by RT-PCR (Fig. 12). Amplification of transcripts from individual E7.5 embryos with *brachyury*-specific primers showed only a marginal *brachyury* signal in the *grp94**-/-* samples, while *hgprt* transcripts were easily amplified. However, a second T-box protein, Eomes, which is

involved in gastrulation and mesoderm induction at an earlier stage than *brachyury* [25], was expressed in *-/-* embryos. By whole mount *in situ* hybridization *eomes* is expressed in WT E7.5 embryos primarily at the primitive streak and in the extra-embryonic region [26]. In mutant embryos, the expression domain of *eomes* comprised a larger portion of the egg cylinder, including the area where the primitive streak would be expected to develop (Fig. 11D). The *eomes* expression pattern in E7.5 *grp94*^{-/-} embryos is very similar to that of E6.5 WT embryos [26]. Consistent with this result, RT-PCR analysis shows that *eomes* transcripts are readily detected in mutant embryos at a level intermediate within the range seen in WT E7.5 embryos (Fig. 12C). The variability in WT embryos is consistent with the progressively restricted expression of *eomes* between E6.5 and E7.5 [26]. Finally, a later mesoderm marker, *pMesogenin1* [27], was undetectable by RT-PCR (data not shown, N=2 mutant embryos). Together, the RT-PCR, hybridization analysis and the morphological data indicate that the defect in *grp94*^{-/-} development is at an early gastrulation stage when the primitive streak should develop. Furthermore, GRP94 activity appears to be needed between the initial wave of *eomes* expression and the normal time of *brachyury* expression.

Live-born heterozygotes are normal

No phenotypic differences were observed between live-born heterozygote and WT mice. Appearance, weight, life span and fertility were all normal (data not shown). To investigate whether this was due to upregulation of GRP94 expression from the remaining allele, total protein was isolated from livers and spleens of *grp94*^{+/+} and *grp94*^{+/-} mice and GRP94 expression was quantified by immuno-blotting. As shown in Figure 13A, the amount of GRP94 in heterozygous tissues was close to 50% of WT levels, indicating that there was no upregulation of expression from the WT allele. Furthermore, the levels of three other major ER chaperones were quantified. The levels of BiP, calnexin, and ERp72 were identical in heterozygotes and WT animals (S. Vogen and T. Gidalevitz, data not shown), showing that these ER chaperones did not compensate for the decreased expression of GRP94. We conclude that half the normal expression of GRP94 is sufficient for normal murine physiology.

Since GRP94 is upregulated during the differentiation of resting B lymphocytes into immunoglobulin (Ig) secreting plasma cells [28, 29], we examined the effect of having only half as much GRP94 on B cell differentiation and on Ig secretion. Spleen cells were examined by FACS for surface Ig expression and by ELISA for Ig secretion before and after stimulation with LPS. As seen in figure 13B, there was no difference in the level of surface

Ig expression either before or after 3 days of *ex vivo* LPS stimulation. Numbers of both T and B cells were also similar in mice of both genotypes. Third, no significant difference was detected in the level of IgM secreted by *grp94*^{+/-} and *grp94*^{+/+} splenocytes (Fig. 13C). Therefore, 50% of the normal level of GRP94 is sufficient to support Ig secretion, a
5 physiological response that entails massive upregulation of ER chaperones [28, 29].

Differential requirements for GRP94 under different stress conditions.

An early embryonic lethal phenotype like that seen in *grp94*^{-/-} embryos might be caused by slow proliferation, for instance due to a partial cell cycle block. Another
10 possibility is that mutant embryos survive only as long as the cells contain a sufficient level of maternally-derived GRP94. To address these possibilities, we derived ES cell lines from pre-implantation E3.5 blastocysts. A matching pair of ES cell clones was established from *grp94*^{-/-} and *+/+* littermate embryos. The *grp94*^{-/-} ES cells (clone termed 14.1) were able to proliferate in culture for multiple generations, just like the *+/+* ES clone (termed 42.1)
15 (Figure 14A). Thus, GRP94 is not required for cell growth and division *per se*. Furthermore, this observation provides evidence that the development arrest of mutant embryos is not simply due to dilution of maternal GRP94 during early embryogenesis.

Since GRP94 is a well-known stress protein, we examined the sensitivity of the GRP94-deficient cells to three cellular stress conditions: growth in low glucose, response to
20 serum withdrawal and perturbation of calcium homeostasis. Surprisingly, *grp94*^{-/-} cells grew as well as normal cells under low glucose tension (Figure 14B), even as low as 2.5% of the normal glucose level. Thus, despite its transcriptional regulation by glucose depletion, GRP94 is not essential for cell survival under this stress condition. On the other hand, *grp94*^{-/-} cells do not tolerate serum deprivation. Within 3 hrs after withdrawal of serum, 25% of
25 mutant cells were dying, and only 20% survived after 24 hrs without serum, while there is no appreciable cell death of WT cells even after 48 hrs (Figure 14C). GRP94-deficient cells are also more sensitive to treatment with thapsigargin, an inhibitor of the ER Ca⁺⁺-ATPase [30], with extensive cell death after 7 hrs in the presence of 300 nM thapsigargin (Fig. 14D). Furthermore, while WT cells can grow for 5 days in the presence of 1 mM EGTA, *-/-* cells
30 cannot grow under such Ca⁺⁺-chelating conditions (Fig. 14E-F). These studies show that the requirement for GRP94 as a stress protein is selective, just like the requirement for GRP94 as a chaperone: it is essential for some stress responses, but not for all, presumably reflecting its limited substrate profile.

Figure 15 shows that GRP94-deficient cells are sensitive to serum withdrawal. ES cell cultures were shifted from normal growth medium to serum-free medium and live cells were measured at the indicated times. As can be seen, wild type ES cells survive this stress for at least 4 days, while GRP94 $-/-$ cells dies rapidly. Figure 16 demonstrates
 5 that the N-terminal domain of GRP94 is taken up by dendritic cells. The N-terminal domains of GRP94, either N1-355 or N34-355 are bound to purified mouse dendritic cells at 40°C, and are internalized upon warming to 37°C into endosomal vesicles. The proteins are visualized by Texas-red-Streptavidin binding to their C-terminal biotinylated Lys370. A binding assay is shown to the right of the micrograph and quantifies the
 10 binding of N34-355 to dendritic cells. The protein was allowed to bind to the cells at 4°C for 1 hr, either alone or in the presence of alpha 2 macroglobulin or in the presence of fucoidin, the inhibitors of the CD91 receptor and the Scavenger Receptor A, respectively. After the incubation, the cells were washed, lysed and analysed by immunoblotting. The extent of binding was quantified by
 15 phosphorimaging.

GRP94 knockout (KO) cells can differentiate into cell types from all three germ layers as shown in Figure 17. GRP94 $-/-$ or $+/-$ cells were aggregated in hanging drops to form embryoid bodies, which were then induced to differentiate into various cells types by inclusion of DMSO or retinoic acid in the medium.
 20 Neurons (left panel) were identified by their morphology as well as by staining with neuron-specific antibodies to intermediate filament proteins. Hepatocytes (middle panel) were identified by indocyanine green stain as well as by PCR amplification of marker proteins. Adipocytes (right panel) were identified by Oil Red O staining of their lipid granules.

25 Figure 18 reveals that GRP94 deficient cells do not differentiate into muscle. $-/-$ ES cells were never able to give rise to skeletal myocytes (Left , bottom panel) although $+/+$ ES cells readily differentiated into myosin heavy chain positive cells (top panel).

Figure 19 shows that knockout (KO) embryos arrest around E6.5. A-H.
 30 Histological analysis of WT (top panels) and mutant (bottom panels) embryos. Embryos at 5.5, 6.5 or 7.5 days of gestation were fixed, sectioned and stained with hematoxylin and eosin. Note the formation of cavities, amnion and chorion in E7.5 wild type embryo and the formation of left-right and dorsal -vetral asymmetry

axes, whereas mutant embryos fail to exhibit any of these developmental hallmarks.

Discussion

Many molecular chaperones are expressed abundantly and ubiquitously. It was therefore quite possible that ablation of one such chaperone, GRP94, would yield a catastrophic growth defect at the cellular level as soon as maternal GRP94 reached a threshold level. Alternatively, its function might be redundant and simply filled by another chaperone. Therefore, the phenotype of the targeted disruption of *grp94* described here is surprising in its specificity. The embryonic lethality shows that *grp94* is an essential gene for mouse development. Furthermore, in-depth analysis of the defect showed that the first stage which critically depends on GRP94 is gastrulation and mesoderm induction. This is earlier than the first stage that requires HSP90 β , a cytosolic family member of GRP94, whose ablation arrests mouse development at E9.0-9.5 due to defective placental development [31]. The requirement for GRP94 is also earlier than that for calreticulin, another Ca⁺⁺-binding ER chaperone, whose ablation causes defective cardiac development [32].

The developmental arrest of *grp94*^{-/-} embryos is not due to dilution of maternally inherited protein, and is likely autonomous to the embryo. GRP94 is expressed throughout post-implantation embryos as early as E4.5, if not before ([Li, 1991 #1038] and this work). Even more importantly, GRP94-deficient cells are capable of division and even of differentiation in culture, showing that GRP94 is not essential for cell proliferation *per se*. This conclusion extends the observations of Randow and Seed [12] and Ishiguro *et al.* [13] using a GRP94-deficient pre-B cell line and a naturally occurring *Arabidopsis* null mutant, respectively. Therefore, our interpretation of the rather precise stage of the developmental arrest is that GRP94's activity is necessary for proper execution of some aspect of an important checkpoint during embryogenesis.

In the absence of GRP94, embryonic development is arrested at the egg cylinder stage without formation of the primitive streak and the resultant induction of mesoderm. Analysis of transcripts of several mesoderm markers, in particular the transcription factors *brachyury* and *eomesodermin*, suggests that the differentiation program is arrested somewhere between the expression of *eomes* and *brachyury*. The visceral endoderm and the AVE develop normally in GRP94 deficient embryos, as judged by localization of *Lim-1* and *Hex* transcripts and by quantitation of transcripts for transferrin receptor, retinol binding protein, and several other markers. Nevertheless, the differentiation of the anterior region is not entirely normal.

First, the expression domain of *Lim-1* and *Hex* is smaller than that in WT embryos, is much more localized and does not extend the entire circumference of the embryo. Second, the endoderm cells around the embryo proper remain cuboidal rather than becoming squamous. The relation of these defects to the major primitive streak defect is uncertain.

5 The developmental defect is also reflected in the phenotypes of *grp94*^{-/-} ES cells in culture. These cells are more susceptible to stress caused by serum deprivation, as well as to disruption of calcium homeostasis, but surprisingly are no more susceptible to low glucose tension than WT ES cells. These biochemical phenotypes underscore the selectivity of GRP94 even in its role as a stress protein. Furthermore, the *grp94*^{-/-} ES cells are capable of
10 differentiation in culture, giving rise to multiple lineages derived from all three germ layers, but fail to give rise to either cardiac or skeletal muscle cells, again showing some specificity in the requirement for GRP94 (S. Wanderling, O. Ostrovsky and Y. Argon, manuscript in preparation).

 The exact molecular defect that results from the absence of GRP94 has not been
15 defined yet, but it seems reasonable to propose that the deficiency of this chaperone unmasks a critical requirement for GRP94 in the maturation of a developmentally important client protein. Since GRP94 is an ER chaperone, the putative client(s) could be either secreted or membrane-bound, and is likely to participate in cell-cell interactions that are required for mesoderm formation, a highly inductive process. It is noteworthy that the mesoderm
20 induction defect in the *mesd* mouse has recently been identified as due to a defect in an ER resident protein with the capacity to interact with the LRP-5/6 membrane receptors [33]. The GRP94-induced embryonic deficiency may be due to a similar paradigm. Identifying GRP94 client proteins is made more difficult by the absence of structural information on the specificity of GRP94. Only a handful of substrates have been positively identified, and their
25 small number precludes definition of a common motif. The only known client proteins with potential functions in early development are the Toll-like receptors 1, 2 and 4. Significantly, Toll was originally identified in *Drosophila* embryos as critically important for axis formation [34]. A similar function was subsequently identified in *Xenopus* embryos [35]. However, in higher eukaryotes, multiple Toll-like receptors are present and none has so far
30 been shown to function in early mammalian development. If GRP94 recognizes a structural motif common to multiple Toll-like receptors, folding of all might be compromised in the absence of the chaperone, and potentially manifest as a defect in axis formation.

Conversely, genetic ablation of a number of other proteins have established their importance at the time of primitive streak formation and gastrulation. These include

fibroblast growth factor receptors, activin receptors, bone morphogenetic receptors, and several of their respective ligands [36][[37-40]. None of these proteins have been investigated in terms of dependence on GRP94 for membrane expression or secretion, but all are potential clients due to their biosynthesis in the endoplasmic reticulum.

5 In summary, we hypothesize that ER maturation of one or more developmentally important proteins depends critically on the activity of GRP94. In the absence of this molecular chaperone, the substrate(s) will not fold properly and cannot be released by the ER quality control machinery for transport to the cell surface. This in turn prevents critical ligand-receptor interactions from taking place and certain intercellular interactions required
10 for mesoderm induction are precluded.

The following conclusions can be made based on the foregoing results: 1) Grp94 is needed during mammalian development for mesoderm induction; 2) Grp94 is needed for differentiation in vitro of muscle cells, but is not needed for differentiation of other lineages; 3) Grp94 protects embryonic stem cells from apoptosis when deprived of serum, by
15 supporting the secretion of a survival factor(s); 4) The peptide binding site of Grp94 is located in its N-terminal nucleotide binding domain; 5) His 125 is important for peptide binding and contacts the bound peptide; and 6) The same fragment which is sufficient for peptide binding is also sufficient for binding to, and internalization by dendritic cells.

References for Example 2

- 20 1. Lee, A.S., et al., *Transcriptional Regulation of Two Genes Specifically Induced by Glucose Starvation in a Hamster Mutant Fibroblast Cell Line*. J. Biol. Chem., 1983. **258**: p. 597-603.
2. Drummond, I.A., et al., *Depletion of intracellular calcium stores by calcium ionophore A23187 induces the genes for glucose-regulated proteins in hamster fibroblasts*. J. Biol. Chem., 1987. **262**(26): p. 12801-5.
- 25 3. Little, E. and A.S. Lee, *Generation of a mammalian cell line deficient in glucose-regulated protein stress induction through targeted ribozyme driven by a stress-inducible promoter*. J. Biol. Chem., 1995. **270**(16): p. 9526-34.
- 30 4. Kim, Y.K., K.S. Kim, and A.S. Lee, *Regulation of the glucose-regulated protein genes by β -mercaptoethanol requires de novo protein synthesis and correlates with inhibition of protein glycosylation*. J. Cell. Physiol., 1987. **133**(3): p. 553-559.
5. Gass, J.N., N.M. Gifford, and J.W. Brewer, *Activation of an unfolded protein response during differentiation of antibody-secreting B cells*. J Biol Chem, 2002. **277**(50): p. 49047-54.
- 35 6. Kim, S.K., Y.K. Kim, and A.S. Lee, *Expression of the glucose-regulated proteins (GRP94 and GRP78) in differentiated and undifferentiated mouse embryonic cells and the use of the GRP78 promoter as an expression system in embryonic cells*. Differentiation, 1990. **42**: p. 153-159.
- 40

7. McCormick, P.J. and B. Babiarez, *Expression of a glucose-regulated cell surface protein in early mouse embryos*. Dev Biol, 1984. **105**(2): p. 530-4.
8. Li, X.A. and A.S. Lee, *Competitive inhibition of a set of endoplasmic reticulum protein genes (GRP78, GRP94, and ERp72) retards cell growth and lowers viability after ionophore treatment*. Mol. Cell. Biol., 1991. **11**(7): p. 3446-3453.
9. Barnes, J.A. and I.W. Smoak, *Immunolocalization and heart levels of GRP94 in the mouse during post-implantation development*. Anat. Embryol. (Berl), 1997. **196**(4): p. 335-41.
10. Li, L.J., et al., *Establishment of a Chinese hamster ovary cell line that expresses grp78 antisense transcripts and suppresses A23187 induction of both GRP78 and GRP94*. J. Cell. Physiol., 1992. **153**(3): p. 575-582.
11. Little, E., et al., *The glucose-regulated proteins (GRP78 and GRP94): functions, gene regulation, and applications*. Crit. Rev. Eukaryot. Gene Expr., 1994. **4**(1): p. 1-18.
12. Randow, F. and B. Seed, *Endoplasmic reticulum chaperone gp96 is required for innate immunity but not cell viability*. Nat Cell Biol, 2001. **3**(10): p. 891-6.
13. Ishiguro, S., et al., *SHEPHERD is the Arabidopsis GRP94 responsible for the formation of functional CLAVATA proteins*. Embo J, 2002. **21**(5): p. 898-908.
14. Maki, R.G., et al., *Mapping of the genes for human endoplasmic reticular heat shock protein gp96/grp94*. Somat. Cell Mol. Genet., 1993. **19**(1): p. 73-81.
15. Vogen, S.M., et al., *Radicicol-sensitive peptide binding to the N-terminal portion of GRP94*. J. Biol. Chem., 2002. **277**: p. 40742-40750.
16. Rosser, M.F.N. and C.V. Nicchitta, *Ligand interactions in the adenosine nucleotide binding domain of the Hsp90 chaperone, GRP94. I. Evidence for allosteric regulation of ligand binding*. J. Biol. Chem., 2000. **275**(30): p. 22798-22805.
17. Schulte, T.W., et al., *Interaction of radicicol with members of the heat shock protein 90 family of molecular chaperones*. Mol. Endocrinol., 1999. **13**(9): p. 1435-1448.
18. Robert, J., et al., *Phylogenetic conservation of the molecular and immunological properties of the chaperones gp96 and hsp70*. Eur J Immunol, 2001. **31**(1): p. 186-95.
19. Varlet, I., J. Collignon, and E.J. Robertson, *nodal expression in the primitive endoderm is required for specification of the anterior axis during mouse gastrulation*. Development, 1997. **124**(5): p. 1033-44.
20. Dufort, D., et al., *The transcription factor HNF3beta is required in visceral endoderm for normal primitive streak morphogenesis*. Development, 1998. **125**(16): p. 3015-25.
21. Palmieri, S.L., et al., *Oct-4 transcription factor is differentially expressed in the mouse embryo during establishment of the first two extraembryonic cell lineages involved in implantation*. Dev Biol, 1994. **166**(1): p. 259-67.
22. Barnes, J.D., et al., *Embryonic expression of Lim-1, the mouse homolog of Xenopus Xlim-1, suggests a role in lateral mesoderm differentiation and neurogenesis*. Dev Biol, 1994. **161**(1): p. 168-78.
23. Thomas, P.Q., A. Brown, and R.S. Beddington, *Hex: a homeobox gene revealing peri-implantation asymmetry in the mouse embryo and an early*

- transient marker of endothelial cell precursors*. Development, 1998. **125**(1): p. 85-94.
24. Duncan, S.A., A. Nagy, and W. Chan, *Murine gastrulation requires HNF-4 regulated gene expression in the visceral endoderm: tetraploid rescue of Hnf-4(-/-) embryos*. Development, 1997. **124**(2): p. 279-87.
 25. Russ, A.P., et al., *Eomesodermin is required for mouse trophoblast development and mesoderm formation*. Nature, 2000. **404**(6773): p. 95-9.
 26. Ciruna, B.G. and J. Rossant, *Expression of the T-box gene Eomesodermin during early mouse development*. Mech Dev, 1999. **81**(1-2): p. 199-203.
 27. Yoon, J.K., R.T. Moon, and B. Wold, *The bHLH class protein pMesogenin1 can specify paraxial mesoderm phenotypes*. Dev Biol, 2000. **222**(2): p. 376-91.
 28. Lewis, M.J., R.A. Mazzeella, and M. Green, *Structure and assembly of the endoplasmic reticulum. The synthesis of three major endoplasmic reticulum proteins during lipopolysaccharide-induced differentiation of murine lymphocytes*. J. Biol. Chem., 1985. **260**: p. 3050-3057.
 29. Wiest, D.L., et al., *Membrane biogenesis during B cell differentiation: most endoplasmic reticulum proteins are expressed coordinately*. J. Cell Biol., 1990. **110**(5): p. 1501-11.
 30. Thastrup, O., et al., *Thapsigargin, a tumor promoter, discharges intracellular Ca²⁺ stores by specific inhibition of the endoplasmic reticulum Ca²⁺-ATPase*. Proc. Natl. Acad. Sci. USA, 1990. **87**: p. 2466-2470.
 31. Voss, A.K., T. Thomas, and P. Gruss, *Mice lacking HSP90beta fail to develop a placental labyrinth*. Development, 2000. **127**(1): p. 1-11.
 32. Guo, L., et al., *Cardiac-specific expression of calcineurin reverses embryonic lethality in calreticulin-deficient mouse*. J Biol Chem, 2002. **277**(52): p. 50776-9.
 33. Hsieh, J.C., et al., *Mesd encodes an LRP5/6 chaperone essential for specification of mouse embryonic polarity*. Cell, 2003. **112**(3): p. 355-67.
 34. Anderson, K.V., L. Bokla, and C. Nusslein-Volhard, *Establishment of dorsal-ventral polarity in the Drosophila embryo: the induction of polarity by the Toll gene product*. Cell, 1985. **42**(3): p. 791-8.
 35. Prothmann, C., N.J. Armstrong, and R.A. Rupp, *The Toll/IL-1 receptor binding protein MyD88 is required for Xenopus axis formation*. Mech Dev, 2000. **97**(1-2): p. 85-92.
 36. Yamaguchi, T.P. and J. Rossant, *Fibroblast growth factors in mammalian development*. Curr Opin Genet Dev, 1995. **5**(4): p. 485-91.
 37. Mishina, Y., et al., *Multiple roles for activin-like kinase-2 signaling during mouse embryogenesis*. Dev Biol, 1999. **213**(2): p. 314-26.
 38. Roelen, B.A., et al., *Differential expression of BMP receptors in early mouse development*. Int J Dev Biol, 1997. **41**(4): p. 541-9.
 39. Gu, Z., et al., *The type I activin receptor ActRIB is required for egg cylinder organization and gastrulation in the mouse*. Genes Dev, 1998. **12**(6): p. 844-57.
 40. Weinstein, M., et al., *Failure of egg cylinder elongation and mesoderm induction in mouse embryos lacking the tumor suppressor smad2*. Proc Natl Acad Sci U S A, 1998. **95**(16): p. 9378-83.

41. Srivastava, P.K., C.A. Kozak, and L.J. Old, *Chromosomal assignment of the gene encoding the mouse tumor rejection antigen gp96*. Immunogenetics, 1988. **28**(3): p. 205-7.
- 5 42. Dechert, U., et al., *A protein kinase isolated from porcine brain microvessels is similar to a class of heat-shock proteins*. Eur. J. Biochem., 1994. **225**(3): p. 805-9.
43. Tybulewicz, V.L., et al., *Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene*. Cell, 1991. **65**(7): p. 1153-63.
- 10 44. Hogan, B.L., et al., *Manipulating the mouse embryo, a laboratory manual*. Second edition. 1994: Cold Spring Harbor Laboratory Press.
45. Simeone, A., D. Acampora, A. Mallamaci, A. Stornaiuolo, M. R. D'Apice, V. Nigro, and E. Boncinelli. 1993. A vertebrate gene related to
15 orthodenticle contains a homeodomain of the bicoid class and demarcates anterior neuroectoderm in the gastrulating mouse embryo. *Embo J* **12**:2735.
46. Coucouvanis, E., and G. R. Martin. 1999. BMP signaling plays a role in visceral endoderm differentiation and cavitation in the early mouse embryo. *Development* **126**:535.
- 20 47. Wilkinson, D. G., S. Bhatt, and B. G. Herrmann. 1990. Expression pattern of the mouse T gene and its role in mesoderm formation. *Nature* **343**:657.

25

EXAMPLE 3**A tumor-protection agent including a peptide capable of binding GRP94 protein.**

This example describes modulation of the immune system response to tumors by using the molecular chaperone GRP94 to bind peptides to present tumor
30 antigens. The invention is based on the supposition that the peptide specificity of GRP94 makes it particularly effective as a tumor-protection agent. Thus the invention provides a tumor vaccine based on the peptide-binding activity of a molecular chaperone, GRP94. In one aspect peptide sequences such as those provided in Table 3 will be complexed with GRP94 or HSP90 mini chaperones.

35 Following complex formation, an effective amount of a composition comprising the complex will be administered to the cancer patient to stimulate a tumor specific CTL response. Alternatively, tumor associated peptides may be isolated from the patient to be treated and complexed with the GRP94 and HSP90 mini chaperones described herein. Either approach should stimulate immuno modulated tumor
40 reduction or rejection. A similar approach can be employed for treating and

eradicating viral infections using complexes comprising virus specific peptides and the mini-chaperones of the invention.

Recombinant proteins (GRP94 derived or HSP90 derived) are incubated with synthetic peptides, typically at a vast molar excess of peptide because of the slow on-rate of binding. 4 micromoles of GRP94 can be saturated with 800 micromoles of synthetic binder peptide. The association can be enhanced by a 10 min 50°C treatment of the protein, and in our hands the loading is highly efficient - up to 85% of the protein can be loaded with peptide.

10

Table 3

Examples of antigenic peptides that can be loaded on GRP94:

Peptide Name	Sequence	Source	Restricted	GRP94 binding	Tumor relevant
VSV8	RGYVYQGL	VSV N protein	K ^b	yes	mouse model
OVA 257-264	SIINFELK	Influenza	K ^b	yes	mouse model
RAH	RAHYNIVTF	HPV16 E-6	HLA-A2	yes, weak	Human ovarian carcinoma common antigen
PSA16	VLVASRGRAV	PSA 16-25	HLA-A2	unknown	Human prostate common antigen
PSA 141	FLTPKKLQCVDLHV ISNDVCAQV	PSA 141-170	HLA-A2 and -- A3	unknown	Human prostate common antigen
MAGE 3	FLWGPRALV	Tyrosinase	HLA-A2	yes	Human melanoma
Ras p5-14	KLVVVGAGGV	Mutant ras 5-14	HLA-A2.1	unknown	Shared antigen many malignancies

Using a newly devised peptide-binding assay, peptide libraries will be screened with recombinant GRP94 to identify high- and low-affinity binding peptides. The optimal length and other properties of binder peptides will be deduced from the use of libraries of permuted synthetic sequences. Consensus binder sequences will then be determined by panning a large complexity phase display library. Binder peptides will then be compared to the peptides preferred by other chaperones, and most importantly to MHC class I- and class II-binding peptides. These experiments will help determine the selectivity of the GRP94-peptide representation pathway.

GRP94 will be genetically engineered to enhance its peptide presenting activity. As described in Example 1, the peptide-binding site of GRP94 has been mapped by a combination of biochemistry and site-directed mutagenesis and the data related to a computer structural model of the chaperone. To further

characterize this molecule, the inventor will search for GRP94 versions with altered affinity and/or specificity for peptides and test such engineered versions of GRP94 in tissue culture and then in mouse models for augmenting specific killer T cell responses. It is possible that high affinity binder peptides are better presented
5 because they remain bound to GRP94 during endocytosis. Alternatively, peptides with moderate affinity to GRP94 may be presented preferentially, because they can be transferred to MHC class I more efficiently.

The minimal GRP94 derivative, which can still be taken up by antigen presenting cells and stimulate T cells is described herein. Various macrophages
10 and dendritic cells (lines in culture and *ex vivo* derived) will be incubated with peptide-loaded recombinant constructs derived from GRP94 and their ability to represent the peptide will be tested by measuring T cell responses in culture. Such a mini-chaperone is more likely to be free of other activities of the full-length chaperone and therefore be more suitable as a tumor vaccine.

15 One way to artificially increase the amount of tumor-specific peptides available for T cell recognition and stimulation is to introduce such peptides as complexes with the protein GRP94 as shown in Figure 20. GRP94 is a ubiquitous protein that binds peptides, including mutated peptides within tumor cells. The elegant work of Srivastava's lab showed that GRP94 bound to tumor peptides can
20 be used to vaccinate mice which then mount 10-200 fold better T cells responses when challenged with tumors, compare to control mice (see Blachere, N.E., et al., *Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity*. J. Exp. Med., 1997. 186:1315-1322). The frequency of tumor rejection by GRP94-injected mice is
25 impressive. This approach is now being tested in clinical trials. Its big advantage is the utilization of a self-protein, to which there is no significant immune response, as a means of delivering the peptide antigens.

It has previously been reported that at least two drugs inhibit GRP94's peptide binding activity (see Schulte, T.W., et al., *Interaction of radicicol with*
30 *members of the heat shock protein 90 family of molecular chaperones*. Mol. Endocrinol., 1999. 13:1435-1448). These studies localized the site of peptide binding to the first 200 amino acids of the protein sequence (see Vogen, S.M., et al., *Radicicol-sensitive peptide binding to the N-terminal portion of GRP94*. J. Biol. Chem. 2002. 277:40742-40750). Using the ability to produce recombinant

protein, the inventor showed that peptide binding and inhibitor binding map to distinct sites in GRP94 and importantly, that the peptide specificity of this chaperone differs from the specificity of others, such as BiP or HSP70 as disclosed by Vogen et al. Finally, the GRP94-deficient cells derived from our knockout
 5 mouse embryos described in Example 2 can be used as hosts for testing the activity of engineered versions of the proteins.

It is already established that the GRP94-bound peptides are presented to T cells indirectly, via macrophages and/or dendritic cells as described in Figure 20. These cells take up the injected GRP94 (whether via CD91-dependent endocytosis
 10 as described by Binder et al. or via another route as described by Berwin, B., et al., *CD91-Independent Cross-Presentation of GRP94(gp96)-Associated Peptides*. J Immunol, 2002. 168:4282-4286) transfer the tumor peptide from GRP94 to MHC class I by some ill-defined pathway, and then display the peptide on the surface in complex with class I molecules, for T cell stimulation (see Berwin, B., et al.,
 15 *Transfer of GRP94(Gp96)-Associated Peptides onto Endosomal MHC Class I Molecules*. Traffic, 2002. 3:358-366).

To define the spectrum of GRP94 binding peptides we propose to use library approaches. We developed a 96-well plate-format binding assay using a recombinant GRP94 version, which should enable us to determine the optimal
 20 features of binder peptides as shown in Figure 21. We will pan a library of chemically synthesized versions of the best-known binder peptides (vsv8: RGYVYQGL; peptide A: KRQIYTDLEMNRLGK), attached to pins or to nitrocellulose in the plate format. The library will consist of progressive truncations from each end of the two peptides and of systematic amino acid
 25 substitutions. Specificity of binding will be ascertained by sensitivity to the inhibitor radicicol as described by Vogen et al. In this fashion, we will determine the length and hydrophobicity that are optimal for binding as well as requirements for key side chains. This approach will be further strengthened if a synthetic peptide capability and a robotic assay system are made available for this screening.

30 Once the optimal length is known, we will employ peptide phage display libraries using libraries already in our possession. Phage displaying GRP94 binding peptides will be isolated and sequenced, in order to derive consensus sequences. Since our assay is quantitative, the resultant peptides will also be rank ordered. The human genome databases will be then mined to find out how often

these peptides occur in human proteins, and in what kind of proteins. An important component of this approach will be comparisons of GRP94-binding peptides with peptides known to stimulate T cells. We have a collection of such peptides, each with its corresponding T cell clone or hybridoma, for this purpose.

5 If the majority of GRP94-binding peptides are structurally different from peptides that recognized by T cells, this method of immunization against tumors is not likely to be widely applicable. However, inspection of the small subset of known GRP94-binding peptides suggest that this will not be the case and that there is considerable similarity to peptides recognized by T cells.

10 Thus far, the minimal peptide-binding domain of GRP94 is amino acids 34 to 221. Using a similar assay as above, we will randomly mutate this sequence at an average hit rate of 1-2 mutations per sequence and select recombinant proteins with reduced affinity for the known peptide VSV8. These will be sequenced to determine all the amino acids that affect peptide binding. Preliminary data using
15 site-directed mutagenesis suggest that Trp 202 and His136 are involved in peptide binding, as well as demonstrating the feasibility of our approach for mapping the binding site.

In parallel, we will engineer GRP94 so that it binds peptides better and/or differently than the naturally occurring protein in order to generate a “designer
20 version” that is more effective in augmentation of T cell responses. Variants with increased peptide affinity may sensitize the immune system when even low levels of peptide-GRP94 are administered. Alternatively, higher affinity may be detrimental, as it may make dissociation of GRP94 from peptide harder in the macrophage/dendritic cell environment. We will therefore screen for mutants that
25 confer altered recognition of peptides.

Once these mutants are characterized in cell-free peptide binding assays, we will test them for peptide presentation to T cells, initially using antigen presenting cells in culture (as described herein) and then by immunization of mice, as described in references by Tamura et al., Basu et al., Suto et al., and Blachere et
30 al.

Figure 22 provides the nucleic acid and amino acid sequences of wild type GRP94.

References for Example 3

1. Tamura, Y., et al., *Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations*. Science, 1997. 278:117-120.
- 5 2. Basu, S., et al., *Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway*. Int Immunol, 2000. 12:1539-1546.
- 10 3. Binder, R.J., D.K. Han, and P.K. Srivastava, *CD91: a receptor for heat shock protein gp96*. Nat Immunol, 2000. 1:151-155.
4. Suto, R. and P.K. Srivastava, *A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides*. Science, 1995. 269:1585-1588.
- 15 5. Blachere, N.E., et al., *Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity*. J. Exp. Med., 1997. 186:1315-1322.
- 20 6. Velders, M.P., H. Schreiber, and W.M. Kast, *Active immunization against cancer cells: impediments and advances*. Semin Oncol, 1998. 25:69 7-706.
7. Melnick, J., J.L. Dul, and Y. Argon, *Sequential interaction of the chaperones BiP and GRP94 with immunoglobulin chains in the endoplasmic reticulum*. Nature, 1994. 370:373-375.
- 25 8. Schulte, T.W., et al., *Interaction of radicicol with members of the heat shock protein 90 family of molecular chaperones*. Mol. Endocrinol., 1999. 13:1435-1448.
- 30 9. Vogen, S.M., et al., *Radicicol-sensitive peptide binding to the N-terminal portion of GRP94*. J. Biol. Chem.. 2002. 277:40742-40750.
10. Berwin, B., et al., *CD91-Independent Cross-Presentation of GRP94(gp96)-Associated Peptides*. J Immunol, 2002. 168:4282-4286.
- 35 11. Berwin, B., et al., *Transfer of GRP94(Gp96)-Associated Peptides onto Endosomal MHC Class I Molecules*. Traffic, 2002. 3:358-366.
12. Argon, Y. and B.B. Simen, *GRP94, an ER chaperone with protein and peptide binding properties*. Semin Cell Dev Biol, 1999. 10:495-505.
- 40 13. Baker-LePain, J.C., et al., *GRP94 (gp96) and GRP94 N-terminal geldanamycin binding domain elicit tissue nonrestricted tumor suppression*. J Exp Med, 2002. 196:1447-1459.
- 45 14. Linderoth, N.A., A. Popowicz, and S. Sastry, *Identification of the peptide-binding site in the heat shock chaperone/tumor rejection antigen gp96 (Grp94)*. J. Biol. Chem., 2000. 275:5472-5477.

While the invention has been described in detail and with reference to specific examples thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.

What is claimed is:

1. A nucleic acid encoding a truncated GRP94 mini-chaperone protein.
- 5 2. The nucleic acid of claim 1, wherein said nucleic acid encodes a GRP94 protein variant selected from the group consisting of amino acids 34-355 of SEQ ID NO: 2, amino acids 34-221 of SEQ ID NO: 2, and amino acids 70-221 of SEQ ID NO: 2.
- 10 3. The nucleic acid of claim 2, contained within an expression vector.
4. A GRP94 mini chaperone protein encoded by a nucleic acid of claim 2.
- 15 5. A composition comprising the protein of claim 4, contained within a pharmaceutically acceptable carrier.
6. The composition of claim 5, further comprising a peptide complexed to said GRP94 mini-chaperone protein.
- 20 7. The composition of claim 6, wherein said peptide in said complex comprises a tumor specific antigen.
8. The composition of claim 6, wherein said peptide in said complex
- 25 comprises a viral antigen.
9. A method for stimulating an immune response to tumor tissue for the treatment of malignancy, comprising:
 - a) forming a complex between at least one mini-chaperone
 - 30 as claimed in claim 4 and at least one tumor specific peptide comprising a tumor specific antigen;
 - b) administering an effective amount of said complex to a patient in need thereof, such that a tumor specific cytotoxic T cell (CTL) response

is mounted; said CTL response causing a reduction in said tumor tissue thereby treating said malignancy.

10. The method of claim 9, wherein said at least one peptide comprises
5 a plurality of shared tumor antigens.

11. The method of claim 10, wherein said shared tumor antigens are selected from the group consisting peptides set forth in Table 3.

10 12. The method of claim 9, wherein said at least one tumor specific peptide is isolated from said patient and used to form the complex of step a).

13. A method for stimulating an immune response to a viral infection treatment of said infection, comprising:

15 a) forming a complex between at least one mini-chaperone as claimed in claim 4 and at least one virus specific peptide comprising an antigen specific for said virus;

b) administering an effective amount of said complex to a patient in need thereof, such that a virus specific cytotoxic T cell (CTL) response is
20 mounted; said CTL response causing a reduction in said viral load thereby treating said infection.

14. The method of claim 13, wherein said at least one peptide comprises a plurality of virus specific antigens.

25

15. A transgenic mouse embryo harboring a homozygous null mutation in its endogenous GRP94 gene wherein said mutation has been introduced into said mouse via homologous recombination in embryonic stem cells, and further wherein said mouse does not express a functional mouse GRP94 protein.

30

16. The transgenic mouse embryo of claim 15, wherein said null mutation has been introduced into an ancestor of said mouse at an embryonic stage following microinjection of embryonic stem cells into a mouse blastocyt.

17. The transgenic mouse embryo of claim 15, wherein said null mutation has been introduced into an ancestor of said mouse at an embryonic stage following co-incubation of embryonic stem cells with a fertilized egg or morula.

5 18. A GRP94 deficient cell line derived from the transgenic mouse embryo of claim 15.

19. The cell line of claim 18, which is an embryonic stem cell line.

10 20. The cell line of claim 19, which has been induced to undergo cellular differentiation.

21. The GRP-94 deficient cell line of claim 20, which has been induced to differentiate into a cell type selected from the group consisting of neuron,
15 adipocytes, hepatocytes and lymphocytes.

22. A method for screening for therapeutic agents which selectively affect GRP94 activity, comprising:

a) administering a test compound to the cells of claim 18 and cells
20 derived from wild type mouse embryos;

b) assessing said GRP94-deficient and wild type cells for an alteration in a GRP94-related physiological process, thereby identifying agents which selectively modulate GRP94 activity.

25 23. A method for screening for therapeutic agents which selectively affect GRP94 activity, comprising:

a) administering a test compound to the cells of claim 19 and cells derived from wild type mouse embryos;

b) assessing said GRP94-deficient and wild type cells for an
30 alteration in a GRP94-related physiological process, thereby identifying agents which selectively modulate GRP94 activity.

24. A method for screening for therapeutic agents which selectively affect GRP94 activity, comprising:

a) administering a test compound to the cells of claim 21 and cells derived from wild type mouse embryos;

b) assessing said GRP94-deficient and wild type cells for an alteration in a GRP94-related physiological process, thereby identifying agents
5 which selectively modulate GRP94 activity.

25. A nucleic acid encoding an HSP90 mini chaperone comprising amino acids 1-210 of human HSP90, wherein at least one amino acid residue
10 selected from the group consisting of Thr90, Ile81, Pro82 has been altered to another amino acid.

26. An HSP90 mini chaperone protein encoded by the nucleic acid molecule of claim 25.
15

27. A pharmaceutical composition comprising the HSP90 mini chaperone of claim 26 in a pharmaceutically acceptable carrier.

28. A method for stimulating an immune response to tumor tissue for
20 the treatment of malignancy, comprising:

a) forming a complex between at least one mini-chaperone as claimed in claim 26 and at least one tumor specific peptide comprising a tumor specific antigen;

b) administering an effective amount of said complex to a
25 patient in need thereof, such that a tumor specific cytotoxic T cell (CTL) response is mounted; said CTL response causing a reduction in said tumor tissue thereby treating said malignancy.

29. The method of claim 28, wherein said at least one peptide
30 comprises a plurality of shared tumor antigens.

30. The method of claim 29, wherein said shared tumor antigens are selected from the group set forth in Table 3.

31. The method of claim 28, wherein said at least one tumor specific peptide is isolated from said patient and used to form the complex of step a).

32. A method for stimulating an immune response to a viral infection
5 treatment of said infection, comprising:

a) forming a complex between at least one mini-chaperone as claimed in claim 26 and at least one viral specific peptide comprising an antigen specific for said virus;

b) administering an effective amount of said complex to a
10 patient in need thereof, such that a virus specific cytotoxic T cell (CTL) response is mounted; said CTL response causing a reduction in said viral load thereby treating said infection.

32. The method of claim 31, wherein said at least one peptide
15 comprises a plurality of virus specific antigens.




Figure 1A




Figure 1B



Figure 1C




Figure 2A




Figure 2B




Figure 3A




Figure 3B




Figure 3C

	G		F		135(100)		174(134)			
dog94	ELTVRK	CDKEKNL	ELTVRK	CDKEKNL	TDTGVGMTRE	ELVKNLGTIA	KSGTSEFLNK	MTEAQEDGQS	.TSELIGQFG	VGfys
pig94	ELTVRK	CDKEKNL	ELTVRK	CDKEKNL	TDTGVGMTRE	ELVKNLGTIA	KSGTSEFLNK	MAEAQEDGQS	.TSELIGQFG	VGfys
human94	ELTVRK	CDKEKNL	ELTVRK	CDKEKNL	TDTGVGMTRE	ELVKNLGTIA	KSGTSEFLNK	MTEAQEDGQS	.TSELIGQFG	VGfys
erp99	ELTVRK	CDKEKNL	ELTVRK	CDKEKNL	TDTGVGMTRE	ELVKNLGTIA	KSGTSEFLNK	MTEAQEDGQS	.TSELIGQFG	VGfys
fly94	ELHIRK	ADKENKAL	ELHIRK	ADKENKAL	MDSGIGMTHQ	DLINNLGTIA	KSGTADFLAK	MQDPSKSEGL	DMNDMIGQFG	VGfys
C.eleg94	EMSVRK	ADRENRL	EMSVRK	ADRENRL	TDTGVGMTRE	DLINNLGTIA	RSGTSEFLSK	IMDTATSSDQ	.QQDLIGQFG	VGfys
barley94	KLEIQK	LDKENKIS	KLEIQK	LDKENKIS	RDRGVGMTKE	DLIKNLGTIA	KSGTSAFVER	MQTGGDL.N.	LIGQFG	VGfys
cros94	KLEIQK	LDKENKIS	KLEIQK	LDKENKIS	RDRGIGMTKE	DLIKNLGTIA	KSGTSAFVER	MQTSGDL.N.	LIGQFG	VGfys
human90	ELHINDI	PNKQDRT	ELHINDI	PNKQDRT	VDTGIGMTRK	DLINNLGTIA	KSGTRAFMEA	LQAGADI..S	MIGQFG	VGfys
rat90	ELKIDFI	PNPQEAT	ELKIDFI	PNPQEAT	VDTGIGMTRK	DLINNLGTIA	KSGTRAFMEA	LQAGADI..S	MIGQFG	VGfys
C.eleg90	ELFIRIT	PNKEEKT	ELFIRIT	PNKEEKT	MDTGIGMTRK	DLVNNLGTIA	KSGTRAFMEA	LQAGADI..S	MIGQFG	VGfys
C.alb90	ELFIRFI	PQNDQKV	ELFIRFI	PQNDQKV	RDSGIGMTRK	DLVNNLGTIA	KSGTRSEMEA	LSAGADV..S	MIGQFG	VGfys
yeast90	DLFIRIT	PDKENKITA	DLFIRIT	PDKENKITA	RDTGIGMTRK	DLINNLGVIA	KSGTRQFMEA	AASGADI..S	MIGQFG	VGfys

Figure 4A




Figure 4B




Figure 5A




Figure 5B




Figure 5C




Figure 5D




Figure 6A




Figure 6B




Figure 6C




Figure 7A




Figure 7B




Figure 7C




Figure 8A






Figure 8B





Figures 9A-9H




Figures 9I-9L

Figures 10A-10B






Figures 11A-11G




Figures 12A-12D

28/38




Figures 13A-13C


A.




B.




C.




D.



E.



F.



Figures 14A-14F





Figure 15



Red: N-terminal domain of GRP94, Blue: DAPI

Figure 16




Figure 17




Figure 18




Figure 19




Figure 20




Figure 21

The amino acid sequence of human GRP94

(Genbank accession number NM003299)

MRALWVLGLCCVLLTFGSVRADDEVVDVGTVEEDLGKSREGSRTDDEVVQREEEAIQLDGLN
ASQIRELREKSEKFAFQAEVNRMMKLIINSLYKNKEIFLRELISNASDALDKIRLISLTDEN
ALSGNEELTVKIKCDKEKNLLHVTDGTGVMTREELVKNLGTIAKSGTSEFLNKMTEAQEDGQ
STSELIGQFGVGFYSAFLVADKVIVTSKHNNDTQHIWESDSNEFSVIADPRGNTLGRGTTIT
LVLKEEASDYLELDTIKNLVKKYSQFINFPIYVWSSKTETVEEPMEEEEAAKEEKEESDDEA
AVEEEEEEEKPKTKKVEKTVWDWELMNDIKPIWQRPSKEVEEDEYKAFYKSFSKESDDPMAY
IHFTAEGEVTFKSILFVPTSAPRGLFDEYGSKKSDYIKLYVRRVFITDDFHDMMPKYLNFKV
GVVDSDDLPLNVSRETLLQHKLLKVIRKKLVKRLDLMIKKIADDKYNDTFWKEFGTNIKLG
IEDHSNRTRLAKLLRFQSSHPTDITSLDQYVERMKEKQDKIYFMAGSSRKEAESSPFVERL
LKKGYEVIYLTPEVDEYCIQALPEFDGKRFQNVAKEGVKFDESEKTKESREAVEKEFEPLLN
WMKDKALKDKIEKAVVSQRLTESPCALVASQYGWSGNMERIMKAQAYQTGKDISTNYIASQK
KTFEINPRHPLIRDMLRRIKEDEDDKTVLDLAVVLFETATLRSGYLLPDTKAYGDRIERMLR
LSLNIDPDAKVEEEPEEEPEETAEDTTEDTEQDEDEEMDVGTDEEEETAKESTAEKDEL

Sequence in orange - the signal sequence of human GRP94

Sequence in red - the sequence contained in the constructs used in
this invention**Figure 22A**

38/38

The nucleotide sequence of human GRP94

(Genbank accession number NM003299)

```

1  gtgggaggac  cgcgcggctg  gaggtgtgag  gatccgaacc  caggggtggg  ggggtggaggc
61  ggctcctgcg  atcgaagggg  acttgagact  caccggccgc  acgccatgag  ggccctgtgg
121  gtgctgggcc  tctgctgcgt  cctgctgacc  ttcgggtcgg  tcagagctga  cgatgaagtt
181  gatgtggatg  gtacagtaga  agaggatctg  ggtaaaagta  gagaaggatc  aaggacggat
241  gatgaagtag  tacagagaga  ggaagaagct  attcagttgg  atggattaaa  tgcatacaca
301  ataagagAAC  ttagagagaa  gtcggaaaag  tttgccttcc  aagccgaagt  taacagaatg
361  atgaaactta  tcatcaattc  attgtataaa  aataaagaga  ttttcctgag  agaactgatt
421  tcaaagtctt  ctgatgcttt  agataagata  aggctaatat  cactgactga  tgaaaatgct
481  ctttctggaa  atgaggaact  aacagtcaaa  attaagtgtg  ataaggagaa  gaacctgctg
541  catgtcacag  acaccggtgt  aggaatgacc  agagaagagt  tggttaaaaa  ccttggtacc
601  atagccaaat  ctgggacaag  cgagttttta  aacaaaatga  ctgaagcaca  ggaagatggc
661  cagtcaactt  ctgaattgat  tggccagttt  ggtgtcgggt  tctattccgc  cttccttgta
721  gcagataagg  ttattgtcac  ttcaaaacac  aacaacgata  cccagcacat  ctgggagtct
781  gactccaatg  aattttctgt  aattgctgac  ccaagaggaa  acactctagg  acggggaacg
841  acaattaccc  ttgtcttaaa  agaagaagca  tctgattacc  ttgaattgga  tacaattaaa
901  aatctcgtca  aaaaatatcc  acagttcata  aactttccta  tttatgtatg  gagcagcaag
961  actgaaactg  ttgaggagcc  catggaggaa  gaagaagcag  ccaaagaaga  gaaagaagaa
1021  tctgatgatg  aagctgcagt  agaggaagaa  gaagaagaaa  agaaaccaa  gactaaaaaa
1081  gttgaaaaaa  ctgtctggga  ctgggaactt  atgaatgata  tcaaaccaat  atggcagaga
1141  ccatcaaaag  aagtagaaga  agatgaatac  aaagctttct  acaaatcatt  ttcaaaggaa
1201  agtgatgacc  ccatggctta  tattcacttt  actgctgaag  gggaagttac  cttcaaatca
1261  attttatttg  taccacatc  tgctccacgt  ggtctgtttg  acgaatatgg  atctaaaaag
1321  agcgattaca  ttaagctcta  tgtgcgccgt  gtattcatca  cagacgactt  ccatgatatg
1381  atgcctaaat  acctcaattt  tgtcaagggt  gtgggtggact  cagatgatct  ccccttgaat
1441  gtttcccgcg  agactcttca  gcaacataaa  ctgcttaagg  tgattaggaa  gaagcttggt
1501  cgtaaaacgc  tggacatgat  caagaagatt  gctgatgata  aatacaatga  tacttttttg
1561  aaagaatttg  gtaccaacat  caagcttggt  gtgattgaag  accactcgaa  tcgaacacgt
1621  cttgctaaac  ttcttaggtt  ccagtcttct  catcatccaa  ctgacattac  tagcctagac
1681  cagtatgtgg  aaagaatgaa  ggaaaaacaa  gacaaaatct  acttcatggc  tgggtccagc
1741  agaaaagagg  ctgaatcttc  tccatttggt  gagcgacttc  tgaaaaaggg  ctatgaagtt
1801  atttacctca  cagaacctgt  ggatgaatac  tgtattcagg  cccttcccga  atttgatggg
1861  aagaggttcc  agaatgttgc  caaggaagga  gtgaagtctg  atgaaagtga  gaaaactaag
1921  gagagtcgtg  aagcagttga  gaaagaattt  gagcctctgc  tgaattggat  gaaagataaa
1981  gcccttaagg  acaagattga  aaaggctgtg  gtgtctcagc  gcctgacaga  atctccgtgt
2041  gctttggtgg  ccagccagta  cggatggtct  ggcaacatgg  agagaatcat  gaaagcacia
2101  gcgtaccaaa  cgggcaagga  catctctaca  aattactatg  cgagtcagaa  gaaaacattt
2161  gaaattaatc  ccagacaccc  gctgatcaga  gacatgcttc  gacgaattaa  ggaagatgaa
2221  gatgataaaa  cagtttttga  tcttgctgtg  gttttgtttg  aaacagcaac  gcttcggtca
2281  gggatatctt  taccagacac  taaagcatat  ggagatagaa  tagaaagaat  gcttcgcctc
2341  agtttgaaca  ttgaccctga  tgcaagggtg  gaagaagagc  ccgaagaaga  acctgaagag
2401  acagcagaag  acacaacaga  agacacagag  caagacgaag  atgaagaaat  ggatgtggga
2461  acagatgaag  aagaagaaac  agcaaaggaa  tctacagctg  aaaaagatga  attgtaaatt
2521  atactctcac  catttggatc  ctgtgtggag  agggaaatgt  aaatttacat  catttctttt
2581  tgggagagac  ttgtttttga  tgccccctaa  tccccctctc  ccctgcactg  taaaatgtgg
2641  gattatgggt  cacaggaaaa  agtgggtttt  ttagttgaat  tttttttaac  attcctcatg
2701  aatgtaaatt  tgtactattt  aactgactat  tcttgatgta  aaatcttgtc  atgtgtataa
2761  aaataaaaaa  gatcccaaat

```

Figure 22B